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ABSTRACT 
Tropomyosin is one of the components of the thin filaments of muscle, binding to actin, 
and, together with troponin, regulating contraction in a calcium-dependent manner (Cho 
et al.,l990). The.-e are at least four distinct tropomyosin genes in ·1ertebrates and each 
may encode at least six different isoforms of tropomyosin by alternate splicing (Novy et 
aL, 1993; MacLeod et al., 1988). The alpha-tropomyosin gene TPM1 has recently been 
localised to 15q22 (Eyre et aL, 1994) and has been shown to be mutated in some cases of 
familial hypertrophic cardiomyopathy (Thierfelder et al., 1994). The alpha-tropomyosin 
gene TPM3 has been recently localised to 1q22-q23 (Wilton et aL, 1994) and has been 
shown to be mutated in a family with autosomal dominant nemaline myopathy (Laing, 
1994, unpublished observations). 
Each muscle-specific gene is possibly associated with an inherited muscle disease, if 
there is a disease causing mutation in the gene. Precise mapping of muscle genes 
therefore becomes important in relation to mapping muscle diseases (Eyre et al., 1993). 
A sequence tagged site (STS) (Olson eta!., !989) was developed for the hnman beta 
tropomyosin gene (TPM2). The STS was used to ampi::fy DNA from somatic cell 
hybrids to localise TPM2 to human chromosome 9. Genomic dones isolated with the 
STS product were in tum used in fluorescent in situ hybridisation (Callen et al., 1992) to 
metaphase chromosome spreads to further localise TPM2 to 9pl3.1 (Hunt eta!., 1995). 
This project should assist those laboratories searching for candidate genes of inherited 
muscular diseases that are linked within the region of the TPM2 gene and may assist in 
the precise diagnosis of people with these diseases (Akkari, 1994). Localising TPM2 
also lays a foundation for a better understanding of the role of tropornyosins in muscle 
and nonmuscle cells. 
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A polymorphism was also discovered in the 3'UTR of TPM2, using single strnnded 
conformation analysis (SSCA). The pnmers used were 
5'-AAGTCTATGCCAGAAGATG-3' and the complementary strand 
5'-CCGTGACCGAAGTAGGAAAT-3' creating a 259 bp sequence tagged site (STS). 
Sequencing of the STS revealed that there were two variations of the 11th base in the 
3'UTR: a guanine and an adenine. Genomic DNA from 97 unrelated individuals was 
screened by SSCA and the allelic frequency was detennined to be for the common allele 
(gunnine) 0.91 nnd the rare allele (adenine) 0.09. The heterozygosity was 0.16. There is 
a Bgl I restriction site at the common allele polymorphic location. A Bgl I restriction 
digest of the 259 bp STS produces two fragments (88 & 171 bp) for homozygous 
individuals with the common allele, three fragments (88, 171 and 259 bp) for 
heterozygous individuals and a single fragment (259 bp) for homozygous individual with 
the rare allele. 
The discovery of this polymorphism will be entered on the CEPH map and is useful for 
researchers as a linkage and physical marker in the human genome project, especially 
since the TPM2 gene has now been localised to 9p13.1. 
iv 
Acknowledgements 
Declaration 
Abstract 
Contents 
List of Tables 
List of Figures 
List of Abbreviations 
Chapter 1: Introduction 
CONTENTS 
1.1 The Tropomyosin Protein 
1.2 Tropomyosin's Role in Muscle Contraction 
Pa&e No. 
(i) 
(ii) 
(iii) 
(v) 
(ix) 
(x) 
(xi) 
I 
1.3 The Tropomyosin Genes and Alternative Splicing of the Different 4 
Isofonns 
1.4 Significance ofLocalising TPM2 10 
1.5 Project Outline II 
Chapter 2: Development of a STS for human skeletal ~-tropomyosin (TPM2) 12 
2.1 Introduction 
2.1.1 The Po!ymerase chain reaction (PCR) 
2.1.2 Primer selection and criteria 13 
2.1.2.1 Primer sequence unique from other TPM genes 15 
2.1.2.2 Primer sequence unique to muscle TPM2 
isoform to avoid amplifying pseudogenes 
2.1.2.3 STS to include intronic sequence 
2.1.2.4 Primers' GC ratio 
2.1.2.5 Secondary and tertiary structures 
2.1.2.6 Primer complementarity 
2.2 Materials and Methods 
2.2.1 Primer selection 
2.2.2 TPM2 PCR conditions 
2.2.2.1 PCR cycling conditions: 2 step on automatic 
thennal cycler 
2.2.3 Agarose gel electrophoresis 
2.2.4 Staining agarose gels 
2.2.5 DNA markers 
2.2.5.1 Lnmbda bacteriophage cut with Hind Ill 
2.2.5.2 Lambda bacteriophage cut with Pst I 
2.2.5.3 pUC !9 cut with Hpa II 
v 
17 
18 
19 
'20 
21 
22 
23 
2.2.6 Purifying the TPM2 PCR STS DNA 25 
2.2.6.1 Low melting point agarose gel (LMPAG) 26 
2.2.6.2 Purification of DNA using WizardTM PCR 
Preps DNA purification system (Promega) 27 
2.2.7 Measuring the absorbance of nucleic acids on a 
spectrophotometer 28 
2.2.8 Dideoxy chain tennination automatic cycle sequencing 29 
2.2.8.1 Introduction 
2.2.8.2 Cycle sequencing- dyedeoxy tenninator cycle 32 
2.2.8.3 Applied Biosystems Incorporated (ABI) 
sequencing clean up to remove unincorporated 
ddNTP's 33 
2.2.9 Using the radioactive random labelled TPM2 STS 
on a genomic hybridisation membrane 34 
2.2.9.1 Random primer labelling introduction 
2.2.9.2 Random primer labelling protocol 38 
2.2.9.3 PEl strip test 39 
2.2.9.4 Sephadex G-50 spin column 40 
2.2.9.5 Prehybridisation of the genomic blot 42 
2.2.9.6 Hybridisation of the radiolabelled TPM2 STS 
probe to the genomic blot 43 
2.2.9.7 Washing the membrane at increasing stringencies 44 
2.2.9.8 Stripping the genomic blots 45 
2.3 Results 
2.4 Discussion 
Chapter 3: Using the TPM2 STS on a somatic cell hybrid panel 
3.1 Introduction 
3.2 Mat~iials and Methods 
3.3 Results and Discussion 
Chapter 4: Using the TPM2 STS in FISH 
4.1 Introduction 
4.2 Materials and Methods 
4.3 Results 
4.4 Discussion 
Chapter 5: Isolation of a clone from a genomic library 
5.1 Introduction 
5.2 Materials and Methods 
vi 
54 
57 
58 
61 
65 
66 
68 
--- --- --· -- ... - - . . ... ···---·-·-·- -· .......... -- .. ----· ... --. -- . ' . ------- ~ ·-- ..... _______ ,_ .. --·------- . -- -·- ------ ----
5.2.1 Determining if the 1.5 kb TPM2 STS was in the library 
5.2.1.1 Protocol 
5.2.2 Aliquots of library 
5.2.3 Bacterial culture plating and propagating 
the host strain (K802) 
5.2.4 Library plating/titering 
5.2.5 Membrane replicas of the agar plates 
5.2.6 Hybridisation of the membrane replicas using 
the radiolabelled 1.5 kb TPM2 STS 
5.2.7 PCR assay of DNA from clone eluates to 
confirm clones contain part of the TPM2 gene 
5.2.8 Isolation of DNA from phage lysates 
5.2.8.1 Preparation of bacterial host (K802) cells 
5.2.8.2 Phage high-titre stock pmparation 
5.2.8.3 Plate lysate preparation 
5.2.8.4 Lysate processing 
5.2.8.5 DNA extraction 
5.2.9 Restriction digests of clones to determine 
69 
70 
73 
75 
77 
78 
79 
82 
if they are different 83 
5.2.10 Hybridising radiolabelled clones DNA to genomic blots 84 
5.2.11 Using primers as radio labelled probes on membrane 
lifts of the colony plaques to determine if the clones 
had the same part of the TPM2 gene 85 
5.2.11.1 Purpose for end-labelled primer experiment 
on clones 
5.2.11.2 Stripping membranes and prel1ybridisation 
using oligonucleotide hybridisation solution 
5.2.11.3 Kinase 5' end labelling of oligonucleotides 86 
5.2.12 PCR assay of DNA from clones to confirm 
they contained part of the TPM2 gene 87 
5.2.13 Sequencing the clones and PCR assays to confirm 
they were specific to TPM2 
5.3 Results and Discussion 
5.3.1 Determining if the 1.5 kb TPM2 STS 
was in the genomic library 
5.3.2 Primary and secondary screening of the plaque 
membrane lifts 
vii 
89 
90 
5.3.3 Primers polynucleotide kinase 5' end-labelled as 
probes on the secondary plaque lifts to detennine 
if the clones contain both exons 6 and 8sk 
5.3.4 PCR assay on clones 1-4 eluates 
5.3.5 Lysate processing 
5.3.6 DNA extraction 
5.3.7 Restriction digests of clones 2 and 4 DNA to 
95 
96 
98 
detennine if they were the same clones 99 
5.3.8 PCR assay of clones DNA using the 1.5 kb TPM2 STS 101 
5.3.9 Sequencing clones 2 and 4 DNA and 
the 1.5 kb TPM2 STS 102 
5.3.10 Hybridising clones DNA to genomic blot 105 
Chapter 6: Use of genomic clones for FISH 108 
6.1 Introduction 
6.2 Materials and Methods 
6.3 Results and Discussion 
Chapter 7: Identification of a polymorphism in the TPM2 gene 
7 .I Introduction 
Ill 
7.1.1 Polyacrylamide gel electrophoresis for running SSCPs 112 
7.2 Jl.;laterials and Methods 113 
7.2.1 Amplifying exons lsk to 2sk in clones DNA 
7.2.2 Amplifying exon 8sk- 3' untranslated region ofTPM2 114 
7.2.3 TPM2 Exon 8sk- 3' UTR SSCP in 
10 unrelated individuals 
7 .2.4 Pouring an acryla.'llide gel 
7.2.5 Running the gel 
7.2.6 Fixing and drying the gel 
7.2. 7 TPM2 8sk - 3'UTR SSCP on DNA from 
97 unrelated individuals 
7.2.8 TPM2 8sk- 3'UTR SSCP on DNA from 9 families 
to determine if polymorphism segregates in a 
Mendelian fashion 
7.2.9 Sequencing of the TPM2 polymorphism from 
exon 8sk.F- 3'UTR.R from band stabbing an 
acrylamide gel 
7 .2.10 Sequencing homozygous individuals for the TPM2 
115 
118 
119 
120 
121 
(8sk.F- 3'UTR.R) common and rare aUele 122 
7.2.11 Restriction digest of -250 bp TPM2 STS (8sk- 3'UTR) 
viii 
---- -- ---· ·- --· •...... · ,._ .. __ ,_ ,_ ·-· ··---------· -·--·-·-----·------~· ----···--- ··-· .. --. - ·--· ....... ··--
7.3 Results and Discussion 124 
7.3.1 Amplifying exons 1sk to 2sk in clonal DNA 
7.3.2 .'\mplifying exon 8sk to 3'UTR ofTPM2 123 
7.3.3 TPM2 exon 8sk- 3'UTR SSCP in 10 unrelated individuals 125 
7.3.4 TPM2 8sk- 3'UTR SSCP in 97 unrelated individuals 128 
7.3.5 TPM2 8sk- 3'UTR SSCP on DNA in 9 Families 
to determine if the polymorphism segregates 
in a Mendelim1 fashion 
7.3.6 Sequencing of the TPM2 polymorphism from exon 
8sk- 3'UTR from band stabbing an acrytamide gel 132 
7.3.7 Sequencing homozygous individuals for the TPM2 
(8sk ·· 3'UTR) common and rare allele 139 
7 .3.8 Restriction digest of 259 bp TPM2 STS (8sk - 3'UTR) 141 
Chapter 8: General Discussion 148 
8.1 Localised inherited muscle disorders 
8.2 Determining if the 259 bp TPM2 STS is a pseudogene 
8.3 Long range PCR STSs for use in FISH 
8.4 Linkage of the TPM2 Polymorphism 
8.5 Linkage results and CEPH mapping 
8.6 Finding a microsatellite close to the TPM2 gene 
8.7 Conclusion 
References 
Appendix 1 - Tropomysosin gene sequences 
Appendix 2 - Buffers and solutions 
Appendix 3 - TPM2 FISH localisation to 9p 13 - Accepted for publication 
by Cytogenetics and Cell Genetics 
IX 
149 
ISO 
!51 
154 
156 
157 
-- -------------·--------- ·-- --------·-·--- --·····-··- -----···· ............. --------· ... __ , ___ .. -------- ..... -_., ................... ---------·--- ... 
LIST OF TABLES 
Page No. 
1.1 Organisation of the tropomyosin gene 7 
2.1 Primer used for amplifying TPM2 19 
2.2 Primer combinations used to produce an STS 20 
2.3 TPM2 STS DNA concentrations on a spectrophotometer 47 
2.4 (A) Sequence ofTPM2 STS from primer DS 869 (exon 6 forward) 
compared to TPM2 and other TPMs 
(B) Sequence ofTPM2 STS from primer DS 869 (exon 6 forward) 
compared to TPM2 and other TPMs 
3.1 Cytogenetic analysis of NIGMS Human/Rodent Somatic Cell 
50 
51 
Mapping Panel 2 59 
5.1 Caesium chloride concentration step gradient 80 
5.2 EMBL3 SP6!f7clones DNA concentration on a spectrophotometer 98 
5.3 Sequence of clone 4 compared to TPM2 and otherTPM"s 104 
7 .I Sequence of TPM2 SSCP from band stabs 135 
7.2 Sequence ofTPM2 SSCP from homozygous alleles 136 
8.1 Markers and their recombination frequency with theTPM2 polymorphism 153 
LIST OF FIGURES 
1.1 Tropomyosin and its association with troponin 
1.2 Calcium ion regulation in muscle contraction 
1. 3 The exons and introns in TPM3 
I .4 Alternative splicing of the TPM3 gene 
2.1 The polymerase chain reaction 
2.2 DNA markers used 
2.3 Deoxy chain termination in sequencing 
2.4 Random primer labelling 
2.5 Southern blotting 
2.6 PEl strip test 
2.7 (A) TPM2 STS (1.5 kb) 
(B) TPM2 STS on low melting point agarose gel (LMPAG) 
(C) Purified TPM2 STS on 2% gel 
2.8 Sequence ofTPM2 1.5 kb STS from primer DS 869.6F 
(Exon 6 Forward) 
2.9 Sequence ofTPM2 1.5 kb STS from primer DS 866.8skR 
Page No. 
2 
3 
8 
9 
14 
24 
31 
35 
37 
40 
46 
48 
(Exon 8sk reverse) 49 
2.10 Radiolabelled 1.5 kb TPM2 STS used as a probe on a genomic blot 52 
X 
2.11 Distances of lambda Hind ill marker fragments from the well 53 
2.12 Graphic map of restriction sites in TPM2 exon sequence 
from Exons 6-8sk (eDNA) 212 bp 56 
3.1 1.5 kb TPM2 STS vs NIGMS Human Rodent Somatic Cell Hybrid 
Mapping Panel 2 by PCR 60 
4.1 Biotin-avidin Jetection systems 
for fluorescence in situ hybridisation (FISH) 63 
5.1 EMBL3, EMBIA & EMBL3 SP6m Vector Maps 67 
5.2 Screening a Phage Library 74 
5.3 CsCl concentration step gradients to purify bacteriophage A 81 
5.4 (r-32p) ATP Showing the rPhosphate Position 88 
5.5 1.5 kb TPM2 STS (exons 6-8sk) in EMBL3 SP6ff; genomic library 91 
5.6 Primary screening of the membrane plaque lifts 92 
5.7 Secondary screening of the membrane plaque lifts 93 
5.8 Kinase 5' end labelling of primers as probes on the 
secondary membrane plaque lifts 94 
5.9 PCR as1iay of DNA from clone eluates DNA 97 
5.10 Clones 2 and 4 DNA on a 0.8% agarose gel 
5.11 Restriction digests of clones 2 and 4 DNA 
to determine if they were the same clones 100 
5.12 1.5 kb TPM2 STS of clones 2 and 4 purified DNA 
5.13 Sequence of the TPM2 STS using clone 4 as lhe template DNA 103 
5.14 Radio labelled clone 4 DNA hybridised to a genomic blot 107 
6.1 Localisation of human skeletal P- tropomyosin (TPM2) to 9pl3.! 110 
7.1 Acrylamide gel electrophoresis 117 
7.2 
-250 bp TPM2 STS (exons 8sk- 3'UTR) from clones 2, 4 & 
human genomic DNA 126 
7.3 SSCP of DNA from 10 unrelated individuals from the -250 bp 
TPM2 STS (exon 8sk- 3'UTR) 127 
7.4 SSCP frequency- unrelated individuals 61- 103 129 
7.5 Segregation of polymorphic alleles in Family I 130 
7.6 Segregation of polymorphic alleles in Family 2 131 
7.7 Band stab gel of rare aliele from heterozygous individuals and 
common allele from homozygous individuals 133 
7.8 Band stab gel re-exposed to confinn exact alleles were stabbed 134 
xi 
7.9 Restriction sites for the 259 bp TPM2 STS sequence 
of the Common Allele 
7 .I 0 Restriction sites for the 259 hp T?M2 STS sequence 
of the Rare Allele 
7.11 Graphic map showing the restJ iction sites of the 259 bp TPM2 STS 
(A) The common allele has an extra restriction site (Bgl I) 
at base 88 
(B) The rare allele does not have the restriction site (Bgl I) 
at base 88 
7.12 Predicted restriction digest of 259 bp TPM2 STS (ex on Sck- 3'L1TR) 
polymorphism using Bgl I 
7.13 Restriction digest of 259 bp TPM2 STS (ex on Ssk - 3'UTR) 
polymorphism using Rg1 I 
8. I Genetic linkage sex-averaged map of chromosome 9 
3'UTR 
(u_32P)dCTP 
AB1 
ANRI 
bp 
BSA 
CCD 
eDNA 
CEPH 
cpm 
DAPI 
ddATP 
ddCTP 
ddGTP 
ddNTP 
ddTTP 
DNA 
dNTP's 
dsDNA 
ECLJ 
EMBL3SP6m 
LIST OF ABBREVIATIONS 
3 Prime Untranslated Region 
Radioactive isot0iJC of phosphorus in the alpha position in 
deoxycytu~·ine triphosphate 
Applied Biosystems Incorporated 
Australian Neuromuscular Research Institute 
Nucleotide Base Pairs 
Bovine Serum Albumin 
Charged Coupled Device 
Complementary Deoxyribonucleic Acid 
Centre d'Etude du Polymorphisme Humain 
Counts Per Minute 
4', 6~diamidino~2-phenylimdole 
Dideoxyadenine ~}'riphosphate 
Dideoxycytosine Triphosphate 
Dideoxyguanine Triphosphate 
Dideoxynucleotide Triphosphate 
Dideoxythymine Triphosphate 
Deoxyribonucleic Acid 
Deoxynucleotide Triphosphate 
Double Stranded Deoxyribonucleic Acid 
Edith Cowan University 
Vector for human genomic library 
xii 
143 
144 
145 
146 
147 
152 
--- ------------- ---·- ----·-----------·--···-~'-···~~--~·-"-....___"~'-
EtBr 
FISH 
hrs 
kb 
LMPAG 
min 
mRNA 
NHMRC 
PCR 
pfu 
PNK 
RNA 
rpm 
sk 
SSCA 
SSCP 
ssDNA 
STS 
Tr.:bule 
TPM 
TPM2 
uv 
v 
Ethldium Bromide 
Fluorescence ill situ hybridis~luuJl 
Hours 
DNA nucleotide kilobases 
Low Melting Point Agarose Gel 
Minutes 
Messenger Ribose Nucleic Acid 
National Health & Medical Research Council 
Polymerase Chain Reaction 
Plaque Fanning Units 
Polynucleotide Kinase End Labelling 
Ribose Nucleic Acid 
Revolutions per Minute 
Muscle Specific Exon only Spliced with Muscle Isofonns 
Single Stranded Conformation Analysis 
Single Stranded Conformation Polymorphism 
Single Stranded Deoxyribonucleic Acid 
Sequence Tagged Site 
Transverse tubule 
Tropomyosin 
Tropomyosin 2 gene 
Ultraviolet light 
Volts 
ERllATA 
Figure 7.2 on p. 126 should read -250 bp of the STS size, instead of 500 bp. 
xili 
" 
,, 
'I 
' 
CHAPTER 1 
INTRODlJCTION 
1.1 THE TROPOMYOSIN PROTEIN 
Tropomyosin (TPM) is an important component of the contractile unit in skeletal muscle, 
playing a pivotal role in regulating the interaction between actin and myosin filaments 
(Gunning, et al., 1990). Tropomyosins are rod-like, actin-binding proteins found in most 
muscle and nonmuscle tissues. In muscle, tropomyosin's structure is two alpha-helical 
chains (except for the extreme ends) wound around the long pitch grooves of the helical 
actin filament, in a coiled-coil structure, head to tail (see Figure 1.1) (Wolfe, 1993). 
Muscle tropomyosin is 284 amino acids long, spans seven actin monomers and makes 
seven half-turns per molecular length. In nonmuscle cells tropomyosins are associated 
with the actin-containing microfilaments of the cytoskeleton (MacLeod, et al., 1987). 
Certain non-muscle tropomyosins, the best studied being platelet, are shorter, only 247 
amino acids in length and have a length corresponding to six half-turns per molecule and 
six instead of seven actin monomers (Hitchcock-DeGregori & Varnell, 1990). Different 
isoforms of tropomyosin have been described, though a specific function for the protein 
is best defined in skeletal muscle (Cho, eta!., 1990; MacLeod & Gooding, 1988). 
1.2 TROPOMYOSIN'S ROLE IN MUSCLE CONTRACTION 
Striated muscle contraction is regulated by Ca2+ through the troponin-tropomyosin 
complex (see Figure 1.2). For muscJes at rest, tropomyosin nonnally blocks all the actin 
binding sites with myosin on the actin microfilaments. The troponin subunits Tnl and 
TnT normally bind to tropomyosin holding it in the myosin blocking position (a&c). 
When a nerve impulse causes a voltage change in a muscle cell plasma membrane, the 
I 
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FIGURE 1.1 
Tropomyosin and its Association with Troponin. 
(a) The coiled-coil structure of Tropomyosin 
(b) Sequence structure of striated and smooth forms of 
tropomyosin, showing the locations in which the amino acid sequence 
is conserved (C) and variable (V) among different tropomyosin types. 
Nonmuscle tropomyosins are shorter in length but have conserved 
segments at equivalent distances from the C-tenninal end. 
(c) The arrangement of tropomyosin and the TnC, Tnl and TnT subunits 
of troponin on striated muscle microfilaments. 
(After Wolfe, 1993) 
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v v v 
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Tnl TnC TnT 
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actin tropomyosin 
FIGURE 1.2 
Calcium Ion Regulation in Muscle Contraction 
The actin-linked control mechanism involving blockage by tropomyosin of 
the crossbridge binding sites on rnicrofilarnents, as seen in a cross section 
of a microfilament. 
(a) In the blocking position, tropomyosin covers binding sites for myosin 
crossbridges. 
(b) Movement of tropomyosin toward the microfilament groove exposes 
the myosin-binding sites and triggers the crossbridging cycle (c) and (d). 
(After Wolfe, 1993) 
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a- when low [Ca2+] 
tropomyosin blocks 
myosin-actin interaction 
ltopomyosin 
c - tropomyosin binds with 
Tnl and TnT, in blocking 
position, when low [Ca2+] 
actin 
movement 
inLO groove 
b- when high [Ca2+] 
tropomyosin moves into 
actin groove 
d - when released Ca2+ binds 
TnC, the tropomyosin and 
Tnl and TnT bonds break 
impulse travels via the transverse tubule (T tubule) to the sarcoplasmic reticulum and 
causes a release in Ca2+ from the Ca2+ -ATPase pump. The Ca2+ binds with the third 
troponin subunit, TnC, and it undergoes conformational changes and increases its affinity 
to Tnl and TnT, weakening the tropomyosin and Tn! and TnT bonds (b&d). 
Tropomyosin then moves towards the actin microfilament groove exposing the myosin 
binding sites, allowing a series of processes so the muscle contracts (Borovikov, et al., 
1993; MacLeod & Gooding, 1988; Wolfe, 1993). 
Hitchcock-DeGregori and Varnelli, (1990) have experimentally shown that muscle 
tropomyosin has periodic binding sites with actin in two sets of seven sites. This 
corresponds to the seven actin monomers it spans and the two states it exists in, ie. either 
muscle contraction or rest. One set of seven sites function in actin binding and both sets 
of seven function in the calcium regulation via troponin of muscle contraction (Hitchcock-
DeGregori & Varnell, !990). 
1.3 THE TROPOMYOSIN GENES AND ALTERNATIVE SPLICING OF 
DIFFERENT ISOFORMS 
There are at least four separate, non overlapping tropomyosin genes, that encode at least 
six different isoforms of tropomyosin in muscle and non-muscle human fibroblasts (see 
Table I) (Clayton, eta!., !988; Gunning, eta!., 1990). Three of the four tropomyosin 
genes have been sequenced from expressed mRNA encoding the human skeletal muscle 
isoforms, TPMI (MacLeod & Gooding, 1988), TPM2 (Widada, eta!., !988), TPM3 
(MacLeod, eta!., 1986; Reinach & Macleod, 1986). TPM4 was sequenced from a 248 
amino acid eDNA, cytoskeletal nonmuscle isoform (MacLeod, et al., 1987). Isofonns are 
different expressions of a tropomyosin gene. Each tropomyosin gene encodes different 
isoforms in the. different types of muscle. 
There are basically two types of muscle, striated and smooth muscle. Striated muscle 
consists of three major types, fast (psoas-glycolitic fast or gastrocenemius-·oxidative 
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fast), slow (soleus) and cardiac muscle. There are two subtypes of cardiac muscle, atrial 
and ventricle muscle (Gunning, et al., 1990; Wolfe, 1993). This accounts for the six 
different possible isoforms produced by the tropomyosin genes ie. (1. fast, 2. slow, 3. 
atrial, 4. ventricle, 5. smooth, 6. non-muscle). The expression ofTPMl, 2, and 3 is well 
defined in mammalian muscle fibroblasts. There is little data on the expression of TPM4 
in muscle e:otcept for the detection of muscle-like exons in the human gene and the 
observation of a different sized transcript in total rat skeletal muscle. In contrast, non-
muscle isoforms are poorly defined (see Table l.l for a summary of the TPM isoforms) 
(Gunning, et al., 1990; Libri, et al., 1990). 
Eukaryotic genes consist of exons and introns, while prokaryotic genes have no introns. 
The exons are the regions of the gene that are transcribed to produce mature mRNA and 
usually contain coding information for protein translation. Introns are regions in between 
the exons that are not translated to produce a protein product. The gene is transcribed by 
the protein RNA polymerase into mRNA or the complementary sequence of the gene 
strand transcribed. The mRNA strand sequence is then spliced so the introns are removed 
and the mature mRNA is translated into a protein by ribosomes (Gelehrter & Collins, 
1990; Micklos & Freyer, 1990; Wolfe, 1993). 
The TPM isoforms in the different types of muscle and non muscle are produced by 
differential RNA splicing of the genes. This means the gene has the same number of 
exons or protein coding regions, but when the whole gene is transcribed, the mRNA is 
spliced alternatively into different messenger RNA (mRNA) fragments, which are then 
translated into the different protein isoforms. TPM3 consists of thirteen exons and the 
gene is around 42 kb long (see Figures 1.3 & 1.4) . Five exons are common to muscle 
and non-muscle cells, while three are unique to non-muscle cells (Clayton, et al., 1988; 
Gunning, et al., 1990; MacLeod & Gooding, 1988; MacLeod, et al., 1987). Alternative 
splicing occurs at three distinct points in the gene family, as seen on Figure 1.4. It is 
suggested the other TPMs have a similar gene structure with alternative splicing 
producing the different isoforms. In particular, TPM2's alternative splicing only occurs 
5 
on exons 6 and 9, while exon 2 does not undergo alternative splicing (Widada, et al., 
1988). Two groups of tropomyosin isofonns have been described: there are 284 amino 
acids present in muscle and non-muscle isoforms and there are 248 amino acids that are 
unique to non-muscle cells (see Table I) (Clayton, eta!., !988; Gunning, eta!., 1990; 
MacLeod & Gooding, 1988; MacLeod, eta!., 1987; Novy, eta!., 1993; Ruiz-Opazo & 
Nadal-Ginard, 1987; Ruiz-Opazo, el a!., 1985). 
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Table 1.1 
Organisation Of The Human Tropomyosin Gene 
GENE AMINO ACIDS 
TPM1 284 
Chrom. 15 284 
(Eyre, et al., 1994) 284 
TPM2 284 
284 
TPM3 284 
Chrom. 1 248 
(Wilton, et al., 1995) 
TPM4* 
19? 
(Laing, 1994b) 
248 
285? 
ISO FORMS 
(i) a-Tmf (fast twitch muscle} 
(ii) Tm2 (non-muscle) 
(iti) Tm3 (non-muscle) 
(iv) ~-Tm (striated muscle) 
(v) Tm1 (non-muscle) 
(vi) a-Tms (slow twitch muscle) 
(vii) Tm5 (non-muscle) 
(viii) Tm4 (non-muscle) 
(ix) Has the potential to encode a 
muscleTm 
*(Tropomyosin 4 may be different in the number of exons and the splicing pattern) 
(Gunning, et al., 1990; Libri, et al., 1990) 
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FIGURE 1.3 
The Exons and Introns in TPM3. 
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Vll-70bp 
lkb 4kb l Okb 
42kb 
(After Clayton et al., 1988) 
FIGURE 1.4 
Alternative SplicinR of the TPM3 Gene 
The gene consists of 13 exons, only five of which (open) are common to 
both isoforms. The remaining exons are alternatively spliced to produce the 
sL .. d muscle and non-muscle isofonns. Alternative splicing occurs at 3 
distinct points in the gene and on a mutually exclusive basis. The 3' 
untranslated region is indicated as 3'UTR (After Clayton eta!., 1988). 
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1.4 SIGNIFICANCE OF LOCALISING TPM2 
There are many inheritecl muscular diseases which have been localised in the genome by 
linkage analysis, but for wt.ich no disease-causing mutation in a gene has been found. 
Each muscle-specific gene is possibly associated with an inherited muscle disease. 
Precise mapping and localisation of muscle genes in the human genome, therefore 
becomes important in relation to mapping inherited muscle diseases (Eyre, et al., 1993). 
The alpha-tropomyosin gene TPM I has recently been localised to 15q22 (Eyre, et a!., 
1994) and has been shown to be mutated in some cases of familial hypertrophic 
cardiomyopathy (Thierfelder, eta!., 1994). The alpha-tropomyosin gene TPM3 has been 
recently localised to lq22-q23 (Wilton, et al.,!995) and has been shown to be mutated in 
a family with autosomal dominant nemaline myopathy (Laing, eta!., 1994). 
Mapping muscle geues may also have implications for developing diagnostic tests for 
these diseases, especially prenatal tests and genetic counselling for people affected 
(Akkari, et al., 1994). By localising TPM2 it also lays a foundation for better 
understanding the role of tropomyosins in muscle and non-muscle tissues. 
The contex~ of this project in collaboration with the Australian Neuromuscular :!{esearch 
Institute (ANRI) was to localise TPM2, a possible candidate gene for the inherited mu~cle 
disease, autosomal dominant nemaline myopathy. While this project was being carried 
out, it was found that a point mutation in TPM3 caused one form of autosomal dominant 
nemaline myopathy in a Western Australian family (Laing, eta!., 1994). Yet it is still 
important to map TPM2, as it may be a candidate gene for other muscle diseases, 
including other nemaline myopathies. 
!0 
1.5 PROJECT OUTLINE 
There we-re six major components of the project: 
1. To produce a sequence tagged site (STS) that is unique to only the TPM2 
gene. 
2. To physically map the human skeletal TPM2 gene by initially using this STS in 
a somatic cell hybrid panel. 
3. To refine the mapping by using the STS in FISH to human metaphase 
chromosome spreads, or if 3 does not work, to: 
4. Use the STS as a probe to isolate pure genomic clones from a genomic library, 
for use in FISH of human metaphase chromosome spreads, to physically map 
the location of the TPM2 gene more precisely. 
5. To identify a polymorphism in the TPM2 gene, so it could be used in linkage 
studies and entered on the CEPH map. 
II 
CHAPTER 2 
DEVELOPMENT OF AN STS FOR HUMAN SKELETAL 
MUSCLE ~-TROPOMYOSIN (TPM2) 
2.1 INTRODUCTION 
The aim of developing a specific STS for human skeletal P-tropomyosin (TPM2) was to 
use it on a somatic cell hybrid panel, for use in FISH directly, or as a probe to isolate a 
larger genomic clone from a library that contains all or part of the TPM2 gene, for use in 
FISH. 
2.1.1 The Polymerase Chain Reaction 
The polymerase chain reaction (PCR) is a fairly recent development in molecular biology 
that amplifies a short sequence of DNA around a billion times between two primers 
(Mullis, et al., 1986). The standard PCR can amplify a product up to approximately 6 kb 
and from less than picograms (lQ-l2g) amounts of specific DNA, to around microgram 
(IQ-6g) amounts, which can then be easily measured by agarose gel electrophoresis. The 
primers are chemically synthesised oligonucleotides, 20-35 nucleotides long with a free 
hydroxyl group present on the 3' end of the primer. The 3' end of a DNA strand, is 
where the ribose sugar tenninates the alternate phosphate-sugar DNA backbone. The 
opposite 5' end of the strand terminates with a phosphate group, except that primers are 
synthesised with the 5' end dephosphorylated (Wilton, 1993). 
If a primer is 20 nucleotides long with a random sequence, then because there are four 
nucleotides possible at each site, the chance that a primer will have the same sequence in 
two places in the genome is (1/4)20 x (1/4)20 or lxJ0-26, Because there are 3x109 bases 
in the genome, then a 20mer primer should usually have more than enough sequence to 
be unique in the genome, by a factor of JOl7. The specific amplified PCR product is 
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referred to as a STS as the primers and the sequence amplified between them is unique 
(Olson, eta!., 1989). 
The reaction takes place by heating the target DNA which denatures the strands. The 
reaction is ihen cooled and the primers which are present in high concentration anneal to 
their complementary sequence. A polymerase enzyme attaches to the 3' hydroxyl group 
of the primer and extends along the target sequence adding complementary nucleotides 
present in the reaction mixture to make the template double stranded. DNA synthesis 
proceeds in the 5' to 3' direction (see Figure 2.1). The polymerase does this about one 
thousand bases per minute. The particular polymerase enzyme, is derived from a bacteria 
(Thermus aquaticus) found in hot springs, so it can withstand high temperatures. The 
second primer is designed to anneal to the complementary strand of the first primer and 
its hydroxyl group is also on the 3' end of the primer. In this way the polymerase extends 
the template between the two primers. With alternate heating and cooling the template 
DNA is continually denatured and extended and therefore is multiplied in an exponential 
fashion, with the new product acting as a template for the next. The polymerase will 
extend past the other primer but in an arithmetic fashion, while the template between the 
primers will increase in an exponential fashion, so most of producl DNA is of a defined 
length and can bt. measured by gel electrophoresis. After 30 cycles, taldng about five 
minutes each, the target DNA between the primers is increased a billion fold in a small 
10-100 ~L eppendorf tube. The reaction efficiency is reduced after about 40 cycles, 
unless new enzyme and primers are added (Doggett, 1994; Gelehrter & Collins, 1990; 
Saiki, 1990; Wilton, 1993). 
2.1.2 Primer Selection and Criteria 
The exon sequence of TPM2 had already been determined (Widada, et al., 1988). 
Widada ru1d his colleagues achieved this by obtaining transcribed mRNA of TPM2 in 
muscle tissue and using th~ ~nzyme reverse transcriptase to produce a complementary 
strand of DNA or eDNA copy of the TPM2 gene. They produced a complete eDNA 
13 
, 
I 
:\ 
--~ 
····-----------··--------- ·- -----·-·-- .. ··-··---- -----·- -------- "--·--·~---·---------------------
FIGURE 2.1 
The Polymerase Chain Reaction (After Doggett, 1994 ). 
14 
Reaction miXIure includes DNA 
sample; two single-stranded 
primers, each with a 20-base 
sequence comple'mentary to the 3' 
end of one strand of the target 
sequence; heat stable Taq 
polymerase: and deoxyribo-
nucleoslde tliphosphates (dNTPs). 
Phase 1 
Denature unamplified DNA at gs~c 
to form single-stranded templates. 
Phase 2 
Anneal primers to template at about 
so~c. 
Phase 3 
Synthesize new strands at 72"C. 
Phases 1 and 2 
Denature products of Cycle 1 and 
anneal primers to template strands. 
Phase 3 
Synthesize new strands. 
Phases 1 and 2 
Denature products of Cycle 2 and 
anneal primers to template strands. 
Phase 3 
Synthesize new strands. 
l r~qPoly ~1\{(\el f>. -<,_'?. Prime dOjp lllerilsa s·~ dGTp b~ s.....:,.e 6 ,_,~ 
s ~ 3' lliilllilllilllllllillll!lliliiiiillllilliilllllllillilllli!fiii!DIIiiillllllill s· 
4 Target SC!qUenco i 
I 
CYCLE 1 
Unamplified DNA 
(Hydrog<!n bonds bctwoon the 1wc DNA 
s1ronds am shCIWI1 as vertlcallin.as) 
5' ------'-'--='-'------- 3' 
} Template strands 
~ s 
5' -----===:------;:l!lllll!lllls7- 3' --~5~·mnmn~3~· -~--3~·::::~5• __ • • 
5
'_ 
1 
il!!i!!!!\!!Blli!!!!!l!!i!ll!\\!\til!\\\!!ll\!l!!l!!!!li!l! s 3' 
3. _ 5' i!iliiliiilill!iijllllljllljiljjlljlijilllljli!lijjljjjllljlj I 7 
CYCLE2 5'3~~ 5' 5' 5' 
s s 
. I 
5 II !II aD i 1!11111111 ii 111111111!11 IIIII illllili!lli!i Ill!!! ill II Ill s 
5' 
Each primer binds to its 
complementary sequence at 
the 3' end of a strand of the 
target sequence. 
Each new strand is 
synthesized in the 5'-to-3' 
direction. 
5' milhllili!!IW.dlllli!illiliitllliU!!!!!!!''!! 5• ~ 
5. . First two template strands that 
·@II II II I I ll!llijj II Ill! Ill Ill! II 1111 II II! I ill! ill 5. span the target sequence only 
5' 
5
' i!ililllilili!iiilillllllll!lll!!ijjlll!llllllii!llillllj!il!ll!!l 5' 
5
' mrrrmrrr 
5' 
5' 
5' 
5' 
5' 
5' 
I 
CYCLE3 
111!1!1111!1 5' 
5' 
5' 
5' 
5' 
5' 
5
' liilllliiililillililili!lllllllilillllliltliili!lilllllil!ll!l!![[ 5' 
5
' lliiijjll!illliilllllillllliili!lljjil!lllll!ll!!!!l 5' --
5' iiljjiiiliililj!!lllllllliljl!!lllillll!ll!!!!lll!!i 5' ===~ 
5' !liilliiiill!iiiiljlllliii!l!jiiiii!llil!lll!!ll!!l! 5' -
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Eight template strands that 
span the target sequence only 
Continue for 20 to 30 cycles to produce over 106 copies of target sequence. 
sequence of the adult skeletal isofonn of human skeletal muscle P-tropomyosin, or 
TPM2. Likewise, the exon sequence of TPM 1 (MacLeod & Gooding, 1988), TPM3 
(Clayton, et al., 1988) and TPM4 (MacLeod, et al., 1987) have been determined. Using 
the TPM2 sequence, primers can be selected and synthesised for use in the polymerase 
chain reaction (PCR), to amplify a segment of the TPM2 gene. 
Primers must be specific for amplifying a segment of the human skeletal muscle TPM2 
gene, so no other non-muscle TPM2 isoforms or pseudogenes are amplified. Primers 
were synthesised that had the following criteria: 
2.1.2.1 Primer sequence unique from other TPM genes 
The primers must be designed to have a unique sequence that is different from the other 
three tropomyosin genes, so the other genes are not mistakenly amplified. 
2.1.2.2 Primer sequence unique to muscle TPM2 isoform to avoid 
amplifying pseudogenes 
A primer that includes specific skeletal muscle exon sequence that is spliced with the 
human skeletal TPM2 gene, will ensure that no nonmuscle TPM2 isoforms are amplified 
and that the STS is muscle specific (Clayton, et al., 1988; Widada, et al., 1988). This 
will also avoid amplifying pseudogenes. 
Pseudogenes are DNA sequences that have the structure of expressed genes and were, 
presumably, once functional, but have acquired one or more mutations during evolution 
that render them incapable of producing a functional protein product. There are two major 
classes of pseudo genes (Singer & Berg, 1991). 
The f.~st class of pseudogenes can be silent, or they may be transcribed and even 
translated into aberrant polypeptides. They are often found closely linked to the 
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corresponding functional gene and may be flanked by sequences homologous to those 
that flank the corresponding functional gene. Such pseudogenes usually contain introns 
and appear to be the result of tandem duplications of DNA segments (Singer & Berg, 
199 I). An example of these types of pseudogenes are those found in the a and p-globin 
gene clusters (Gelehrter & Collins, 1990). Most gene families or clusters have members 
that are pseudogenes that usually represent a small minority of the total gene number 
(Lewin, 1994). Usually these types of pseudo genes do not affect the localisation of a 
gene, because they are so close to the real gene and FISH mapping is broad scale, 
local ising a gene to a chromosomal band. On metaphase spreads, FISH resolution is 10~ 
20 million bp, or to a chromosomal band, which is 0.3~0.6% of the genome, or 
approximately 8~ 16% of an average chromosome (Davies & Read, 1992). So if this type 
of pseudogene was mistakenly amplified and used as a probe for FISH, it would usually 
not affect the mapping location of the real gene. 
There is another class of pseudogenes, called processed pseudogenes which have a 
similar sequence to the real gene, except only the exon sequence of the gene is conserved 
like a eDNA copy (ie. there are no introns and no protein product is produced). They are 
not generally linked to the corresponding functional gene but are dispersed throughout the 
genome, even to different chromosomes (Lewin, 1994; Singer & Berg, 1991). A theory 
for the presence of this type of pseudo gene is that they were expressed mRNA that has 
been reverse transcribed back into DNA by the enzyme reverse transcriptase, which is 
present in retroviruses and reinserted in the genome. Since they may occur in other parts 
of the genome it is important that they are net mistakenly amplified or this will interfere 
with loca!ising the TPM2 gene (Gelehrter & Collins, !990; Singer & Berg, 1991). To 
detect this class of pseudogenes, primers ~an be used to amplify from genomic DNA, 
which includes the exons and introns and this can be compared using the same primers 
on eDNA, which only includes exon sequence. Any pseudogenes amplified would be 
smaller than the expected STS as they don't include the introns and their size can be 
predicted from the eDNA sequence. A pseudogene could then be detected by agarose 
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electrophoresis since their products would be smaller and migrate faster than the genomic 
STS (Eyre, et al., 1994; MacLeod & Gooding, 1988). 
For processed pseudogenes to be inherited, they had to be mRNA that was reverse 
transcribed in the germ line cells, or in the cells that gave rise to genn cells. Usually, it is 
only transcribed general metabolic genes that produce this class of pseudogenes. Because 
muscle genes are not expressed in genn line cells, then there are likely to be no muscle-
specific TPM2 exons present as pseudogenes. Therefore, primers synthesised from 
unique muscle specific exon sequence, should exclude amplifying processed 
pseudogenes. However, the non-muscle TPM2 isoforms are likely to produce 
pseudogenes as they are present in germ line cells. Clayton et al. (1988) found at least 
seven non-allelic TPM3 pseudogene sequences in the human genome, all derived from 
the nonrnuscle isoform Tm5 (see Table 1). No such pseudogene sequences were found 
being derived from the TPM3 muscle specific exons. Therefore, by including a primer in 
a muscle-specific exon, specific to human skeletal muscle TPM2 and not the nonmuscle 
isofonns, excludes the chance of localising a pseudo gene (Eyre, et al., 1994; Singer & 
Berg, 1991). 
2.1.2.3 STS to include intronic sequence 
If one primer is located in one exon and the other primer in another exon so intronic 
sequence is included, that will make the STS unique to TPM2. Intronic sequence is less 
conserved over evolutionary time than the exon sequence, as introns are not essential to 
protein synthesis and have little selection pressure at the phenotypic level (Lewis, 1994). 
This means the intron sequence in the STS will make it more unique than just having 
exon sequence alone. Ideally the primers should be designed to have intron sequence, but 
because the intron sequence was not known, only exon sequence could be used. By 
having intronic sequence in the STS, when it is used as a probe, excludes the possibility 
of isolating processed pseuc!ogenes in a genomic library and localising processed 
pseudogenes for FISH (Eyre, et al., 1994). 
2.1.2.4 Primer's GC ratio 
The guanine and cytosine ratio of the primers (GC ratio) should ideally be 50:50 with the 
adenine and thymine ratio (AT ratio). This is because guanine and cytosine form three 
hydrogen bonds in double stranded DNA, while adenine and thymine form two hydrogen 
bonds (Freifelder, 1987). If the GC ratio is higher than the AT ratio then the primer will 
anneal at a higher temperature because there are more hydrogen bonds. If the AT ratio is 
higher then a lower annealing temperature is required, as there would be less hydrogen 
bonds. The GC ratio should be noted so the cycling conditions can be altered accordingly 
(Wilton, 1993). 
2.1.2.5 Secondary and tertiary primer structures 
The primers should be designed to avoid internal secondary and tertiary structures so they 
don't fold upon themselves and inhibit the PCR reaction (Wilton, 1993). 
2.1.2.6 Primer complementarity 
The primers should be designed to avoid complementarity between them otherwise they 
will bind to each other and not the target DNA, which is called a primer dimer (Wilton, 
1993). 
Once a human skeletal muscle specific TPM2 STS has been produced, it can be used on a 
somatic cell hybrid panel to localise the TPM2 gene to a chromosome, or part of a 
chromosome. An STS produced that is larger than I kb can be used directly in FISH for 
more precise mapping. If it is smaller than 1 kb, or it does not work in FISH, then the 
STS can be used to isolate a larger clone from a human genomic library (Akkari, et al., 
1994). 
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2.2 MATERIALS AND METHODS 
2.2.1 Primer Selection 
The sequence of TPM2 is given in Appendix 1, from which the primers were selected 
and chemically synthesised, by ANRI. 
Table 2.1 
Primers Used F'or Amplifying TPM2 
Sequence 5'~ 3' Primer No. Ex on 
AACGCCATCGACCGCGCCGAG DS 840.1skF I (Skeletal muscle-specific) 
Forward 
AAGTATTCTGAATCCGTGAAG DS 841.2skR 2 ("Muscle-specific) Reverse 
TTGAAATCCCTGGAGGCCCAG DS 752.5skF 5 ("Muscle-specific) Forward 
ATTCCACCAAAGAAGATAAA DS 869.6F 6 (Forward) 
GCTGAGACCCGAGCAGAGTT DS 868.7F 7 (Forward) 
GAAAACCATCGATGACCTAGAA DS 753.7R 7 (Reverse) 
AAGTCTATGCCCAGAAGATG DS 870.8skF 8 ("Muscle-specific) Forward 
AGTTACTGTAGTGGAGGGAG DS 866.8skR 8 (" Muscle-specific) Reverse 
CCGTGACCGAAGTAGGAAAT DS867. 3'UTR.R 3'UTR (Reverse) 
A combination of these primers (see Table 2.1) were used in a PCR reaction on genomic 
DNA to see if a TPM2 STS was produced. The combination of primers was selected 
according to the criteria listed in the introduction (2.1.2). The expected STS size (see 
Tab!e 2.2) was deduced from the structure of the TPM3 gene in Figure 1.3. 
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Table 2.2 
Primer Combinations Used To Produce An STS 
Primers Expected STS Size lkb) 
lskF (DS 840) · 2skR (DS 841) -0.2 
SskF (DS 752) -7R (DS 753) -1.0 
SskF (DS 752) - 8skR (DS 866) -2.0 
SskF (DS 752)- 3'UTR.R (DS 867) -2.2 
6F (DS 869) - 8skR (DS 866) -1.4 
6F (DS 869)- 3'UTR.R (DS 867) -1.5 
7F (DS 868) - 3'UTR.R (DS 867) -1.0 
8skF (DS 870)- 3'UTR.R (DS 867) 259 bp 
2.2.2 TPM2 PCR Conditions 
For a 25 flL Reaction:- Final Cone. 
Target Genomic DNA (50 ng) 5.0 f!L 2 ng/f!L 
5X 2200 Buffer (buffer, nucleotides and MgCI2) 5.0 flL 2 mM, 200f1M 
(5X Ttlz buffer, 10 mM MgCh, I mM dNTP's) 
Tth DNA polymerase (!liotech) (5.5 units/mL) O.lf!L 0.2~ u/f!L 
Primer mix (10 ng/f!L of each primer) 2.0 f!L 0.8 ng/flL 
H20 to 25 f1L 12.9 uL 
TOTAL 25.o uL 
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2.2.2.1 PCR cycling conditions: 2 step on automatic thermal cycler 
Two thermal cyclers were used throughout the project for PCR reactions. The MJ 
Research MinicyclerTM (Bresatec) required the additicn of paraffin oil to the reactions to 
prevent evaporation during cycling. The other cycler was the MJ Research PTC-100 
Programmable Thennal Controller (Bresatec), which had a hot bonnet, so the addition of 
paraffin to the reactions was not necessary. 
time 
temp 94°C 5 min 30 sec (denaturing) 
58°C 6 min (annealing and extension) 
# cycles xi x35 
4°C indefinitely 
2.2.3 Agarose Gel Electrophoresis 
Agarose gel electrophoresis separates a wide range of DNA fragments depending on the 
agarose concentrations. 
0.7% agarose 
1.0% agarose 
2.0% agarose 
3.0% agarose 
10 to 0.8 kb 
6 to 0.4 kb 
4 to 0.2 kb 
2 to 0.1 kb (Wilton, 1993) 
Because the PCR STS was 1.5 kb, a 2% agarose gel was chosen. 4 ~L of PCR product 
was run with 1 ~L 5X agarose loading buffer on 2% agarose gel, in IX TAE buffer, at 
IOOV, for 45 min (see Appendix 2 for buffers used). The Biorad 3000Xi power pack 
was most often used, with Biorad agarose gel buffer tanks, gel trays and combs, though 
other power packs and gel trays were used. 
21 
2.2.4 Staining Agarose Gels 
The gel was then stained in 0.5 Jlg/mL of ethidium bromide for 10 min to observe the 
DNA bands on a ultraviolet (UV) light, 305 nm transilluminator (Fotodyne Inc.). The 
ethidium bromide interchelates between the G:C bases of DNA and becomes associ:~~ed 
with the DNA bands in the geL The DNA absorbs the UV light and transfers this energy 
to the ethidiurn bromide and emits light in the red-orange region of the visible spectrum 
(Wilton, 1993). The gel was photographed using a mounted Polaroid CU-5 Land Camera 
(focal length 127 mm) at maximum aperture (4.7) for 0.25 sec. The black and white film 
used was Polaroid Type 667. 
2.2.5 DNA markers 
To determine the size of the DNA fragments in agarose gel electrophoresis, DNA markers 
of known sizes are run with the PCR products. Four markers were used in this project 
for agarose gel electrophoresis. Lambda (A) bacteriophage when cut with the restriction 
enzyme Hind III provided a high molecular weight marker and when cut with Pst I 
provided high to medium weight markers. The plasmid pUC 19 cut with the restriction 
enzyme Hpa ll and pGEM® (Promega) produce low molecular weighl markers. 
2.2.5.1 Lambda bacteriophage cut with Hind III 
For a 50 lJ.L Reaction 
lOX Buffer B (Promega) 
Acetylated BSA (I mg/mL) 
Spermidine (0.1 M) 
A. Phage (400 ng/~LL) (Promega) 
Hind III (12 uii!L) 
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5!lL 
5!lL 
0.8 IlL 
38.21!L 
ii'L 
2.2.5.2 Lambda bacteriophage cut with Pst I 
For a 50 JlL Reaction 
lOX Buffer H (Promega) 
Acetylated BSA (I mg!mL) 
Spermidine (O.IM) 
A, Phage ( 400 ngii!L) (Promega) 
Pst I (12 uii!L) 
2.2.5.3 pUC 19 cut with Hpa II 
For a 50 JlL Reaction 
lOX Buffer A (Prornega) 
Acetylated BSA (lrng!mL) 
Spermidine (O.IM) 
pUC 19 (500 ng/f!L) (Promega) 
Hpa II (12 u/I!L) 
5 f!L 
5 f!L 
0.8 f!L 
38.2 f!L 
I f!L 
5 f!L 
5 f!L 
0.8 f!L 
38.2 f!L 
I f!L 
(Promega. 1991) 
Note, enzymes have specific pH, temperature and ionic requirements, hence the lOX 
buffer which contains Na+ and Mg2+ ions, Tris-HCI as a pH buffer and diothiothreitol. 
The acetylated bovine serum albumim (BSA) is a source of neutral protein to add to 
enzyme reactions. Enzymes in a reaction containing less than 0.1 mg/mL protein, rapidly 
denature in dilute reactions. BSA should be used at a final concentration of 0.1 mg/mL 
(Sambrook, et al., 1989). 
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FIGURE 2.2 
DNA Molecular Weight Markers Used 
DNA Source Restriction Enzymes 
(A) A. DNA Pstl 
(B) A. DNA Hind Ill 
(C) pUC 19 HpaiT 
(D)pGEMI Hinf I, R.w 1, Sin I 
l(Promega, 1993/94) 
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(A) Lambda cut with Psi I (C) pUC 19 cut with H pa II 
= ~2! bp 
11 SOl bases 404 
4749/4709 331 
2556 2459 2443 
-
2838 242 2140 1986 190 1780 
147 
l(l'J3 
-
1159 111/110 
805 67 
= 34/26 
468 
-
514 
448 
339 
247 264 
-
(B) Lambda cut wit~ ~:ind III (D) pGEM 
23 kb 2645 bp 
9.4 1605 
6.6 1198 
4.4 
2.3 676 
2.0 
517 
460 
560bp 
396 
- 350 
222 
-
lOObp 179 
126 
75 
65/51 
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The restriction digest reactants were mixed lightly in a 0.6 mL eppendorf and incubated at 
370C for l hour to allow the enzyme digestions to take place. One unit of restriction 
enzyme activity is defined as the amount of enzyme required to produce a complete digest 
of one microgram of substrate DNA (or fragments) in 60 minutes at the appropriate assay 
temperature in a 50 ~L reaction volume (Promega, 1993/94). Therefore, I ~of each 
restriction enzyme was more than enough to ensure complete digestion. The tubes were 
then heated to 950C for 5 min to denature and deactivate the enzymes. Each restriction 
digest was then added to 50 ~L of Ficoll IX loading buffer. Usually 3 ~L of a marker 
was loaded in a well for agarose electrophoresis, or was determined empirically. Note 
that pOEM marker was supplied by Promega. 
2.2.6 Purifying the TPM2 PCR STS DNA 
Once a TPM2 PCR STS had been developed, it had to be confirmed that the STS was 
from the TPM2 gene. The most precise method for doing this was to sequence the STS. 
Before this could be done, the PCR product had to be purified for sequencing. This 
involved running the PCR product on a low melting point agarose gel (LMPAG) (Biorad) 
and cutting the DNA band out. The DNA in the agarose was then purified in a resin 
column (Wizard1M PCR Preps Purification System- Promega). The purified DNA was 
re-run on a gel and the absorbance of the purified DNA was checked to measure the DNA 
concentration, before the template was used for sequencing. 
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2.2.6.1 Low melting point ag3rose gel (LMPAG) 
The TPM2 PCR STS is firstly amplified in a 50 IlL reaction to produce sufficient 
template. 
For a 50 uL Reaction:- Final Cone. 
Target Genomic DNA (50 ng) 5.0 11L I ng/I!L 
5X 2200 Buffer (buffer, nucleotides and MgCI2) 10.0 IlL 2 mM,200 11M 
(5X Tth buffer, 10 mM MgCiz, I mM dNTP's) 
Tth DNA polymerase (Biotech) (5.5 units/mL) 0.2 11L 0.22 uii'L 
Primer mix (I 0 ngii!L of each primer) 4.0 11L 0.8 ngii!L 
H20 to 251!L .l1.2..J.tL 
TOTAL 50.0 IlL 
The cycling conditions were the same as those used in 2.2.2.1. 
The amplification was run first on a nonnal 2% agarose gel to see if it had worked, as 
LMPAG is very expensive. 3 ~L ofPCR product was run with 0.6 J.LL 5X Ficoll agarose 
loading buffer on a 2% agarose gel, in IX TAE buffer, at lOOV, for45 min. The gel was 
stained in ethidium bromide for 10 min and photographed. 5 J.LL of 5X Ficollloading 
buffer was added to the rest of the reaction (47 J.LL) and run on a thickly poured ( -1 em) 
2% LMPAG (Bio-Rad), as for a normal2% agarose gel (2.2.3). 
The LMPAG was then stained with 0.5 l!gimL ethidium bromide for 10 min and the 
DNA bands were observed on the UV transilluminator. The bands were cut out using a 
clean sterile scalpel b.iade as quickly as possible, because the UV light can nick the DNA 
strands. The band was isolated in about 300 IlL of agarose. 
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2.2.6.2 Purification of DNA using Wizard™ PCR Preps DNA 
Purification System (Promega) 
The Wizard™ PCR Preps System (Promega) purifies double-stranded DNA from 
contaminants such as primer-dimers and amplification primers, unincorporated 
nucleotides and enzymes (Promega, 1993). 
For each PCR product:-
I. The DNA band was excised quickly (to avoid nicking the DNA) from the gel and 
placed into a 1.5 mL centrifuge tube. 
2. The tube was heated at 700C until the agarose completely melted. 
3. I mL of Magic PCR Preps Resin was added to the melted agarose and 
vortexed for 20 sec to mix. 
4. The minicolumn was placed on the end of a 3 mL syringe barrel, by the luer-lock 
extension of the minicolumn. 
5. The plunger was removed and the resin/DNA mix was pi petted into the syringe 
barrel. 
6. The syringe plunger was inserted slowly and the slurry was pushed through the 
minicolurnn and into a 1.5 mL centrifuge tube. 
7. The syringe was removed from the minicolurnn and then the plunger was 
removed from the syringe. 
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8. The syringe barrel was reattached to the minicolumn and 2 rnL of 80% isopropyl 
alcohol was pipetted into the syringe barrel to wash the column. The plunger was 
inserted and the isopropyl alcohol was pushed through the minicolumn. 
9. The minicolumn was removed and placed on a 1.5 mL centrifuge tube and 
centrifuged at 12 000 xg, to dry the resin. 
10. The minicolumn was transferred to a new 1.5 mL tube and 50 )lL of HzO was 
added to the minicolumn for approximately 1 minute (the DNA would remain 
intact on the minicolumn for up to 30 minutes). 
11. The minicolumn and tube were centrifuged for 20 seconds at 12 000 xg, to elute 
the DNA into the tube. 
12. The minicolumns and all old 1.5 mL tubes were discarded. 
13. The sample was kept at 4°C or -zooc. 
14. 2 J.LL of the Wizard prep sample was run on a 2% agarose gel with a marker to see 
the recovery of the product. 
(Promega, 1993) 
2.2.7 Measuring the absorbance of nucleic acids on a spectrophotometer 
The absorbance of the purified DNA was measured on a Beckman DU 650 
spectrophotometer and the concentration of DNA was calculated. 
Aa absorbance of 1 at 260 nm lA260 for double stranded DNA (dsDNA) is 50 ng/~ 
" " lA260 for single stranded DNA (ssDNA) is 33 ng/~ 
, , lA260 for RNA is 40 ng/~L 
(Promega, 1991; Wilton, 1993) 
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( 
Therefore, dsDNA concentration :::::: absorbance x dilution factor x 50 ng/J!L 
and ssDNA " " X " " X 33 ng/!lL 
Note, that any contaminating RNA at IA20o will be read at 40 ng/!lL and contaminating 
primers being ssDNA will be read at 35 ngi!lL. So it was important to run the purified 
DNA on a gel to see if there was any contaminating RNA at the bottom of the lane in the 
gel. 
The purity of the DNA sample can be measured for contaminants such as protein or 
phenol by the A20o/A28o ratio. Pure DNA will have en A26o/A2so ratio of 1.8-2.0. 
Phenol absorbs strongly at 270 nm and proteins absorb at 280 nm (Wilton, 1993). The 
absorbance curve can be observed on the spectrophotometer for peaks at 270 nm and 280 
nm suggesting phenol and protein contamination respectively (Wilton, 1993). 
2.2.8 Dideoxy Chain Termination Automatic Cycle Sequencing 
2.2.8.1 Introduction 
Automatic cycle sequencing is based on the Sanger dideoxy sequencing method (Sanger, 
1981). The PRISMfM Ready Reaction DyeDeoxy Terminator Cycle Sequencing Kit 
(Applied Biosystems) was used. The kit produces chain terminated fragments from 
unlabelled primers extended by the thermostable Taq DNA polymerase. Each 
dideoxynucleotide (ddNTP) is labelled with a different fluorescent dye; ddATP-green, 
ddCTP-blue, ddGTP-yellow and ddTTP-red. These four ddNTPs are present in the 
reaction at approximately 1-2% of the concentration of the normal deoxynucleotides 
(dNTP's). The Taq polymerase extends the DNA from a single primer by incorporating 
the dNTP's until a fluorescently labelled ddNTP is incorporated in the chain causing the 
chain to terminate (Applied-Biosystems, 1993). This occurs at random, so from the 
primer, different chain lengths will be produced each with different fluorescently labelled 
ends (see Figure 2.3). A dideoxynucleotide has a hydrogen instead of an -OH group 
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linked to the 3'-carbon in the ribose sugar. Therefore there is an oxygen missing from the 
3'-carbon. Dideoxynucleotides can be inserted during DNA replication, but synthe.;is 
stops at an insertion point because there is no 3'-0H for the addition of the next 
nucleotide in the chain (Wolfe, 1993). The four base reactions occur simultaneously in 
the one tube. Alternate heating and cooling in a thermal cycler causes the DNA to 
denature and become single stranded when heated. Cooling causes the primers to anneal 
to the template DNA and the polymerase extends the complementary DNA strand with 
dNTP's until a fluorescently labelled ddNTP is incorporated and causes the chain to stop. 
Heating again releases the primers, denatures the DNA and the cycle continues (see 
Figure 2.3). Because only a single primer is used per reaction, the DNA templates are 
linearly amplified. This is unlike the normal PCR that exponentially amplifies the target 
DNA. The accuracy of the sequencing can be compared by using the complementary 
primer to sequence in the reverse direction, as long as the other primer is within 
approximately 500 bases (Applied-Biosystems, 1993; Brown, 1994; Manomi, et al., 
1992). 
The uninc::n})orated dye terminators are removed by organic extraction. The reaction 
products were loaded into a single lane and separated by acrylamide gel electrophoresis 
on the automatic sequencer. The smallest DNA end labelled chains travel the fastest 
through the gel, while the larger fragments take longer. As the fragments separate by size 
they pass through a fixed position in the gel. A laser excites the fluorescent dye of each 
coloured end-labelled DNA fragment as it scans back and forth across this area of the gel. 
A photomultiplier tube (PMT) detects the fluorescent light colours and converts it into an 
electrical signal that is transmitted to a computer for storage and processing. Each scan 
consists of four passes, once through each of the four coloured filters, which measures 
the colour of each end-labelled base as it passes through the gel. The raw data is analysed 
by the computer, which then prints the analysed sequence of the DNA template (Applied-
Biosystems, 1993; Brown. 1994; Manorni, et al., 1992). 
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FIGURE 2.3 
Dideoxy Chain Termination in Sequencing 
(After Brown, 1994) 
31 
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Template DNA 
(B) Strand Synthesis 
r- DNA Polymerase 
5 
'Tllmllm11m11rrl rr111rr11rr1 rr11 rr11 rr11 TTl I"II ,.el ___. 
3' 
(C) Strand Termination 
/ 
5
'TIIITITTIInii""IITIITIII'TIInii""IITII"TIInii""[ITIImll,llrrlrriii"TIITIII,IIIKK 
3' 
ddNTP 
5' 
5' 
-------·-··- --·-~·-·- ·-·----·--·--··-·-----"-'·-~~·-···-·- ------ ~ .... - -
2.2.8.2 Cycle sequencing - dyedeoxy terminator cycle 
For a 15 ~L Reaction:-
"Prism Cocktail" 
Primer (20 ng!ML) 
Template (50-300 ng) 
H20 up to 15 ML 
Paraffin overlay 
"Prism Cocktail" contains:-
ddATP-
ddCTP-
ddGTP-
ddTTP-
IlL 
7.5 
2 
I drop 
~ 
Green 
Blue 
Yellow 
Red 
Taq polymerase enzyme 
dNTP' s and buffer 
Cycline Conditions 
time 
temp 94oc 15 sec 30 sec denaturing 
500C I min (annealing) 
6QOC 4 min (extension) 
#cycles xl 
4°C 
x35 
indefinitely 
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2.2.8.3 Applied Biosystems Inc. sequencing clean-up to remove 
unincorporated ddNTPs 
Upon completion of the cycling:-
Transferred sequencing reaction to a fresh tube (0.6 mL eppendorf) with minimal 
oil carryover 
Added 80 ~ water 
Added 100 ~ ABI phenol 
Mixed thoroughly and centrifuged at 12 000 rpm for 5 min at 40C 
Transferred aqueous phase (top phase) to fresh tube 
Repeated phenol extraction 
Transferred aqueous phase to a fresh tube 
Added 151!L 2M Na Acetate pH 5.0 
300 11L absolute ethanol 
Mixed well and spun 12 000 rpm, 15 min, 4°C 
(pre-chilling is not necessary) 
Discarded supernatant (above pellet) 
Washed pellet (small, clear and not coloured) with 70% Ethanol and used a pipet 
to remove as much ethanol as possible 
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Centrifuged again 12 000 rpm, 5 min, 4°C 
Brief vacuum dried for 5-10 min (Speedvac Model SVC 100- Savant) 
Eppendorfs wem capped and reactions can be left at this stage ready for 
sequencing loading 
(ANRI, 1994) 
The 1.5 kb product was sequenced using an ABI 373A DNA sequencer to confirm that 
the STS product was part of the TPM2 gene. 
2.2.9 Using the Radioactive Random Labelled TPM2 STS on a Genomic 
Hybridisation Membrane 
2.2.9.1 Random primer labelling introduction 
The TPM2 STS was radioactively labelied and hybridised with a genomic blot to see if 
the STS would hybridise to genomic DNA before it was used for FISH. 
This Prime-a-Gene labelling system was developed by Feinberg and Volgelstein (1984), 
and is where a mixture of random hexanucleotides primers is used to prime DNA 
syntf.·)sis in vitro from any linear double stranded DNA template. The hexamer primers 
anneal to the DNA template at random positions and Klenow DNA polymerase extends 
from the random primers. A radioactive nucleotide such as (a-32P) dCTP and normal 
nucleotides (dATP, dGTP, dTTP) are incorporated in the synthesis of a complementary 
strand which is labelled radioactively as the (a-32p) dCTP is incorporated. Probes can be 
generated up to 50% of the length of the original template with a high specific activity 
(often> J09 cprnlp.g) (see Figure 2.4) (Feinberg & Vogelstein, 1984; Promega, 1991). 
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FIGURE 2.4 
Random Primer Labelling 
(After Promega, 1993) 
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The STS is then denatured and the radioactively labelled complementary strand 
hybridises to a human genomic blot. The actual genomic blots used were prepared and 
supplied by ANRI, however the process of how they were made wUI be discussed. 
A genomic blot is a Southern Blot of total genomic human DNA. Isolated DNA from 
different people is digested with a restriction enzyme that cuts the DNA at a specific 
sequence producing different sized fragments. The digested DNA from different 
individuals is electrophoresed on an agarose gel in different lanes so that the DNA 
fragments separates according to size, the smallest fragments travelling the furthest and 
fastest. The gel is then rinsed in an acid solution that depurinates or 'acid nicks' the 
DNA, which cuts the DNA into smaller fragments at some of the purine bases (ie. 
adenine and guanine) so the DNA can travel through the gel more easily. The gel is then 
rinsed in an alkaline solution which denatures the DNA in the gel. The gel is then vacuum 
blotted so the depurinated and denatured DNA travels on to a nitrocellulose or nylon 
membrane where it hybridises to the membrane in the band paUern that was present in the 
gel. The membrane is then rinsed in a pH neutralising solution and dried (Gelehrter & 
Collins, 1990; Wilton, 1993). 
The radioactive STS probe is denatured by heating and hybridised to the human genomic 
membrane where it anneals to the complementary sequence in the genome. The 
membrane is then washed to remove the excess or unincorporated probe on the 
membraiJe and then dried and autoradiographed. The probe may anneal at different bands 
on the membrane because the restriction enzyme may have cut the complementary DNA 
sequence at two or more places where the probe would anneal, so there may be several 
bands present on the autoradiograph (Gelehrter & Collins, 1990; Wilton, 1993) (see 
Figure 2.5). 
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FIGURE 2.5 
Southern Blotting to Produce Genomic Blots 
(After Gelehrter, 1990) 
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2.2.9.2 Random primer labelling protocol 
The following reaction is optimised for labelling 25 ng of DNA template, however when 
25 ng of the purified TPM2 STS was used the labelling was too weak, so 5 J.LL of 24 
ng/J.LL DNA template was used (ie. 120 ng). 
I. The TPM2 DNA template was denatured by heating at 95-lOOOC for 2 
min, then snap chilled in an ice bath. 
2. The reaction was assembled on ice in a separate microcentrifuge tube by 
adding the following reagents in the order listed. 
Component Volume 
(a) Labelling 5X buffer 
(b) Mixture of unlabelled dNTP's 
(dGTP, dATP, dTTP, I J.lL each (3 J.LL total) 
(c) Denatured DNA template (25 ng) but used 120 ng 
(d) (a-32p) dCTP (Bresatec) behind perspex screen 5 J.lL 
(50 J.LCi, 3000 Ci/mmole) 
(d) Acetylated (nuclease free) BSA (lO mg/mL) 
(e) Klenow enzyme 
(f) Sterile H20 to final volume 50 J.LL 
5 units 
Final Cone. 
IX 
20 !1M each 
2.4 ng/J.lL 
50 J.!Ci 
0.4J.Lg!J.LL 
0.1 u/J.LL 
3. The reaction was mixed gently and incubated at room 1cmpt•rature (250C) 
for 60 min in a PCR minicycler. 
4. The reaction was terminated by heating to 95·1 00°C for 2 min and chilling 
in an ice bath. EDT A was added to 20 mM and used direcUy in the 
hybridisation reaction or stored at -20°C. 
(Promega, 1991) 
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2.2.9.3 PEl strip test 
The percentage incorporation of 32p into the probe by random priming was checked by 
using PEl Cellulose thin layer chromatography (see Figure 2.6). 
1. An approximate 8 em strip of PEl paper was cut and a line was drawn in 
pencil! em from the bottom of the strip and an "x" was marked in the middle 
of the line. 
2. 0.5 ~of the random priming reaction was placed on the "x". 
3. Approximately 5 mL cf 0.75 M KzHzP04 (pH 3.0) was pipetted into a 
Coplin jar and !he labelled PEl strip was placed in the jar so that only the top of 
the strip touched the side of the jar. 
4. The KzHzP04 solvent front was allowed to move to the top of the strip. 
5. The cpm of the strip were measured at the "x" and up the strip where the 
solvent had moved the unincorporated 32p in dCTP in a tear fashion. 
Efficiency labelled= cpm at "x" I (cpm up the strip+ cpm at "x") 
If the labelling efficiency was too low (0-20%) then the random priming reaction 
was repeated using more template (ie. >25 ng DNA). 
2.2.9.4 Sephadex G-50 Spin Column 
The purpose of the Sephadex G-50 spin column is to remove the unincorporated (a-32p) 
dCTP in the random priming reaction. This step is not necessary unless the incorporation 
levels are low in the random priming reaction. The unincorporated ( a-32p) dCTP can be 
removed by size exclusion chromatography on Sephadex G-50 beads. The spin column 
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FIGURE 2.6 
PEl Strip Test to Measure the %Incorporation of the Radioactive Nucleotide in 
the Probe 
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leaves the probe free of unincorporated (a32p) dCTP and also reduces the content of 
DNA oligomers less than 70 bases in length. This therefore, reduces the background 
radiation whe.n using hybridisation probes (Promega, 1991). 
Protocols 
1. A spin column was prepared by plugging a 3 mL syringe with a small piece of 
sterile nonRabsorbent cotton wool. 
2. The 3 mL syringe was filled with Sephadex G50 and compacted with the 
plunger until it measured about 2 mL and the plunger was then removed. 
3. I mL of STE (DNA buffer- see Appendix 2) was added to the top of the 
syringe and the syringe was placed in a 15 mL polypropylene conical tube and 
centrifuged at 2000 rpm for 5 min on a Beckman model TJ-6 centrifuge. 
4. The syringe was placed in a new 15 mL tube and the random priming reaction 
(stopped) was added to the syringe and centrifuged at 2000 rpm for 5 min on a 
IEC model HN-5 centrifuge. 
5. The syringe containing the unincorporated (a-32p) dCTP was discarded which 
also contained DNA oligomers less than 70 bases in length. 
6. The purified probe was pipetted from the 15 mL tube into a 0.6 mL eppendorf 
tube and denatured by heating to 94°C for 5 min and then snap chilled on ice 
for 1 min. 
7. The denatured probe was added to the prehybridisation solution and genomic 
blot. 
(ANRI, 1994) 
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2.2.9.5 Prehybridisation of the genomic blot 
The human genomic blots are prehybridised in a solution that is used to block non-
specific binding of the probe to the membrane. The prehybridisation solution contains 
salmon sperm DNA that binds to the membrane everywhere else the imrnobilised 
genomic DNA did not bind, therefore blocking any unincorporated probe from non-
specifically hybridising to the membrane (Wilton, 1993). 
Prehybridisation solution protocol 
10-20 mL of prehybridisation solution was used per membrane. The reagents were added 
in the following order: 
Hybridisation Solution for 1 membrane final concentration 
I. 5 MNaCI 4mL !M 
2. De-ionised fonnamide 10mL IM 
3. I M Tris pH 7.5 I mL 50mM 
4. 10% SDS 2mL 1% 
5. 10 mg/mL Salmon Sperm DNA 0.2mL 0.1 mg/mL 1 
6. 50% dextran sulphate 4mL 10%2 
Store at -zooc in alil{uots 
1 The salmon sperm DNA was boiled at lOQOC for 5 min, and then snapped chilled on 
ice before adding to the solution. Salmon spenn DNA should have been cut to an average 
size of 500-700 bp. 
2 The formamide was freshly deionised by mixing for one hour at room temperature, 
with two spoonfuls of Mixed Bead Resin (Bio-Rad), then filtered through 305 mm 
diameter Postlip Paper (Hollingsworth & Vose Co. Ltd). 
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Fonnamide acts to keep the DNA probe single stranded (Wilton, 1993). The 10% dextran 
sulphate increases the rate of hybridisation approximately ten-fold, because the nucleic 
acids are excluded from the volume of the solution occupied by the polymer and their 
effective concentration is therefore increased (Sambrook, et al., 1989). 
The 1 M NaCl maximises the rate of annealing of the probe with its target as 
hybridisation is increased in solutions of high ionic strength (Sambrook, et al., 1989). 
The 1% SDS solution is a detergent and acts as a surfactant so the probe will anneal to the 
membrane target more easily (Sarnbrook, et al., 1989). 
The 15 x 20 em genomic blot was placed in a plastic envelop and 20 mL of 
prehybridisation solution was added to the bag and mixed around. The bag was heat 
sealed and air bubbles in the bag were pushed to one corner and heat sealed in. The bag 
with the prehybridisation solution and the genomic blot were placed in a 42oc shaking 
water bath (Grant model SU 5/6) for I hour. For newly made genomic blots or 
imrnobilised DNA on nylon membranes, the first time they are used for hybridisation 
they had to be prehybridised for approximately 4 hours (ANRI, 1994). 
2.2.9.6 Hybridisation of the radiolabelled TPM2 STS probe to the 
genomic blot 
The 50 rtL of radiolabelled TPM2 STS probe (2.2.9.2) was then added to the 
prehybridisation solution after cutting one corner of the bag with scissors. The air 
bubbles were again removed by heat sealing in one corner and the probe was mixed 
around the bag with a glass rod. The air bubbles were removed to ensure every part of 
the membrane would come in contact with the probe. To avoid contaminating the water 
bath, the hybridisation bag was placed in a large tupperware container filled with water 
and placed in the water bath at 420C and left shaking for 16 hours (ANRI, 1994). 
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2.2.9.7 Washing the membrane at increasing stringencies 
The membrane was then washed at 42°C at increasing stringencies to remove the non-
specific binding of the probe to the membrane. After each wash the membranes 
radioactivity was measured using a geiger counter (Mini Instruments Series 400 -mini-
monitorGM tube). The membranes were washed until the counts per minute (cpm) fell to 
approximately 10-20 cpm. 
1. The membrane was first washed in 200 mL of 2X SSC, the least stringent 
wash for 15 min at 42°C shaking in the water bath. 
2. The second wash was in 2X sse and I% SDS for 15 min at 42oe shaking in 
the water bath. 
3. The third wash was with O.IX sse and 0.1% SDS, the most stringent 
wash, for 15 min at 42°C. If the cpm's were already around 20 cpm then the 
third wash was not necessary. (ANRI, 1994). 
Note that increasing the temperature of the wash also increases the washing stringency. 
The membrane was then blot dried with Whatman 3MM paper and wrapped in Glad 
Wrap. Autoradiography was perfonned with Dupont Cronex 4 X-ray film with Quanta 
III autoradiography intensifying screens at -sooc for an empirically determined time 
(Akkari, et al., 1994). 
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2.2.9.8 Stripping the genomic blots 
The genomic blots after autoradiographing were !>tripped to remove the probe and all 
unspecific labelled DNA, so they could be used again. 
I. The membrane was gently agitated in 500 rnL of 0.4 M NaOH fc 30 min at 
42oe. 
2. The membrane was transferred to a clean dish and gently agitated in 500 
rnL of 0.1X SSe, 0.1% SDS and 0.2 M Tris (pH 7.5) for 30 min at 42oe. 
3. The membrane was briefly rinsed in O.!X SSe and 0.1% SDS. 
4. The activity of the membrane was checked and if at background, it was blotted 
dry and stored at 4oe. 
2.3 RESULTS 
The only primer combination in Table 2.1 that produced an STS from genomic DNA 
initially were primers 869 (exon 6) and 866 (exon 8sk) which amplifi<d a 1.4- 1.6 kb 
(1.5 kb) product (see Figure 2.7A). A blank was run where all the reactants were added 
except the genomic DNA. 
This STS was then amplified in a 50 ~L reaction and run on a 2% LMPAG (see Figure 
2.7B). The DNA band was cut out and purified using Wizard™ PCR Preps DNA 
Puritication System (Promega). 2 ~L of the purified DNA was run on a 2% agarose gel, 
IOOV for 30 min to determine how much product there was after purification (see Figure 
2.7C) and the absorbance of the purified DNA was measured on a spectrophotometer 
(Beckmilll DU 650) to calculate the DNA concentration (see Table 2.3). The measured 
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FIGURE 2.7 
-1.5 kb TPM2 STS From exon 6 to 8sk (skeletal muscle specific 
exon) 
(A) The STS Amplified from Two Genomic DNA Samples and Run on a 2% 
Agarose Gel at IOOV, for I hr. 
(B) The Pooled STS Samples Run on a 2% Low Melting Point Agarose Gel 
(LMPAG) at !OOV, for I hr. 
(C) The STS cut out from the LMPAG and Purified usH:.~ Promega WizardTM 
PCR Purification Preps System. 2% Agarose Gel, at lOOV for 30 min. 
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purified DNA concentration of 24 ng/!lL matches the faint band seen in Figure 2.7C 
which was 2 J.lL (-50 ng) of product run on the gel. The recovery of STS product in the 
purification process was quite low. 
Table 2.3 
TPM2 STS DNA Concentration on Spectrophotometer 
TPM2 STS 1.5 kb 0.0095 
Mean 
A2so 
0.0078 1.22 
Dilution Concentration 
(ng/~tL) 
sox 24 
4 IlL of this template (ie. - 100 ng) was used in the cycle sequencing reaction. Primers 
DS 869 ex on 6 and DS 866 exon 8sk were used to sequence in both directions to verify 
that the STS was indeed from TPM2 human skeletal muscle. The sequencing results 
extended for about 450 bases from one primer (exon 6 forward, see Figure 2.8) and 
about 350 bases from the reverse primer (exon 8sk reverse, see Figure, 2.9). From 
primer DS 869 in exon 6, sequence was obtained from exon 6, all of intron 6, exon 7 and 
approximately the first 150 bases of intron 7. When the sequencing results were 
compared with the TPM2 sequence of Widada et al. (1988), out of 70 bases in exon 7 
only three bases were different as they could not be read (ie. N). The sequencing in exon 
7 was 96% similar to Widada et al.'s TPM2 sequence (see Table 2.4A). The STS and 
other TPM bases that were different lO the TPM2 sequence of Widada et al., are 
underlined. The eight balded bases in the STS were unique only to TPM2. Therefore, 
one can be confident that the 1.5 kb STS was unique to TPM2. 
The sequencing results from the reverse primer (DS 866.8R) in exon 8sk, was not as 
good. The sequence was only readable for 350 bases and included exon 8sk going into 
intron 7. Out of 48 readable bases for exon 8sk, eight bases differed from the published 
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FIGURE 2.8 
Sequence ofTPM 1.5 kb STS from Primer DS 869.6F (Exon 6 Forward) 
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,d..!i ~ Sample 22 Points 864 to 8350 Base 1: 864 
~Bb.s)lsa:ms DyeTerminator{AnyPrimer) ANAl #93081296 
Model 373A Lane 22 TPM2 OS 866 
Version 1.2.1 Signal: G:44 A:29 T:20 C :13 Exon 6-8 Forward 
Wed, 6 Apr 1994 4 :17PM 
X : 0 to 7808 Y : 0 to 1200 
Spacing: 12.44 
Page 1 o~ 2 
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E XON Ss k INTRON 7 
EGURE 2.9 
Sequence ofTPM 1.5 kb STS from Primer DS 866.8R (Ex on 8sk Reverse) 
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Mode/373A 
Version 1.2.1 
Sample 19 
DyeTerminator{AnyPrimer} 
Lane 19 
Signal: G :59 A:39 T:26 C :16 
Points 820 to 8350 Base 1 : 820 
AN R I #93081296 
TPM2 OS 869 
Exon 6-8 Reverse 
Wed, 6 Apr 1994 4 ·.17 PM 
X: 0 to 7261 Y : 0 to 1200 
Spacing: 12.93 
Page 1 ot 2. 
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Table 2.4 
A. Sequence of TPM2 STS from primer DS 869 (exon 6 forward) 
compared to TPM2 and other TPMs 
EXON 6 
TPMl t£,£tttccga caagctgaag gag 
TPM3 ttcttactga ,taag_ct,g,aag gag 
TPM4 ttctgtctga Q.aaactgaaa gag 
TPM2 tgttggagga gaagctgaag gag 
TPM2 STS tgttgg.t_gga gaagntgaag gag 
EXON 7 
TPMl gctgagac.t.c gggctgagtt tgcggagagg tcg_gtaac.t.a 
TPM3 gcg_gagaccc g.t_gctgagtt tgc_tgagagg_ tcggtggcga 
TPM4 gctgagaccc g,tgctgaatt tgcg_gagagg_ gcggt.:!;;.gcaa 
TPM2 gctgagaccc gagcagagtt tgccgagagg tctgtggcaa 
TPM2 STS gctgagaccc gagcagagtt tgccgagagg tctn.tggcaa 
TPMl ag_ttggagaa aagcat.t.gat gac.ttagaag 
TPM3 aggtggag_aa gacg_at_tgat gacctggaag 
TPM4 aactgga§,aa gacQ._at!;_gat gacctggaag 
TPM2 agttggagaa aaccatcgat gacctagaag 
TPM2 STS ngttggagaa naccatcgat gacctagaag 
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B. Sequence of TPM2 STS from primer DS 866 (exon 8sk reverse) 
compared to TPM2 and other TPM's 
EXON8sk 
TPMl 
TPM3 
TPM2 
TPM2 STS 
TPMl 
TPM3 
TPM2 
TPM2 STS 
aggaggtgta Qgctcagaag gtgaagtaca aagccattag 
atgaggtcta tgcccagaag gtgaagtaca aggccattag 
atgaagtcta tgcccagaag atgaagtaca aggccattag 
gtgaagtcta tncccagnag atgaagnaca agnccattaa 
cgaggaactg gacgacgc 
cgaggagctg gacgacgc 
cgaggaactg gacaacgc 
cgaggnactg gaciacgc 
sequence of Widada et al., (1988) (see Table 2.4B). The two balded bases for the STS 
were unique to TPM2. 
Sequencing of the 1.5 kb TPM STS was also performed by ANRI. From the forward 
primer (DS 869.F) the sequencing results in exon 6 and 7 had only one out of 104 bases 
which was different to Widada et al.'s published sequence (anN where the sequencer 
could not distinguish a base). This also confirmed that the STS was specific to TPM2. 
The 1.5 kb purified TPM2 STS was radiolabelled and used as a probe on a genomic blot 
(see Figure 2.10). The efficiency of the labelling after the random priming reaction using 
the PEl strip was approximately 50%. The actual blot membrane had two digests on it. 
Lanes 1-6 and 8 was total human genomic DNA that was digested with the restriction 
enzyme BamH I. Lanes 9-16 was human genomic DNA that was cut with 
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FIGURE 2.10 
Radiolabelled 1.5 kb TPM2 STS Used as a Probe on a Genomic Blot 
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FIGURE 2.11 
Distances of Lambda Hind III Marker Fragments from the Well 
to Compare with the Autoradiograph in Figure 2.12 
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Pvu II. Lane 7 was the 'Allind Ill marker and the different sized fragments in bp from the 
well can be seen in Figure 2.11. These were determined from a photograph of the digests 
when they were run on a gel by ANRI. 
One faint band can be seen on the BamH I digest at 23 mm or approximately 23 kb (see 
Figures 2.10 & 2.11). Three bands can be seen on the Pvu II digest. Two faint bands can 
be seen at 17 mm or greater than the 23 kb t..Hind ill fragment and 25 mrn or around 18 
kb. A strong band was se~n at 87 rnm and represents an approximate 1.8 kb fragment. 
Most lanes had a lot of non-specific smearing. 
2.4 DISCUSSION 
The only TPM2 primer combination in Table 2.1 that produced an STS were primers DS 
869 (exon 6) and DS 866 (exon 8sk) which amplified an approximate 1.4 - 1.6 kb 
(average 1.5 kb) product (see Figure 2.7 A). The expected STS size from Figure 1.3 and 
Table 2.2, using the gene structure for TPM3 (Clayton, et al., 1988), was approximately 
1.4 kb. Therefore, the amplified 1.5 kb PCR product was close to the expected size and 
contained introns 6 and 7. 
Because only one band was visible in Figure 2.7A, then there were no pseudogenes 
amplified. If pseudogenes were amplified it would be expected that more than one band 
would be visible when amplifying genomic DNA. A pseudogene that contained no 
introns 6 and 7 would have an expected size of 200 bp, but this was not observed. 
Sequencing the TPM2 1.5 kb PCR product did confirm that the STS was unique to 
human skeletal muscle TPM2. Sequencing confirmed two introns (6 and 7) were 
included in the amplified STS. It was the first time intron 6 had been sequenced. From 
the reverse primer (DS 866.R in exon 8sk) sequence was obtained from exon 8sk and 
into intron 7, but it did not reach exon 7 after approximately 450 bases. In TPM3 intron 7 
is about 1 kb (Figure 1.3) and it would seem TPM2 is comparable to this. 
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The sequence differed from the other TPM genes (see Table 2.4 and Appendix 1). This 
meant the TPM2 STS could confidently be used as a probe for FISH and to isolate a 
larger clone from a genomic library. The TPM2 STS can also be used on a somatic cell 
hybrid panel as the sequence was unique. 
The 1.5 kb radiolabei!Dd TPM2 STS used as a probe on a genomic blot (Figure 2.!0) 
showed some bands where il was annealing the human genomic DNA There was also a 
lot of non-speci fie binding. The purpose of the TPM2 STS hybridisation to a genomic 
blot was to see if it hybridiscd well to genomic DNA, for use in FISH. From the results 
there was some hybridisation, but the bands were not as defined and clear as it was 
hoped. 
The TPM2 exon sequence from primers DS 869.6F in exert G, to DS 870.8skk in exon 
8sk (see Table 2.4 and Appendix I) was typed into the application package DNA Strider 
version 1.0. The restriction map of the eDNA between these two primers is given in 
Figure 2.12. As can be seen in Figure 2.12, there were no BamH I and Pl'll .ti restriction 
sites in these exons, so the bands from the genomic blot in Figure 2.10 must have been 
from restriction sites present in the approximate 1.3 kb of intronic sequence. 
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FIGURE 2.12 
Graphic Map of Restrictton Sites in TPM2 Exon Sequence 
from Exons 6-8sk (eDNA) 212 bp. 
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TPM2 Exon~ 6-8sk (eDNA) -> Graphic Map 
DNA sequence 212 b.p. attccaccaaag ... atcacctccctc linear 
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CHAPTER 3 
USING THE TPM2 STS IN A SOMATIC CELL HYBRID 
PANEL 
3.1 INTRODUCTION 
A somatic cell is any cell of an organism not involved in the germ line. Somatic cell 
hybrids are made from fusing together cells from different species. For human gene 
mappiag, human and rodent cells hybrids are commonly used, such as fusing together 
human and mouse, or human and hamster cells. These somatic cell hyhrids can be used 
for human gene mapping. After several generations, a cell line becomes fairly stable 
maintaining a specific set of human chromosomes, or a part of the human genome 
(Gelehrter & Collins, 1990). Human STS markers used on the somatic cell hybrid panel 
can localise the STS markers. 
As long as the panel is representative of the human genome, then performing a PCR of 
the panel using the human skeletal muscle specific TPM2 primers, should amplify the 
STS for cell lines containing that part of the TPM2 gene and therefore localise the gene 
(Dubois & Naylor, 1992; Gelehrter & Collins, 1990). 
All work on the somatic cell hybrids was performed by Shelly Dorosz (a research 
assistant at ANRI) except for the PCR optimisation conditions for the 1.5 kb TPM2 STS, 
which was supplied by work done in section 2.2.2. The somatic cell hybrid work is 
described here as 1t relates to localising the TPM2 gene. 
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3.2 Materials and Methods 
A panel of rodent-human somatic cell hybrids was obtained from the National Institute of 
General Medical Sciences Human Genetic Mutant Cell Repository [NIGMS/mapping 
panel #2]. The construction of the mouse-human hybrid cell lines was described by 
Dubois & Naylor (1992) (see Table 3.1). Amplification by PCR was performed with 
50 ng of hybrid DNA and the TPM2 STS primers DS 869.6F and DS 866.8skR as in 
2.2.2-4. The PCR and amplification conditions used, were those that had been optimised 
in 2.2.2. 
3.3 RESULTS AND DISCUSSION 
Table 3. I shows the percentage of a particular chromosome(s) in each of the hybrid cell 
lines as determined by both cytogenetic and Southern blot analyses. The panel of 24 
hybrid cells is ~.:m the most part mono-chromosomal, except GM/NA07299 which 
con~ains chromosomes 1 and X, and GM/NAI0478 which contains chromosomes 4 and 
20 (Dubois & Naylor, 1992). 
Initially it was difficult to obtain the 1.5 kb TPM2 STS, however a product was obtained 
when the amplification conditions that had been optimised in 2.2.2, were used (see 
Figure 3.1). The TPM2 STS gave an amplification product from only the control human 
genomic DNA (a & o) and the somatic cell hybrid GM/NA10611 (n) (Dubois et al., 
1992). Only chromosome 9 was unique to this cell line (see Table 3.1) indicating that 
TPM2 is on human chromosome 9. p and y were mouse and hamster genomic DNA 
respectively, which showed that the primers were specific to human DNA from these 
three species. 
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TABLE 3.1 
Cytogenetic Analysis of NIGMS Human/Rodent 
Somatic Cell Mapping Panel 2 
(After Dubois & Naylor, 1993) 
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TABLE 3.1 
Cytogenetic Analysis of NIGMS Human/Rodent Somatic Cell Mnppinc: Panel 2 (from Camden Literature) 
Hybrid{Dt\'A 
CM/NA07299 
CM/NA\08268 
GM/NA10253 
GM/NA!Oll5 
GM/NAI0114 
GM/NA!0629 
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GM/NA106ll 
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GM/NAl0567 
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FIGURE 3.1 
1.5 kb TPM2 STS vs NIGMS Human Rodent Somatic 
Cell Hybrid Mapping Panel 2 by PCR 
Chromosome H~brid/DNA Cell Line 
a y GM/NA06317 
b X 063188 
c 1&X 7299 
d 5 10114 
e 4 10115 
f 8 101568 
g 3 10253 
stanclard '!. Pst I 
h 21 10323 
19 10449 
J 4&20 10478 
k 14 10479 
17 10498 
m 16 10567 
n 9 10611 
0 6 10629 
p 7 10791 
q 2 108268 
r 12 10868 
s 22 10888 
13 10398 
u 10 109268 
v 11 109278 
w 18 !1010 
X 15 11418 
a Human Genomic NAIMR91 
p Mouse Line 376 NA05862 
y Chinese Hamstn Line RJ K88 NA10658 
s Human Genomk ANRI 
E Blank 
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TPM2 STS vs HUMAN/RODENT HYBRID PANEL 
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CHAPTER 4 
USING THE TPM2 STS IN FISH 
4.1 INTRODUCTION 
Fluorescent in situ hybridisation (FISH) mapping is where a fluorescently labelled probe 
hybridises to human metaphase spreads, so its location can be detennined. 
Cells are grown in culture and treated with colchicine to arrest cells at the metaphase stage 
of mitosh:. Colchicine is believed to prevent the formation of spindle fibres (Biochemica, 
1992). The chromosomes remain within the nuclear membrane and are fixed and spread 
on to a microscope slide. (Davies & Read, 1992). 
The probe is labelled by coupling biotin covalently to it. Although probes can be directly 
conjugated with fluorescent molecules, the most widespread approach is to label the 
probes with report~r molecules such as biotin or digoxigenin that, after hybridisation, 
bind fluorescent affinity agents. The reporter molecules are labelled to the probe using 
nick translation (Trask, 1991 ). 
Nick translation was originally described by (Rigby, eta!., 1977). The process is where 
free 3'-hydroxyl ends or 'nicks' are created within unlabelled double stranded DNA by 
DNase I. DNA polymerase I then catalyses the addition of a nucleotide to the 3'-hydroxyl 
terminus of the nick. At the same time, the 5' to 3' exonuclease activity of this enzyme 
removes the nucleotide from the 5'-phosphoryl terminus of the nick. A new nucleotide 
with a 3'-0H group is incorporated at the position where the original nucleotide was 
excised and results in the movement of the nick (nick lranslation) along the DNA 5' to 3', 
as new nucleotides labelled with biotin are incorporated (Promega, 1991; Sam brook, et 
a!., 1989). Usually biotinylatect nucleotides adenosine and cytosine triphosphates are 
synthesised for incorporation (Biochemica, 1992). Incorporation can be up to 65%. 
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(Promega, 1991). Nick translation reduces the size of the probe after the reaction to 200-
500 bp fragments (Biochemica, 1992). 
Chromosomes within the nuclpar membrane are then denatured by heat or by altering the 
pH on the slide, without destroying the morphology of the chromosomes (Trask, 1991). 
Simultaneously, the probe is also denatured by heat or altering the pH. The slide is then 
incubated with the labelled single-stranded probe which hybridises to any matching 
sequences in the denatured chromosomes. The accuracy of annealing depends on the 
stringency of the hybridising conditions. High stringency hybridisation allows only exact 
complementary stra'lds to rejoin (Davies & Read, 1992; Leversha, 1993). Any unbound 
probe is then washed off the slide at increasing stringencies. Probe segments which bind 
to chromosomal sequences with the greatest similarity (or homology) will withstand 
more stringent washing than those which happen to bind to less closely matched 
sequences (Leversha, 1993). 
After washing, the slides are incubated in immunofluorescent reagents to produce a 
fluorescent signal at the sites of biotin-labelled probe hybridisation (Trask, 1991). The 
signal is developed using a streptavidin or avidin-carrying fluorescent reporter molecule 
that binds to the biotin. One or more layers of antibodies may be included to amplify the 
signal. The antibodies bind to the avidin 30d then allow more avidin-carrying fluorescent 
molecules to bind to the antibody. With successive layers of antibody and avidin, the 
signal is amplified (see Figure 4.1) (Davies & Read, 1992; Leversha, 1993). Avidin or 
specific antibodies can also be linked to fluorochromes such as fluorescein isothiocyanate 
(FITC) or Texas Red. The biotin labelled probe is detected with imrnunochcmicals linked 
t0 different fluorochromes such as FITC-conjugated A vi din in Figure 4.1 (Leversha, 
1993). 
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FIGURE 4.1 
Biotin-Avidin Detection Systems for Fluorescence In Situ Hybridisation (FISH) 
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The chromosomes are then stained with propidium iodide (red), as a counterstain to 
outline the chromosomes and 4', 6-diamidino-2-phenylimdole DAPI (blue), which gives 
a pattern of dark and light G-bands (the same as Giemsa banding) for chromosomal 
identification (Biochemica, 1992; Trask, 1991). 
The FITC signal ( 494 nm maximum excitation yellow) can be detected by a range of 
fluorescent microscopy equipment. One of the latest and most sensitive systems is digit ... l 
imaging microscopy, where a cooled, charged coupled device (CCD) camera cov :Jt.> 
emitted photons over a broad spectrum. The signal is computer enhanced to give a (WO-
dimensional analysis (Biochernica, 1992). 
On metaphase spreads, FISH resolution is 10-20 million bp, which is 0.3-0.6% of the 
genome or 8-16% of an average chromosome lDavies & Read, 1992). 
In interphase nuclei, fluorescent dots can be seen by FISH. These cannot reveal the 
chromosomal location, but if sets of probes with different fluorescent labels are used, 
their distance apart and their order can be established with a resolution as precise as 40 kb 
(Davies & Read, 1992). 
If the TPM2 STS probe is larger than l kb lhen it can be used for fluorescent in situ 
hybridisation (FISH). FISH was carried out on a metaphase spread of normal human 
male chromosomes. Male chromosomes are used because they have both the X and Y 
chromosomes, so every chromosome is included. The STS will anneal to a chromosome 
at a particular band where the gene will be localised. FISH was .:::arrieJ out at the Adelaide 
Children's Hospital by Helen Eyre anrl Dr David Callen, as lhe techniques require 
considerable expertise, beyond the scope of this project (Akkari, et al., 1994; Eyre, et a!., 
!993). 
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4.2 MATERIALS AND METHODS 
The TPM2 STS was larger than 1 kb (1.5 kb) so it was used for fluorescent in situ 
hybridisation (FISH). 
The probes were nick-translated with hiotin-14-dATP and each was hybridised in situ at a 
final concentration of 20 ngllll to metaphases from two nonnal males. The fluorescence 
in situ hybridisation (FISH) method was modified from that previously described 
(Callen, eta!., 1990). Only two rounds of amplification with fluorescein-conjugated 
avidin and biotinylated goat anti-avidin were required. The chromosomes were stained 
before analysis with both propidiurn iodide (as counterstain) and (DAPI) (for 
chromosome identification). Images of metaphase preparations were captured by a CCD 
camera and computer enhanced (Callen, et al., 1992; Eyre, ct al., 1993). 
4.3 RESULTS AND DISCUSSION 
The 1.5 kb TPM2 STS yielded unspecific hybridisation results of this probe to the 
metaphase spreads from two normal males. The probable cause was that the prcbe did 
not have enough sequence, as usually a minimum of 1 kb is required for FISH (Akkari, 
et a!., 1994) and the TPM2 probe was only slightly longer than the minimum required. 
Two approaches could have been taken from here. The first would have been to try to 
amplify a longer TPM2 STS for FISH, but a range of primers had already been tried 
unsuccessfully. The maximum expected STS size with conventional PCR techniques is 
around 4-6 kb (Gelehrter & Collins, 1990; Hayashi, 1994; Saiki, 1989) and there was no 
guarantee another PCR STS would work for FISH. The second approach was to use the 
STS as a labelled probe to isolate a larger genomic clone from a genomic library for usc 
in FISH. In bacteriophage, genomic clones have human inserts of between 8-21 kb that 
would have more DNA sequence to hybridise to the human metaphase spread and so give 
a stronger labelled signal (Clontech, 1994) 
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CHAPTER 5 
ISOLATION OF A CLONE FROM A GENOMIC LIBRARY 
5.1 INTRODUCTION 
The radiolabelled 1.5 kb TPM2 STS was used as a probe to isolate a clone from a 
genomic library. The clone would contain a larger portion of the TPM2 gene and perhaps 
the flanking region for use in FISH. The genomic library was constructed in EMBL3 
SP6ff7 (Clontcch). The DNA was partially digested with Sau3A I and the fragments 
were separated on a sucrose gradient to produce a size range between 8 and 22 kb before 
cloning into the BamH I site of EMBL3 SP6ff7. The average insert size was 15 kb. The 
insert DNA could be excised with Xho I, Sac I, or Sfi I (see Figure 5.1) (Clontech, 
1994). The human insert replaces the stuffer fragment or central portion of phage DNA. 
The stuffer region is not essential for phage growth and reproduction. 
The supplied host strain was Escherichia coli K802 (Clontech, 1994). Bacteriophage 
adsorb to receptors in the outer membrane of£. coli that are encoded by the bacterial 
lamB gene which are normally used to transport maltose into the cell. When culturing the 
host strain on an agar medium, maltose must he included as it induces the synthesis of 
these receptors, so the host strain can be infected by the bacteriophage. Adsorption of 
bacteriophage to maltos~ receptors is facilitated by magnesium ions and occurs within a 
few minutes at room temperature and at 37°C. The bacteriophage DNA is inserted 
through the cell membrane and undergoes lytic growth. The genome of bacteriophage is 
double stranded linear DNA, approximately 45 kb long. After infection, the lifiear DNA 
forms a closed circular molecule that serves as the template for transcription. During lytic 
growth, the circular DNA is replicated many times and a large number of bacteriophage 
gene products are synthesised. 
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FIGURE 5.1 
EMBL3, EMBLA & EMBL3 SP6m Vector Maps 
(After Cion tech, 1994) 
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Progeny phage particles are assembled and the cell eventually lyses, releasing hundreds 
of new infectious viruses (Clarke & Carbon, 1976; Hayes, 1968; Primrose & Dimmock, 
1980; Sambrook, et al., 1989). This process from infection to lysis takes approximately 
15 min at 370C (Clontech, 1994). 
The EMBL3 SP6ff7 vector is a virulent phage so it only undergoes the lytic cycle. The 
phage are plated out by incubating a relatively small number of phage particles ( l-100 
000) to a large number of concentrated bacteria (eg. 100xl06) so that it is likely each 
bacterium is infected by only one phage. The mixture is poured over a nutrient agar plate 
and incubated so the uninfected bacteria forms a confluent film over the plate. Each 
infected bacterium, lyses after a short time releasing several hundred progeny phages 
which then infect adjacent bacteria, which in turn are lysed. This process spreads loca!ly 
through the bacterial population until the bacterial population reaches the stationary phase 
where no more bacteria mulliply and bacterial metabolism declines. The result is a visible 
circumscribed area of clearing in the bacterial growth, known as a plaque (Fraser, 1967; 
Hayes, 1968; Primrose & Dimmock, 1980). This plaque is a clone containing only one 
type of recombinant DNA or human insert. A probe specific to TPM2 was used to isolate 
plaque(s) or done(s) that contained a part of the TPM2 gene so it could be amplified and 
the DNA extracted for use in FISH. 
Firstly, though, the 1.5 kb TPM2 STS primers were used on the EMBL3 library, to see 
if that segment of the TPM2 gene was present in the library. 
5.2 MATERIALS AND METHODS 
5.2.1 Determining if the 1.5 kb TPM2 STS was in the Library 
The 1.5 kb TPM2 STS primer.s that were developed in chapter 2, were used to determine 
if that segment of the tropomyosin 2 gene was present in the library (ie. exons 6 - 8sk). A 
PCR was set up as in chapter 2.2.2 using I ~L of the neat EMBL3 SP6ff7 library, as 
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tho target DNA, for primers DS 869.6F to DS 866.8skR. 50 ng of total genomic DNA 
was also used as a positive control. The PCR for each different target DNA was repeated 
three times to verify the experiment. 
Assuming the EMBL3 SP6ff7 vector had an average human DNA insert of 15 kb and 
that I ~L of the 'neat' library contains 5xto6 pfu/f.LL (Clontech, 1994) and the,re are 
3xl09 bp in the human genome, then: 
The No. of human genomes in l ~L of the EMBL3 SP6ff7 library = 
No. pfu/~L x A veragr. No. bp per human insert I No. bp in human genome 
The No. of genomes in I f.LL of the EMBL3 SP6ff7 library = 5x to6 pfu/uL x 15 000 bp 
3xiQ9 bp 
= 25 genomes 
Using 1 ~L of the EMBL3 SP6ff7 library on average represents 25 genomes of human 
DNA and should provide enough representative samples of the human genome to amplify 
the 1.5 kb TPM2 STS, using the primers. 
5.2.1.1 Protocol 
Reartion Mixture IX 20 uL 
Tth Buffer (5.2200) 5 f.LL 
Primer mix (DS 869 + 866) 2~L 
Tth (5.5 u/~L) 0.1 f.LL 
HzO 12.9 uL 
Total 2o.o uL 
Lanes 1-3 
Lanes 4-6 
Lane7 
3X EMBL3 SP6m bacteriophage 
3X Human genomic DNA (D90-224) 
!X Blank (HzO) 
LaneS A. Pst I Marker 
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SX 
40~L 
16~ 
0.8 f.LL 
to3.2 uL 
t6o.o uL 
The 8X reaction mixture was added with the target DNA to make a 25 Jl.L reaction. So 
20 ~L of the reaction mixture was added to 1 ~L EMBL3 SP6/T7 and 4 ~L HzO, and 20 
J.1L of the reaction mixture was added to 5 J1L of the human genomic DNA and blank. 
Cycling conditions and agamse electrophoresis were the same as 2.2.2-4. 
5.2.2 Aliquots of the Library 
The vector and host stain were stored at -80°C. An aliquot of the EMBL3 SP6ff7 library 
was made as a backup by aliquoting 200 ~L of the neat library using aseptic techniques 
into a 0.6 rnL eppendorf tube and storing it in a different -&OOC freezer. 
5.2.3 Bacterial Culture Plating and Propagating the Host Strain (K802) 
Using aseptic techniques, 5 ~of the host strain K802 was streaked onto a MgS04- free 
2X YT 1.5% bottom agar plate containing 0.2% maltm:e. This was incubated at 37oc 
overnight. From the agar plate a single isolated colony was picked and propagated in 10 
mL 2X YT liquid media and 10 mM MgS04 and 0.2% maltose in a 50 mL polypropylene 
tube. The broth was incubated at 370C on a shaker at 200 rpm (B. Braun Model 
Centornat H), well aerated overnight, for approximately 16 hours, or until the optical 
density at 600 nm (OD6oo) reached 2.0, or until the stationary phase of the culture was 
reached. 850 ~L of the broth culture was added to 150 ~L of glycerol to make a glycerol 
stock. Two glycerol stocks were prepared and stored at -2QOC. Ali working samples 
were taken from the glycerol stocks, while the original host strain was stored at -sooc 
(Clontech, 1994). 
5.2.4 Lil>rary Plating/Titering 
15 em petri dishes were used to plate out the EMBL3 SP6/T7 library requiring 
approximately 50 000 pfu. The library therefore needed to be diluted to yield 50 000 pfu 
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per plate. Since I ~L of the library had between I-9xi06 pfu/~L then to dilute 1 ~L of 
this library to produce 50 000 pfu per plate required: 
l-9x 1Q6 pfu!LtL = ISO ~L of IX lambda dilution buffer (see Appendix 2) 
50 000 pfu 
If 1 ~L of the neat library contained 25 genomes worth of human DNA then I ~L of the 
(!/!SOX) dilution would have: 
25/ISO = 0.14 of the human genome 
Therefore, to plate out one genome's worth of human DNA requires: 
1/0.14 = 7.2 or eight 15 em plates 
The number of clones required (N) to screen to get a particular clone with a probability P. 
N= lnii-Pl 
In (l-l/n) 
where n = genome size Cbpl and P = 0.95, 0.99 etc 
average size of insert (bp) 
(Clarke & Carbon, I 976) 
N = In (! -0.95) = 600 000 clones 
In (1-15 000/3x!09) 
If each 15 em petri dish has 50 000 pfu, then the number of plates required to plate out 
the library to 95% certainty that at least one clone will contain part of the TPM2 gene is: 
600 000/50 000 = 12 plates 
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However, it was decided to plate out at least one genome's worth of the genomic library 
(8 plates) at first, to see if the radiolabelled TPM2 STS would at least give a positive 
signal to some clones. 
Using 8 plates of 50 000 pfu/plate, then rearranging the formula, the probabiiity that at 
least one plaque will contain part of the TPM2 gene is: 
p ~ 1- 0 (N.In(I-Jin) 
P~ ]-e(400000.In(I-15000/3>J09) 
P ~ 0.86 or 86% 
I. Eight 15 em 2X YT 1.5% agar plates were poured having 10 mM MgS04 and 0.2% 
maltose concentration. Using aseptic techniques, enough agar was poured to cover the 
bottom of a 15 em diameter petri dish ( -30 mL). When necessary, the top of the agar was 
flamed to remove bubbles and then left to set for approximately 15 min. 
2. A 10 mL 2X YT broth (+10 mM MgS04 and 0.2% maltose) was inoculated with the 
host strain (K802) from the glycerol stock. It was incubated on a shaker (200 rpm) at 
370C overnight. 
3. To each of eight 50 mL polypropylene tubes was added 200 IlL of the overnight broth 
inoculated with I Ill of the diluted ( 1!180X) EMBL3 SP6/T7 library andre-incubated at 
37oc for 20 min. 
4. After 20 min 10 mL of melted (-500C) top 0.7% agarose (+10 mM MgS04 and 0.2% 
maltose) was added to each of the eight tubes and mix,:d weli. 
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5. The contents of each tube was poured on to the eight separate 2X YT 1.5% bottom 
agar plates (+10 mM MgS04 and 0.2% maltose). The plates were quickly swirled to 
allow even spreading of the agarose. Any bubbles were removed with a flame. 
6. The plates were cooled to room temperature for 10 min to allow the inoculum to soak 
into the agar. 
7. The plates were inverted to prevent contamination and incubated at 37oc overnight or 
until the plaques reached a diameter not exceeding 1.5 mrn, or were just beginning to 
make contact with one another, near confluency (-8-16 hours). Confluent lysis was 
deliberately avoided. 
8. The plates were sealed in parafilrn and stored at 4oc. 
(Clontech, 1994; Sambrook, et al., 1989). 
5.2.5 Membrane Replicas of the Agar Plates 
1. A 137 rnrn diameter nylon nucleic acid transfer membrane (Hybonct-N+, Arnersham) 
was labelled with a ball point pen. Using sterile forceps, lhe membrane was placed onto 
the 2X YT 0.7% top agarose. Trapping air bubbles was avoided. The membrane was 
marked in 3 or 4 asymmetrical locations by stabbing through the membrane and into the 
agar with an 18-gauge needle that was dipped into printer's black ink (see Figure 5.2). 
2. After 2 min, the membrane was carefu!Iy peeled off. The filter was placed plaque side 
up, onto a 15 x 15 ern Whatman 3MM chromatography paper soaked in NaOH 
denaturing solution (see Appendix 2) for 2 min. 
3. The membrane was then placed plaque side up on another 15 x 15 em Whatman 3MM 
paper soaked in the Tris neutralising solution (see Appendix 2) for 2 min. 
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FIGURE 5.2 
Screening a Genomic Library 
(After Deaven. 1994) 
74 
Master plate containing plaques of bacteriophage 
growing on E. coli ce!ls 
I Nitrocellulose filler placed over plate making nitrocellulose replica t of plate 
---.-~ •.-c.;o-'"~:=plica filter I 
- -- --
•• .• .·:·: •.. 8akelil!erandadd . 
32P·Iabeled probe 
containing a shorl sequence 
32P·Iabeled 
nudeic acid 
probe solu1ion 
Hybridization occurs 
in seafod bag at sr 
of the gene of interest 
I 
-
Wash filter and expose lo X·ray film 
Develop film and pick out phage 
plaques from master plate 
4. The membrane was then placed between two Whatman 3MM papers to blot dry. 
5. A second Hybond :r-r+ membrane (the duplicate lift) was placed onto the same plate 
a.,d marked with ink in the same locations. The membrane was peeled off after 2 min and 
denatured and neutralised on the same Whatman 3MM papers as described in Steps 2-4. 
6. The same procedure was used for lifting tile other plates, except the membranes were 
denatured and neutralised on freshly soaked Whatman 3MM papers. 
7. The membranes were left to dry, at room temperature, overnight in a dark place, 
stacked between Whatman 3M papers. 
(Ciontech, 1994; Sambrook, et al., 1989) 
5.2.6 Hybridisation of the Membrane Replicas using the Radiolabeiied 
1.5 kb TPM2 STS 
I. The membranes were placed in a round plastic container with prehybridisation solution 
and incubated at 420C for at least four hours shaking (Stuart Scientific Hybridisation 
Oven/Shaker) (as in section 2.2.9.4). l mL of prehybridisation solution was added per 
membrane. 
2. The randon•ly primed 1.5 kb TPM2 STS (sections 2.2.9.2 • 2.2.9.6) was denatured 
by heating to 950C and snap chilled on ice. 50 J!L of the probe was then added to the 
prehybridised membranes and incubated at 42°C for between 16-20 hrs. 
3. The membranes were removed and washed at increasing stringency until the cpm were 
between 10-20 cpm (section 2.2.9.7). 
4. The membranes were blot-dried on Whatman 3M paper and wrapped in Glad Wrap. 
The duplicate membranes were paired and placed with tape to a large piece of Whatman 
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3MM paper as backing paper, that was cut to fit the size of the autcradiograph cassette, 
so the membranes would not move. The Whatman paper was marked in three 
asyliunetrical places with a fluorescent dy~. The membranes were placed in a cassette for 
autoradiography. Autoradiography was perfonned with Dupont Croncx 4 X~ray film and 
Quanta III autoradiography i.ttensifying screens, at -80°C for an empirically determined 
time, usually overnight. 
5. After developing, the film wa!' aligned with the membranes to make sure they did not 
move. The film was then aligned with the agar plates to select a positivt.> plaque that was 
present on the film frorn the two duplicate lifts. A single isol..:.t~d plaque was picked, but 
in cases where the plaques were becoming confluent, an ag~r plug was removed with 
several plaques (only for the initial screening). 
6. A plaque was picked by cutting off the ,.;nd of a disposable pipette tip on a 200 )lL 
pipette. The tip was pushed througi .. the 0.7% agarose top and bottom agar where a 
positive plaque wa<; selc ... ~;::d and the agar plug was removed by the suction of the pipette. 
The agar plug was placed into a sterile 1.5 mL eppendorf with 200 f!L of I X lambda 
dilution buffer, so the phage eluted into solution. The agar plugs were storeJ at 4oc. 
7. Using the eluted phage from each selected positive plaque, the phage were replated 
(called secondary replating) and titered to obtain 200-1000 plaques on a 15 em petri dish. 
This was achieved by using I, 10, and I 00 f!L of the eluted phage from the agar plug in 
200 )lL of the overnight broth, to obtain the optimum titre on a plate. 
8. The optimum titered plates were lifted using the nylon membranes (called secondary 
lifts) and rescreened using the radiolabelled 1.5 kb TPM2 STS (called secondary re-
screening). The procedure was repeated until I 00% of the plaques showed up as 
positive. This would require rescreening lhree or four times for each different primary 
plaque clone that was selected from the initial screening. 
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9. For each clone a well isolated positive plaque was S( _ _c:d for plate stock. This was to 
grow the clone on many plates to confluency, so the DNA could eventually be extracted 
and purified for use in FISH. 
(Clontech, 1994; Sambrook, et al., 1989) 
5.2. 7 PCR assay of DNA from Clone Eluates to Confirm Clones Contain 
Part of the TPM2 Gene. 
Isolated clones of the final screening were picked. Primers DS 869 (exon 6F) and DS 
866 (exon 8sk.R) were used with the final picked clones to determine if the human 
inserts contained that part of the TPM2 gene. A 25 !JL PCR was set up as in 5.2.1.1 and 
2.2.2-4 with 5 IlL of the clones eluates used as the template DNA. 5 IlL of human 
genomic DNA was used as a positive control and a blank was run as a negative control. 
If the 1.5 kb TPM2 STS showed up as a band from the eluates, it meant the clones 
contained that part of the TPM2 gene (exons 6-Ssk) and that they could be plated out in 
mass, to isolate the DNA from phage lysates. 
5.2.8 Isolation of DNA from Phage Lysates 
5.2.8.1 Preparation of bacterial host (K802) cells 
0.5!!L of the glycerol stock of K802 was incubated in 10 mL of 2X YT broth, 10 mM 
MgS04 and 0.2% maltose. This was left shaking (200 rpm), at 37"C overnight. 
5.2.8.2 High-titre phage stock preparation 
The ratio of phage to bacterial host, determines the success of the phage DNA 
preparation. This must be determined empirically. A yield of 20-40 !lg of phage DNA 
could be expected from 100 mL of phage lysate (Clontech, 1994). 
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!. A selected clone, was titered using the eluted phage from the agar plug (I, 10 and 100 
I!L). 
2. 10 mL of IX lambda dilution buffer and a few drops of chloroform were added to the 
plates that had a tit~e of higher than I 00 pfu. These plates were left shaking overnight at 
4°C to elute the phage. The chloroform lyses the bacterial cell walls so the phage were 
more easily eluted. 
3. The eluted phage from the plates was pooled and poured into a 50 mL Oakridge tube. 
4. 2 mL of chloroform was added to the lysate and vortexed for 2 min to lyse the host 
strain. 
5. The lysate was centrifuged for 10 min at 7000 rpm in a Sorvall (Model RC2-B) 
centrifuge with a SS-34 rotor (maximum radius 4.25 inches). The supernatant was 
collected and re-titered out on a plate, and the volume required for confluent lysis was 
noted. 
6. Steps 1-5 were repeated for each clone. 
(Ciontech, 1994; Sambrook, et al., 1989) 
5.2.8.3 Plate lysate preparation 
For the preparation of large quantities of phage DNA there were two methods available. 
The liquid lysate method is more convenient than the plate lysate method, however phage 
generally grow better in plate lysates, so this method was chosen (Ciontech, 1994). 
1. For each selectr.d clone, ten 15 em petri dishes were plated out to confluent lysis, 
based on the titre of the high-titre stock of each clone. These plates were incubated 
overnight at 37oc. 
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2. !0 mL of IX lambda dilution buffer was added to the ten plates and was left shaking 
at 40C overnight. 
3. The IX lambda dilution buffer was pooled from the ten plates ( -100 mL). This is the 
plate lysate. 
(Clontech, 1994; Sambrook, eta!., !989) 
5.2.8,4 Lysate processing 
I. The lysate was placed into 50 mL Oakridge tubes and centrifuged at 8500 rpm on a 
Sorvall for 10 min at 40C to pellet debris. A 10 mL aliquot of this lysate was kept as a 
very high titre stock. 
2. The supernatant was decanted and pooled and DNase was added to 0.2 J.Lg/mL and 
RNase to 5 !lglmL and left at room temperature for 15 min. This was to degrade the 
DNA and RNA from the host strain. The DNA of the EMBL3 SP6/T7 vector and insert 
was protected from the DNase by the phage's protein coat. 
3. The lysate was separated again into Oakridge tubes and chloroform was added to a 
final concentration of 5% and vortexed for 30 sec. This was to lyse any cells that were 
not previously lysed. 
4. The lysate was then centrifuged at 8500 rpm for 10 min at 4DC, to extract the organic 
components eg. lipid bilayer of cell membranes into the chJorofonn layer. 
5. The aqueous supernatant was pooled and 
-added solid NaCI to I M (eg. 100 mL/1000 mL x 58.44g = 5.84 g) and 
-added polyethylene glycol (PEG) to 10% (eg. 10 gin 100 mL) 
-The NaCI and PEG were dissolved and left on ice for at least one hour. 
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6. This was then centrifuged in Oakridge tubes at 8500 rpm for 15 min •t dOC. The 
supernatant was discarded. PEG and NaCl causes the phage to precipitate and form a 
whitish pellet on the bottom of the OakP.dge tube. As much PEG solution was removed 
as possible, as it can inhibit restriction enzyme digests. 
7. 2 mL of IX lambda dilution buffer was added to each Oakridge tube, to dissolve 
phage pellet. 
8. The phage was pooled into Oaklidge tubes ( -4 mL each) and CsCl was added to 0.5 
glm (ie. 2.0 g per Oakridge tube). 
9. A CsCl step gradient was carefully layered in Beckman polyallomer centrifuge tubes 
(14 mm diameter x 89 mm). 2 mL of each CsCI concentration was added for the 
gradients (see Figure 5.3 & Table 5.1). 
TABLE 5.1 
CAESIUM CHLORIDE CONCENTRATION STEP GRADIENT 
3 
2 
I 
Density (p) CsCl (g) 
1.45 
!.50 
1.70 
30.0 
33.5 
47.5 
!XLDB (mLl 
42.25 
41.0 
37.5 
1.3768 
1.3815 
1.3990 
Reference Index (n) 
Solutions 1 to 3 were consecutively added, very carefully, to the Beckman tube, using a 
5 mL pipette, so the gradient interfaces were well define~. The phage in 0.5 g/mL CsCl 
was added last. 
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FIGURE 5.3 
Caesium Chloride Step Gradients to Purify Bacteriophage A. 
The Bacteriophage). forms a visible band at the 1.45 g/mL and 1.50 g/mL 
interface. 
(After Sambrook et at., 1989) 
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10. The opposite centrifuge capsules were weighed and balanced to a hundredth of a 
gram of each other and then centrifuged at 22 000 rpm, for 2 hrs, at 40C, on a Beckman 
Model LS-M Ultracentrifuge. 
II. The phage should have formed a visible band at the 1.45 g/mL and 1.50 g/mL 
interface. However, all debris between the 0.5 g/mL and 1.50 g/mL interface and the 
pellet on the bottom of the centrifuge tube was also collected and placed into different 1.5 
mL eppendorf tubes. The different samples were collected using a 1 mL pipette with a 
new tip for each sample collected in the different gradients. 
(ANRI, 1994; Clontech, 1994; Sambrook, eta!., 1989) 
5.2.8.5 DNA extraction 
I. The collected volume from the !.45 g/mL and 1.50 g/mL interface was pooled and 2X 
the volume of IX lambda dilution buffer was added to dilute the CsCI. 
2. The measured volume was made to: 
20mMEDTA 
0.5% SDS 
50 ~tg/mL Proteinase K 
5~tg/mL RNase 
This was incubated at 65DC for 15 min. The purpose was to digest any protein 
and RNA present. 
3. Phenol/chlorofonn extraction. Equilibrated phenol:chlorofonn (I: 1) was added to the 
same volume of phage DNA in an Oakridge tube and mixed together thoroughly for 
5 min. This was then centrifuged at 15 000 rpm for 20 min on the Sm-vall centrifuge. The 
chloroform denatures proteins and separates the protein into the organic phase and the 
nucleic acids into the aqueous phase (Sambrook, et al., 1989). 
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4. The supernatant was removed and Step 3 was repeated using the same volume of 
chloroform:isoamyl alcohol (24:1). The mixture was shaken thoroughly for 5 min and 
then centrifuged at 15 000 rpm for 20 min and the supernatant withdrawn. The isomnyl 
' 
alcohol reduces foaming during extraction, caused by the SDS, to give a more defined 
interface (Sambrook, et al., 1989). 
5. To the supernatant was added 2X volume of propan-2-ol. This was mixed thoroughly 
and centrifuged at 15 000 rpm for 10 min. 
7. The DNA precipitated a~, a whitish smear on the bottom of the Oakridge tube. The 
supernatant was decanted and the DNA pellet was washed with 70% ethanol to remove 
added salts. 
8. The DNA was resuspended in 1 mL of TE buffer. 
9. The DNA concentration was measured on a spectrophotometer and the A260/280 ratio 
should be between 1.8-2.0. The DNA was also run on a 0.8% agarose gel with a 
Hind III marker and should form a sharp band with some contaminating RNA. 
(ANRI, 1994; C1ontech, 1994; Sambrook, et al., 1989). 
10. The DNA was purified by adding RNase to 5 [!g/mL and using the WizardTM DNA 
Clean-up System (Promega). The protocol was identical to the Wizard™ PCR Preps 
Purification System (Promega) in 2.2.6.2. 
5.2.9 Restriction Digests of Clones to Determine if they are Different 
The insert DNA can be excised with Xho I, Sac I, or Sfi I as can be seen from Figure 
5.1. Other restriction enzymes were also tried including BamH I, EcoR I and Hind Ill 
and different combinations of two enzymes, were also used. The purpose of the 
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restriction digests was to determine if the human inserts from the isolated clones were 
identical or different. The protocols used for the restriction digests were: 
Template (phage DNA) 
!OX Buffer appropriate to 
restriction enzyme (Prornega) 
Acetylated BSA (I mg/mL) 
Spermidine (0.1 M) 
Enzyme (Promega-usually 12 u/~L) 
H20 to 20~ 
IX 20 ~L Reaction 
empirically 
2~L 
2~ 
0.4 ~L 
I~ 
All digests were at 37°C for one hour. Digests were terminated by heating to 95oc for 
5 min. 
5.2.10 Hybridising Radiolabelled Clones DNA to Genomic Blots 
Approximately I ~g of purified DNA from clones 2 and 4 were labelled by random 
primer labelling and hybridised to genomic blots as in 2.2.9. Clone 2 was hybridised to 
total human genolT'.ic DNA that had been cut with EcoR I. Clone 4 was hybridised to two 
blots on the same membrane of total human genomic DNA. One had been cut with 
BamH I and the other with Pvu II. 
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5.2.11 Using Primers as Radiolabelled Probes on Membrane Lifts of the 
Colony Plaques to Determine if the Clones had the Same Part of the 
TPM2 Gene 
5.2.11.1 Purpose for end-labelled primers experiment on clones 
Primers DS 869.6F and 866.8skR were end~labelled radioactively and used as probes on 
the duplicate secondary membrane lifts of the four clones. This was to determine if the 
clones contained both exons 6 and 8sk, or if the c!ones were cut somewhere in between 
these exons. One primer was used as a probe on one of the secondary membrane 
duplicate lifts of the four clones. The other primer was used on the second lift. If one 
primer hybridised to the clone membranes at the previous positive plaque positions and 
the other primer didn't on the second lift, then it would confinn that the human insert was 
cut somewhere between the two primers in exon 6 and 8sk. If the two primers hybridised 
to the same plaque positions on both of the clones secondary membrane lifts, then it 
would confirm that the human inserts contained both exons 6 and 8sk. 
5.2.11.2 Stripping membranes and prehybridisation using oligonucleotide 
hybridisation solution 
The secondary membrane duplicate lifts (ie. IA+B, 2A+B. 3A+B, 4A+B) were stripped 
of the previous hybridisation using the protocol in 2.:2.9.8. The membranes were 
separated IA-4A to hybridise with primer DS 866 (exon 8sk) and 1B-4B to hybridise 
with primer DS 869 (exon 6). The membranes were prehybridised in two separate plastic 
tubs using oligonucleotide prehybridisation solution. 
Oligonucleotide prehybridisation solution is made up as for normal prehybridisation 
solution as in 2.2.9.5, except water is replaced for fonnamide. Formamide assists double 
stranded DNA to remain denatured or single stranded, which is not required with 
primers, as they are already single stranded. 
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10 rnUmembrane or 40 mL of the oligonucleotide prehybridisation solution was added to 
each tub with the four membranes and incubated at 420C, shaking in a hybridisation 
oven for 1 hour. 
5.2.11.3 Kinase 5' end labelling of oligonucleotides 
This procedure is usefui for radioactive 5' end labelling of oligonucleotides (Promega, 
1991). The kinase reaction requires that the 5' end has been previously 
dephosphorylated, and the primers are already synthesised with the 5' end 
dephosphorylated. Bacteriophage T4 polynucleotide kinase catalyses the transfer of the 
radiolabelled y-phosphate of (y-32P)ATP (see Figure 5.4) to a 5' terminus of 
dephosphorylated DNA (Sambrook, eta!., 1989). 
Reaction: 
Reaction: 
bacteriophage T4 
polynucleotide kinase 
(y-32P)ATP 
dithiothreitol 
Mg2+ 
20 y,L Reaction Final Concentration 
HzO 
Primers DS 866 or 869 (10 ng/~L) 
lOX TM buffer (fris-MgCiz) 
(500 mM Tris-HCI, 100 mM MgCiz) 
DDT (50 mM dithiothreito!) 
(y.32P)ATP (10 ~Ci/~L) 
T4 PNK (3u/~) 
Total 
4~L 
6~L 
2~ 
The reaction was incubated at 37°C for 30 min. 
3 ng/~L 
50 mM Tris-HCI 
lOmMMgCiz 
5mM 
2.5 ~Ci/~L 
0.15 ui~L 
The reaction was stopped by heating to 940C for 5 min, to denature the T4 enzyme. 
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The 5'-cnd radiolabellod primer DS 866 (exon 8sk) was added to the prehybridisation 
solution and membranes IA-4A. The 5'-end radiolabelled primer DS 869 (exon 6)was 
added to membranes 1B-4B. The two hybridisations were left shaking overnight, at 
420C. The membranes were washed at increasing stringencies as in 2.2.9.7, until the 
activities were between 10-20 cpm. The membranes were autoradiographed with Dupont 
Cronex 4 X-ray film with Quanta III autoradiography intensifying screens at -sooc 
overnight, or until images were readable. 
5.2.12 PCR Assay of DNA fl'om Clones to Confirm that they Contained 
Part of the TPM2 Gene. 
Primers DS 869 (exon 6) and DS 866 (exon 8sk) were used with the purified DNA from 
clones 2 and 4 to determine if the human inserts contained that part of the TPM2 gene. A 
PCR was set up with the following conditions: 
For a 25 f!L Reaction:-
5X 2200 Buffer 
(5X Tth buffer, 10 mM MgCI2, I mM dNTP's) 
Tth DNA polymerase (Biotech) (0.5 units/mL) 
Primer mix DS 866 + 869 (20 ng/f!L) 
H20 to 20 f!L 
TOTAL 
Paraffin 1 drop OYerlay 
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5.0 f!L 
1.0 f!L 
2.0 f!L 
12.0 f!L 
20.0 f!L 
7X Reaction 
Mixture (f!L) 
35 
7 
14 
112 
FIGURE 5.4 
(y-' . , ATP Showing they Phosphate Position 
(After Wilton, 1993) 
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o- o- o-
1 I ,21 s· 
-o-p-0-0-p-0-0-p-0-CH ADENINE 
II II II 2 o 
0 0 0 
a y 
OH H 
Target DNA 
2X clone 2 DNA diluted IIIOOX (- IO ng/~L) 
2Xclone4DNA" " " " 
I ~and4!JLofH20 
I ~Land 4 !JL ofH20 
IX Human Genomic DNA as positive control (I 0 ng/~L) 5 ~L 
IX Blank (H20) 5 ~L 
20 ~of the reaction mixture was added to the target DNA. 
PCR Cyclin& Conditions: 2 Step on Automatic Thermal Cycler 
time 
temp 94°C 5 min 30 sec (denaturing) 
ssoc 6 min (annealing and extension) 
# cycles xi x35 
4oc indefinitely 
5.2.13 Sequencing the Clones and PCR Assays to Confirm they were 
Specific to TPM2 
Purified DNA from clones 2 and 4 was sequenced directly to confirm that they contained 
part of the TPM2 gene. Because the human insert is only a portion of the phage DNA 
more template DNA is required for sequencin!;. ABI protocols suggest using l J.tg of 
phage DNA when sequencing (Appiied-Biosystems, I993). The protocols were the same 
as 2.2.8. 
The 1.5 kb TPM2 STS assay (using clones 2 and 4 DNA as the template from 5.2.12) 
was also sequenced to confirm the clone's inserts were specific to TPM2. 200-300 ng of 
TPM2 STS was used as the template for the sequencing as in 2.2.8. 
89 
5.3 RESULTS AND DISCUSSION 
5.3.1 Determining if the 1.5 kb TPM2 STS was in the Genomic Library 
The 1.5 kb TPM2 STS primers were used on the EMBL3 SP6ff7 library to determine if 
there was a clone that contained that part of the TPM2 gene (exon 6-Ssk). In Figure 5.5, 
lanes l-3 show the STS product from the EMBL3 SP6!f7 genomic library. Lanes 4-6 
show the STS using total human genomic DNA as a positive control. Therefore, there 
were clone(s) present in the genomic library that contained exon 6-8sk of the gene and 
the library could be used to isolate clones containing that part of the TPM2 gene for use 
in FISH. 
The DNA from the A. phage was able to be tarE,··eted by the primers, because the initial 
heating period of 5 min denatured the phage's protein coat. 
5.3.2 Primary and Secondary Screening of the Plaque l>•embrane Lifts 
The initial titering of the eight plates to represent one genomes worth of DNA produced 
an average of 50 000 pfu/plate, as was calculated. The plates were near confluent and 
were ideal for the first screening of the duplicate membrane lifts. The labelling efficiency 
of the 1.5 kb TPM2 STS was approximately 50%, as estimated by the PEl strip after the 
random priming reaction. 
Out of the eight plates that were membrane lifted, there were four duplicate plaques that 
were positive on the autorads (See Figure 5.6). The agar plugs contained several plaque 
colonies and not just the one that was positive, because the titre was so high and the 
plaques were so close to each other. These four plaque colonies were picked as agar 
plugs and replated for a secondary screening (see Figure 5.7 ). 
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FIGURE 5.5 
1.5 l<b TPM2 STS (Exons 6-Ssk) PCR Assay of the Genomic 
Library. 
Lanes 1-3 
Lanes 4-6 
Lane? 
LaneS 
is the STS Present in the Genomic Library. 
is the STS from Human Genomic DNA. 
Blank 
A. Pst I Marker 
2% Agarose Gel, IOOV for 45 min 
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1.5 kb TPM2 STS • 
( exons 6-8sk) 
1--4 
~ .... 
EMBL3 Hwnan ; ~ 
~ SP6{f7 Genomic~ ~ 
I II I 
FIGURE 5.6 
Primary Screening Of Duplicate Membrane Plaque Lifts With 
Radiolabelled 1.5 kb TPM2 STS (Exons 6-Ssk). 
Those Plaques that showed up in Duplicate were 
Considered Positive for Containing that Part of TPM2. 
The Arrows Identify the Clones th<· t were picked for a 
Secondary Screening. 
Developed -80°C, for 16 hours with 1 intensifying screen. 
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DUPLICATE MEMBRANE LIFTS 
CLONE I 
CLONE 2 
CLONE 3 
CLONE 4 
FIGURE 5.7 
Secondary Screening of Duplicate Membrane Plaque Lifts. 
Those Plaques that showed up in Duplicate were 
Considered Positive for Containing that Part of TPM2. 
The Labelled Arrows Represent the Clones that were picked 
for Tertiary Screening. 
Developed ~80°C, for 18 hours with I intensifying screen. 
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FIGURE 5.8 
5' End Labelling of Primers DS 869.6F & DS 866.8skR on the Secondary 
Membrane Lifts. Compare the Plaque Positions with Figure 5.7. 
Developed -800C, for 24 hours with 1 intensifying screen. 
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SECONDARY MEMBRANE LIFTS PROBED WITH TPM2 PRIMERS 
CLONE l 
PRIMER DS 866 EXON 8sk 
CLONE 2 
PRIMER DS 866 EXON 8sk 
CLONE 3 
PRIMER DS 866 EXON 8sk 
CLONE 4 
PRIMER DS 866 EXON 8sk 
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5.3.3 Primers Polynucleotide Kinase 5' End-Labelled as Probes on the 
Secondary Plaque Lifts to Determine if the Clones Contain both Exons 6 
and 8sk 
It was noted two of the (clones 2 & 4) had stronger positive signals on the autorads than 
the other two clones ( 1 & 3). When the secondary screening was done this pattern was 
repeated, clones 2 and 4 gave much stronger positive signals than clones 1 and 3 on the 
autorad (Figures 5.6 & 5.7). 
It was suspected only part of the radiolabelled 1.5 kb TPM2 STS was hybridising to 
clones I and 3 giving the weak signal, while all of the radiolabelled STS was hybridising 
to clones 2 and 4 giving stronger signals. The radio labelled 1.5 kb STS contained exons 
6 to exon 8sk. It was therefore hypothesised that clones 1 and 3 only contained part of 
this STS. The primers DS 869 (exon 6) and DS 866 (exon 8sk), were polynucleotide 
kinase (PNK) 5' end labelled and one probe each was hybridised on one of the duplicate 
secondary membrane lifts. If one primer hybridised to clones 1 and 3 membranes at the 
previous positive plaque positions and the other primer didn't on the second lift, then it 
would confirm that the human insert was cut somewhere between the two primers in 
exon 6 and 8sk. If the two primers hybridised to the same plaque positions on clones 2 
and 4 secondary membrane lifts, then it would confirm that the human inserts contained 
both exons 6 and 8sk. 
In Figure 5.8, for clones 2 and 4, the positive plaque positions were identical on the 
duplicate autorads and both primers hybridised to the same plaques as the original 
secondary screening (compare Figures 5.8 and 5.7). Therefore, clones 2 and 4 both 
contained exon 6 and 8sk in the human insert. 
However, for clones 1 and 3 the duplicate positive plaques were not identical and only 
the labelled primer DS 869.6F (exon 6) hybridised to the same plaques as the original 
secondary screening. The other primer DS 866.8skR (exon 8sk) for clones I and 3 
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hybridised to non-matching plaques from the original secondary screening (compare 
Figures 5.7 and 5.8). This meant that the human insert for clones 1 and 3 did not contain 
exon 8 and that the insert was cut somewhere between the 1.5 kb between exons 6 and 
8sk. 
5.3.4 PCR Assay on Clones 1-4 Eluates 
To confirm that clones l and 3 inserts were cut between exons 6-8sk in TPM2, a PCR 
assay using primers DS 869.6F and 866.8skR was performed on eluates from plaque 
colonies that had been selected. This was compared with the PCR assay of clones 2 and 
4 eluates, which from the PNK experiment showed that these clonr,s contained exons 6-
Ssk. 5 ~of eluted phage from the clone eluates was used as template DNA for the 
primers. 
From Figure 5.9, it can be seen that the primers did not amplify the 1.5 kb TPM2 STS 
from clone I (lanes 1-4) and clone 3 (lanes 7-11) insert DNA, but the STS was amplified 
on clone 2 (lanes 5 & 6) and clone 4 (lanes 12-13) eluates. This confirmed the PNK 
experiment that clones I and 3 insert DNA was cut somewhere between exons 6-Ssk in 
the TPM2 gene and clones 2 and 4 contained these exons. 
Therefore, from the positive results, clones 2 and 4 were chosen for isolation of DNA 
using the plate lysate method as in 5.2.8. This was after the clones 2 and 4 were 
rescreened five times so that almost 100% of the plaques showed up as positive. 
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FIGURE 5.9 
PCR Assay of Clone Eluates 
Lanes 1-4 Clone 1 different chosen plaque eluates. 
Lanes 5-6 Clone 2 " " " " 
Lanes 7-11 Clone 3 " " " " 
Lanes 12-13 Clone 4 " " " " 
Lane 14 Human Genomic DNA (Positive Control) 
Lane 15 '/.. Pst I Marker 
2% Agarose Gel, lOOV for 30 min 
FIGURE 5.10 
C!anes 2 & 4 DNA on a 0.8% Agarose Gel 
Lane I Clone 2 Lambda DNA and Human Insert (Before Purification) 
Lane2 Clone 2 " " " " " (After Purification) 
Lane3 Clone 4 " " " " " (Before Purification) 
Lane4 Clone 4 " " " " " (After Purification) 
0.8% Agarose Gel, IOOV for I hr 
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Clone 2 Unpurified 
Clone 2 Purified 
Clone 4 Unpurified 
Clone 4 Purified 
A. Pst I 
J Clone 1 
J Clone 2 J Clone 3 
J Clone 4 
Genomic DNA 
A. Pst I 
5.3.5 Lysate Processing 
The phage lysate from clones 2 and 4 were processed as in 5.2.8.4. The DNA from the 
caesium chloride gradient did not form a distinct band at the 1.45 g/mL and 1.50 g/ml 
interface. There was a debris band in the 1.45 g/mL gradient and a faint band below this 
but the gradient interfaces were difficult to see after centrifuging. A pellet also fanned on 
the bottom of the centrifuge tube. This made it difficult to collect the DNA, but the faint 
band and the pellet at the bottom were collected and placed into different eppendorf tubes. 
In future, a better technique would be to add to the phage 0.5 mg/mL of CsCl2 in IX 
lambda dilution buffer, with 0.5 Jlg/mL ethidium bromide. After centrifuging the tube 
could be placed over a transilluminator and the DNA extracted where it fluoresces in the 
tube. 
5.3.6 DNA Extraction 
The extracted phage DNA in 5.2.8.5 from clones 2 and 4 was electrophoresed on a 0.8% 
agarose gel at IOOV for one hour (see Figure 5.10). To the phage DNA was added 
RNase (5 ~g/mL) and proteinase K (50 ~g/mL) and incubated at 650C for 15 min, to 
digest any RNA and protein present. The DNA was run on a low melting point agarose 
and excised and purified using the Wizard DNA Cleanup System (Promega). It can be 
seen the phage DNA before purification was contaminated with RNA by the white smear 
at the bottom of lanes 1 & 3, which was not present after purification (lanes 2 & 4). 
Because RNA has a similar absorbance at 260 nm (RNA 1A=40 ng/~L) to DNA (DNA 
1A=50 ng/p,L), accounts for the very high nucleic acid concentration of the unpurified 
DNA as seen in Table 5.1. The recovery efficiency of DNA after purification from the gel 
was quite low, using the Wizard DNA Clean-up System (Promega) as can be seen in 
Figure 5.10 from the intensity of the bands before and after purification. 
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Table 5.2 
EMBL3 Clone's DNA Concentrations on Spectrophotometer 
Mean 
A zoo 
Clone 2 (Unpurified) 0. 73 
Clone 2 (Purified) 0.039 
Clone 4 (Unpurified) 0.312 
Clone 4 (Purified) 0.012 
Mean 
Azso 
0.39 
0.019 
0.169 
0.007 
A26otA2so Dilution Concentration 
1.88 
2.1 
1.84 
1.6 
(ng/JlL) 
200X 7 300 
25X 50 
700X 10 000 
25X 15 
Approximately 1 mL of clones 2 and 4 were obtained from the DNA extrac~ion in 
5.2.8.4-5. From the spectrophotometer readings, 50 fig (50 ng/fiL = 50 fig/mL) of 
clone's 2 DNA and 15 fig of clone's 4 DNA was isolated. This compared well the 
ex pee ted recovery of 20 - 40 fig of phage DNA, from the approximate I 00 mL volume of 
lysate (Clontech, 1994). 
5.3. 7 Restriction Digests of Clones 2 and 4 DNA to Determine if they 
were the same Clones 
The restriction enzymes used on clones 2 and 4 DNA were BamH I, EcoR I and 
Hind Ill. Each clone's DNA was cut with the different enzymes and all the combinations 
using two enzymes per digest. This was to determine if the clones were identical, or if 
the human inserts were different. Figure 5.11 shows the different combinations of 
restriction digests on clones 2 and 4, mn on a l% agarose gel, at SOY for 4 hours. It can 
be seen clearly that the two clones are different each having different human inserts. For 
example, in lanes 3 and 4 (clones 2 and 4 cut with BamH I) there are three distinct bands 
in lane 4, clone 4, that are not present in lane 3, clone 2. 
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FIGURE 5.11 
Restriction Digest of Clones 2 and 4 DNA 
Lane 1 :1. Hind III Marker 
Lane2 :1. Pst I Marker 
Lane3 Clone 2 cut with BamH I 
Lane4 Clone 4 " " " 
LaneS Clone 2 cut with EcoR I 
Lane6 Clone4 " " " 
Lane? Clone 2 cut with Hind III 
LaneS Clone4 " " " 
Lane9 :1. Hind lU Marker 
Lane 10 :1. Pst I Marker 
Lane 11 Clone 2 cut with BamH I and EcoR I 
Lane 12 Clone 4 " ., " " " 
Lane 13 Clone 2 cut with BamH I and Hind III 
Lane 14 Clone4 " " " " " 
Lane 15 Clone 2 cut with EcoR I and Hind lii 
Lane 16 Clone4 " " " " " 
Lane 17 :1. Hind lii Marker 
Lane 18 :1. Pst I Marker 
Lane 19 Clone 2 Uncut 
Lane20 Clone 4 Uncut 
The products of the digests were run on a 1% agarose gel, at SOV for 4 hours. 
FIGURE 5.12 
1.5 kb TPM2 STS of Clones 2 And 4 Purified DNA. 
2% Agarose Gel, lOOV for45 min 
100 
A Pst I 
Clone 2 
Clone 4 
A Hindill 
A. Pst I 
~ ] BamHI 
t-) ] EcoR I 
~ 
t-) ] Hindill 
~ 
A. Hindill 
A. Pst I 
~ ] BamHI& EcoRI 
~ ] BamHI&Hindill 
t-) ] EcoR I & Hind ill 
~ 
A. Hindill 
A. Pst I 
t-) ] Uncut 
~ 
From Figure 5.1 showing the restriction map of EMBL3 SP6ff7, and Figure 2.12 
showing the restriction map of the 1.5 kb TPM2 STS, it can be seen none of the 
restriction enzymes cut either the vector arms or the exon sequence of the TPM2 STS. 
Therefore any lanes that showed more than two bands was due to the restriction enzymes 
cutting the insert DNA, other than the exon sequence (exons 6-Ssk) of the STS. 
This meant two different clones that contained part of the TPM2 gene had been isolated 
and could be used in F1SH to veri~r each others localised position. 
The size of clones 2 and 4 inserts cannot be determined precisely from Figure 5.10, but 
can be estimated from the restriction digests in Figure 5.11. It was assumed all the lower 
bands, were the insert DNA, because none of the enzymes used cut the vector EMBL3 
SP6!f7 arms, as can be seen in Figure 5.1. Therefore, the lower molecular weight bands 
must have been insert DNA that was cut. Using the A. Hind III and A. Pst I markers, the 
band sizes can be added to give an approximate insert size. 
For clone 4 in lane 12, three lower bands can be seen (1.5, 2 and 3.5 kb) that add up to 
7 kb and if the band abov<>: these is 8 kb, then this gives an approximate insert size of 15 
kb. 
For clone 2 on another digest (data not shown) the insert was slightly larger than clone 4 
and was estimated to be approximately 16-18 kb. 
5.3.8 PCR Assay of Clones DNA Using the 1.5 kb TPM2 STS 
Primers DS 869 (ex on 6) and DS 866 (ex on 8sk) were used on the purified clones 2 and 
4 DNA to determine if the human inserts contained the 1.5 kb TPM2 STS. Figure 5.12 
shows the STS from clones 2 and 4 in lanes 2 and 3 respectively with the 'J.. Pst I marker 
in lane 1. Human genomic DNA was used as a positive control in lane 4, but it did not 
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amplify. This showed that the purified DNA from clones 2 and 4 contained the 1.5 kb 
TPM2 STS from exons 6 to 8sk. 
5.3.9 Sequencing Clones 2 and 4 DNA and the 1.5 kb TPM2 STS 
The most direct way of continuing that clones 2 and 4 contained part of the TPM2 gene 
was to sequence the insert DNA using primers DS 869.6F (exon 6 forward) and DS 
866.8R (exon 8sk reverse). 1 p,g of each clone was used to allow ensure sufficient 
template. However, no useable sequence was obtained after using this method a few 
times. 
The next most direct method, was to sequence the 1.5 kb TPM2 STS using the two 
clones as template DNA. Figure 5.13 shows the sequence of the TPM2 STS from clone 
4 which has been summarised into Table 5.2. The sequence extended for approximately 
450 bases from primer DS 869 in exon 6, to intron 6, exon 7 and into intron 7. When 
the sequencing results were compared with that of Widada et al. (1988) TPM2 sequence, 
out of 70 bases in exon 7 only one base was different and two bases could not be read 
(ie. N). The one base that was different in exon 7 was a thymine from Widada's 
sequence was substituted for an adenine. The thymine is conserved in all the TPM's. The 
base mismatch is not likely to be real because the adenine was next to a 'N' in the 
sequence, so it was not sequencing well at that point. The sequence variations were likely 
to be due to the template preparation, the sequencing reaction or the sequencer tracking, 
reading and analysing the fluorescent end labelled products. The sequencing from the 
reverse primer (DS 866.8skR) in exon 8sk was not useable. 
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FIGURE 5.13 
Sequence ofTPM2 STS using Clone 4 as Template DNA from 
Primer DS 869.6F in Ex on 6. 
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Table 5.3 
Sequence of Clone 4 compared to TPM2 and other TPM's 
EXON 6 
TPMl t.Q.Qtttccga ga,sgctgaag gag 
TPM3 ttcttactga .ta.Mct.Qaag gag 
TPM4 ttctgtctga .Qa.Mctgaaa gag 
TPM2 tgttggagga gaagctgaag gag 
Clone 4 tgt.Qggagga ga~gttgang gag 
EXON 7 
TPMl gctgagac.t,c gggctgagtt tgcggagagg tcggtaac.!;.a 
TPM3 gcggagaccc g_tgctgagtt tgc.tgagagg tcggtggc.Qa 
TPM4 gctgagaccc g,tgctgaatt tgcagagagg gcggt.tgcaa 
TPM2 gctgagaccc gagcagagtt tgccgagagg tctgtggcaa 
Clone 4 gctgagaccc nagcagagtt tgccgagagg tctgtggcaa 
TPMl agt tggag·aa aagcat.tgat gac.ttagaag 
TPM3 ag.Qtgga,gaa g:ac2_at.tgat gacctggaag 
TPM4 a£!.Qtggas_aa gacg_at.tgat gacctggaag 
TPM2 agttggagaa aaccatcgat gacctagaag 
Clone4 agttggagaa aaccaangat gacctagaag 
From the TPM2 STS sequence of exon 7, it mRtched Widada et al. published sequence 
by 96%. The underlined bases frw TPMs l, 3 and 4 and clone 4 are those bases that 
differ to the TPM2 sequence. The 'me balded bases in clone 4 are those bases that are 
only unique to TPM2. Therefore, it can be confident that clone 4 was specific to TPM2. 
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Anthony Akkari at ANRI, also sequenced the STS product from primer DS 869.6F and 
out of 35 readable bases in exon 6 only one base could not be read (ie. N) and all 70 
bases in exon 7 matched Widada et al. sequence and also confirmed that clone 4 was 
specific to TPM2. 
Clone 2's sequencing results were not useable, but from the 1.5 kb TPM2 STS that was 
amplified from the clone's DNA as template, it can be confident that the clone 2 was also 
specific to TPM2. 
Anthony Akkari also sequenced clone 2 from tt.o reverse primer DS 866.8skR. Out of 54 
readable bases in exon 8sk, only three bases could not be read (ie. N) and matched 
Widada et al.'s sequence by 94% and therefore confirmed that clone 2 was specific to 
TPM2. 
5.3.10 Hybridising Clones DNA to Genomic Blot 
IIJg of clone 4 DNA was radiolabelled and hybridised to a human genomic blot that had 
been cut with BamH I and Pvu I!. In Figure 5.14, the human DNA in lanes 1-6 and 8 
and had been cut with BamH I. Lane 7 was a'}., Hind III marker and lanes 9-16 were 
human DNA that had been cut with Pvu II. There were no discrete consistent bands 
across either digest, except in lane 7 where the EMBL3 SP6ff7 arms, hybridised with 
the A. phage DNA that had been cut with Hind lii. The probe hybridised unspecifically to 
the digested human DNA as there were only smears in the lanes. It was hoped that the 
probe would hybridise at distinct bands, indicating that the probe insert would hybridise 
well with genomic DNA, especially when used for FISH. 
Clone 2's hybridisation to human DNA that had been digested with EcoR I was also 
unsuccessful as not enough template DNA was labelled (data not shown). 
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The experiment was not repeated as the use of the labelled clones on genomic blots was 
not essential to the project. It only gives an indication of the hybridising ability of the 
clones to genomic DNA and time spent optimising the conditions was not a priority. The 
clones may stiH hybridise successfully in FISH. 
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FIGURE 5.14 
Radiolabelled Clone 4 DNA Hybridised to a Genomic Blot 
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CHAPTER 6 
USE OF GENOMIC CLONES FOR FISH 
6.1 INTRODUCTION 
Approximately 10 J.lg of clones 2 and 4 DNA was sent to the Department of Cytogenetics 
and Molecular Genetics, at Adelaide Children's Hospital, for use in FISH. 
6.2 MATERIALS AND METHODS 
The same methods were used as in 4.2. 
6.3 RESULTS AND DISCUSSION 
Clones 2 and 4 were used for FISH to metaphase spreads from three nonnal males. 
Twenty-five metaphases from the first nonnal male were examined for fluorescent signal 
with clone 2. Eighteen of these metaphases showed signal on one or both chromatids of 
chromosome 9 in the region 9p13-p21; 95% of this signal was at 9pl3.1 (see Figure 
6.1 ). There was a total of 11 non-specific background dots observed in these 25 
metaphases. A similar result was obtained from hybridisation of this probe to 15 
metaphases from the second nonnal male and from hybridisation using the probe of clone 
4 to 20 metaphases from the 3rd normal male (data not shown) (Hunt, et al., 1995). 
The 1.5 kb TPM2 STS that was used as a probe for FISH, didn't work, yet the genomic 
clones 2 and 4 were both successful in FISH. All probes were reduced to 200-500 bp 
fragments by the nick translation, and so were likely to be equally specific as probes for 
the TPM2 gene. It was likely the greater amount of labelled DNA in the genomic clones 
(-15-18 kb) was able to hybridise to the metaphase chromosomes and give a stronger 
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signal, than the 1.5 kb TPM2 STS. This probably explains why the genomic clones 
worked in FISH and the 1.5 kb TPM2 STS was unsuccessful. 
The localisation to 9pl3.1 confinned and refined the somatic cell hybrid panel localisation 
to chromosome 9. 
' \'. 
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FIGURE 6.1 
Metaphase showing FISH with the probe TPM2.2. 
(a) Normal male chromosomes stained with propidium iodide. 
Hybridisation sites on chromosome 9 are indicated by arrows. 
(b) The same metaphase as (a) stained with DAPI for chromosome 
identification. 
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CHAPTER 7 
IDENTIFICATION OF A POLYMORPHISM IN THE TPM2 
GENE 
7.1 INTRODUCTION 
The majority of human DNA is not involved in coding sequences and is therefore not 
subject to tight selection. If the sequence is compared in a noncoding autosomal region 
from 10 individuals, then a nucleotide will be found approximately every 200 bp at which 
there is a sequence vari::ttion (Gelehrter & Collins, 1990). These variations are usually 
due to simple base changes and are called DNA polymorphisms (Gelehrter & Collins, 
1990). A DNA polymorphism is, then, is a region of variable sequence between different 
individuals. 
A method to find polymorphisms involves testing approximately 10 people. If one allele 
is polymorphic then the frequency of alleles having the polymorphism is approximately 
5%, as 10 people each have two alleles. A polymorphism with a frequency less than this 
would not be generally useful as a marker in the genome, as very few families would be 
informative in demonstrating Mendelian segregation. If a polymorphism is identified, 
then its frequency can be refined by screening 50- 100 individuals (Cichon, et al., 1994; 
Rnlfs, et al., 1994; Shen, et al., 1994). 
A technique to identify sequence variation is the single stranded conformation 
polymorphisms (SSCP). SSCP is where a PCR amplified segment of the gene ( 100-350 
bases) is denatured into single strands and snap chilled so the fragments collapse in the 
most stable single stranded tertiary form. The PCR incorporates a radioactive nucleotide 
such as (a.-P32) dCTP. The strands are separated OP.. a nondenaturing polyacrylamide gel 
under constant voltage so the polymorphisms keep their tertiary forms. Any fractionated 
bands that are different for different individuals indicate a polymorphism. These can be 
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cut out, reamplified by PCR and sequenced to determine the different nucleotide sequence 
between individuals. If the polymorphism is inherited in a Mendelian fashion, then the 
polymorphism can be used for linkage studies and entered on the CEPH map (Hayashi, 
1991; Wilton, 1993). 
CEPH is the French Centre d'Etude du Polymorphisme Humain or the world database 
centre for mapping human polymorphisms (Dausset, et al., 1990). CEPH makes 
available DNA samples from a panel of reference families for the determination of 
genotypes for various DNA polymorphisms, which may be used for the construction of a 
genetic linkage map of the human genome. CEPH provides access to DNA from a 
common set of families for researchers investigating this area. Forty families were 
selected in 1984, based on large sibship size, with multigenerations to demonstrate 
Mendelian segregation of discovered polymorphisms. Families were chosen for their 
large sibship size and not for inherited diseases. The DNA of each individual was isolated 
from cultured lymphoblastoid cell lines (LCL). Researching collaborators investigate the 
genotypes with their probes, to test for segregation of these markers in the panel of 
families. This then contributes to the linkage analysis database and the map construGtion 
(Dausset, et al., 1990). 
7.1.1 Polyacrylamide Gel Electrophoresis for Running SSCPs 
Polyacrylamide gel electrophoresis is used to separate different DNA fragments. 
Acrylamide is an organic monomer with the following structure: 
CH2=CH-C-NH2 
II 
0 
acrylamide 
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N,N'-methylenebisacrylamide 
(Sambrook, et al., 1989) 
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usually supplied by ammonium persulfate (NH4)2SzOs and is stabilised by TEMED 
{N,N,N',N'-Tetramethylethylene diamine). Cross-linking of the chains is performed by 
N,N'-methylenebisacrylamide in the reaction. The porosity of the gel is determined by 
the length of the chains and the degree of cross-linking (Sambrook, et al., 1989). 
The length of the chains is determined by the concentration of the acrylamide (between 
3.5% and 20% ). The greater the concentration is, the less porous and greater resolving 
power of the gel to separate molecules of DNA (Sarnbrook, et al., 1989). 
The acrylamide to bisacrylamide ratio also detennines the amount of cross-linking and 
resolving power of the gel. For example an acrylamide to bisacrylamide ratio of 29:1 is 
where I molecule of cross-linker is included for every 29 monomers of acrylantide. The 
less the ratio is, or the more bisacrylamide, the greater the resolving power of the gel is, 
as it has more cross-linking and so the gel is less porous (Sambrook, et al., 1989). 
The resolving power of acrylamide gels is such that they can separate molecules of DNA 
that differ in length by as little as 0.2% or for example, 1 bp in 500 bp (Sambrook, et al., 
1989). 
7.2 MATERIALS AND METHODS 
7.2.1 Amplifying Exons lsk to 2sk in clones DNA 
TPM2 primers DS 84G (exon lsk forward) and DS 841 (exon 2sk reverse) were used on 
clones 2 and 4 DNA in a PCR reaction to see if the clones contained exons lsk- 2si.~ of 
the TPM2 gene which may be used to identify a polymorphism. The reaction was set up 
as follows: 
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Reaction Mixture 
Tth Buffer (S.z200J 
Primers 840 + 841 ( 10 ng/j.lL of each primer) 
Tth (5 .. 5 ufj.lL) 
HzO 
Total 
Lanes I +2 2X genomic clone 2 (10 ng/f!L) 
Lanes 3+4 2X genomic clone 4 (15 ng/f!L) 
JX 20 UL 
Sfl,L 
2fl,L 
0.1 IlL 
12.2 uL 
20.0 uL 
7X 
35 IlL 
14 IlL 
0.7 IlL 
90.3 ML 
140.0 ML 
I j.lL + 4 fl,L HzO 
I fl,L + 4 J.!L HzO 
Lanes 6+ 7 2X total human genomic DNA (10 ng/fl,L) 5 IlL 
Lane 8 IX blank (HzO) 5 IlL 
The 7X reaction mixture was added with the target DNA to make a 25 J..LL reaction. So 
20 j.lL of the reaction mixture was added to lj.lL of clones 2 and 4's DNA and ·1j.lL of 
HzO. 20 IlL of the reactiorl mixture was also added to 5 J.!L of the human genomic DNA 
and blank. Cycling and agarose electrophoresis conditions were the same as 2.2.2-4. 
7.2.2 Amplifying Exon Ssk to 3' Untranslated Region of TPM2 
TPM2 primers DS 870 (exon 8sk forward) and DS 867 (3'UTR reverse) were used on 
clones 2 and 4 DNA in a PCR reaction to see if the clones contained the 3'UTR of the 
TPM2 gene. Human genomic DNA was also used as a positive control. The experiment 
was set up as in 7.'2.1, except the different primers were used. 
7.2.3 TPM2 Exon Ssk - 3'UTR SSCP in 10 Unrelated Individuals 
Primers DS 870 (8sk.F) and DS 867 (3'UTR.R) were used on 10 unrelated individuals 
to attempt to discover a polymorphism that would have an allele frequency greater than 
5%. The PCR conditions used were: 
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For a 10 ~tL Reaction:-
Target DNA (50 ng) 5.0 ~tL (10 ng/~tL) 
5X )50 Buffer 2.0 ~tL 
(5X Tth buffer, 5 mM MgClz, 250 j.tM dNTP's) 
Tth DNA polymerase (5.5 units/~tL) 0.1 IlL 
Primer mix (870 + 867) (20 ng/j.tL) 1.0 j.tL 
(a-P32) dCTP (10 j.tCurie/j.tL) (Bresatec) 0.1 j.tL 
HzO 1.8 ~L 
TOTAL 10.0 j.tL 
lOX unrelated individuals DNA (10 ngi!!L) 5.0 j.tL 
PCR Cyclin~ Conditions: 3 Step on Automatic Cycler 
time 
temp 94°C 4.5 min 30 sec (denaturing) 
62°C 1 min (annealing) 
72°C I min (extension) 
# cycles xl x30 
4°C indefinitely 
7.2.4 Pouring an Acrylamide Gel 
1. The glass plates were thoroughly cleaned with hot water, Pyroneg detergent and a 
cloth. 
2. The plates were rinsed by spraying 100% ethanol and they were left standing upright 
to dry. 
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3. The front plate was silicor,ised under a fumehood by mixing 0.5 mL of dimethyl-
dichlorosilane with 5 mL of chloroform and wiping over the gel surface side of the plate 
with Kimwipes (lint-free tissue paper). Tl1~.s was so the gel would lift freely off the front 
plate and stay to the back plate. The back plate was lightly siliconised by wiping the 
moist Kimwipes over the gel surface side of the back plate. This was to ensure that the 
acrylamide gel poured easily and evenly between the plates. 
4. The plates were assembled with the spacers and the bottom and sides of the plates 
were taped to prevent the gel leaking. Bulldog clamps were placed down the sides of the 
plates (see Figure 7.1). A plastic weclgo was used to slightly separate the plates. 
5. 70 rnL of 12% or 6% non-denaturing acrylamide gel (39:1 acrylamide to 
bisacrylamide) (see Appendix 2) was de-gassed in a 100 rrJ.... beaker for 20 min, to 
remove the dissolved air. Otherwise fine bubbles come out of solution when the gel is 
poured, over the surface of the plates. 
6. 100 IlL of TEMED and I 00 IlL of 25% ammonium persulphate (APS) were added to 
the accylamide and quickly mixed. 
7. The plates were raised about 30° and immediately the gel mix was drawn up into a 
50 mL syringe and carefully squirted between the glass plates next to the plastic wedge. 
If the plates were clean, the gel should move up the plates as a uniform front with no air 
bubbles. When the gel mix reached a few em from the top of the plates, the plates were 
placed horizontal and the wedge was removed and the rest of the gap was filled by the 
gel. 
9. Any bubbles fmmed were removed by a thin plastic hook (Promega). 
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FIGURE 7.1 
Acrylamide Gel Electrophoresis 
(Sambrook et al., 1989; ANRI, 1994) 
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10. A 0.35 mm thick well fanner was placed in the top of the plates 3/4 of the way in and 
clamped with buiidog clamps. Gel was poured around the well fanner occasionally to 
prevent the acrylamide from drying out and shrinking back into the plates. 
11. The gel was allowed to set for at least one hour. Usually the gel polymerised within 
the first 5-10 min. To store the gel, damp paper towels were placed over the well former 
and the top of the plates was wrapped in glad wrap to prevent the gel drying out. The gel 
could be stored for several days at 4oc. 
(ANRI, 1994; Sambrook, eta!., !989) 
7 .2.5 Running the Gel 
l. The Hoefer Pokerface II electrophoresis equipment was used, which consisted of a 
lower buffer tank, an upper buffer chamber and heat distributing back plate, two plastic 
side clamps and electrodes. 
The power pack used was the Biorad 3000Xi, which is capable of supplying constant 
voltage up to !500V. 
2. The clamps, paper and any glad wrap were removed. 
3. The backing plate was fastened to the back glass plate with the side clamps. 
4. The lower buffer chamber was filled with about 500 mL of IX TBE, or until the 
buffer was a few em above the glass plates when the gel assembly stood in the lower 
buffer chamber. The upper buffer chamber was filled with lX TBE, until it was a couple 
of em above the top of the front glass plate. 
5. The well fermer was removed and a sharks tooth well comb was inserted until the 
teeth just entered the gel surface. 
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6. After the PCR reaction (7.2.3), formamide loading buffer (FLB) was added to each 
tube in a ratio of 1:1 (ie. 10 !!L). The PCR reaction and FLB were heated to 95oc for 5 
min to denature the DNA. The samples were then snap chilled on ice to form single 
stranded confonnation fragments in the most stable tertiary form. 1 JlL of each sample 
was loaded in each lane. 
7. The electrodes were attached and the samples were run into the gel by focusing at 
1250V for 1 min. 
8. The samples were then run at 400V, for 16-20 hrs, at room temperature, overnight. 
400V was used so the gel did not overheat and denature the single stranded 
confonnation. 
(ANRI, 1994) 
7.2.6 Fixing and Drying the Gel 
1. The electrodes and gel assembly were removed and the top and bottom buffer 
chambers were emptied down the radioactive flushing sink. 
2. The gel assembly was disassembled by removing the side clamps and the backing 
plates. 
3. The glass plates were laid down horizontaily over the flushing sink and the plates 
separated using a metal spatula. The front glass plate was removed. 
4. Strips of tissue paper were placed around the edge of the horizontal gel and fixative 
(10% acetic acid and 10% methanol, see Appendix 2) was poured over the entire gel. The 
tissue paper acted to drain away the fixative. 
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5. The fixative was successively poured over the gel for about 10 min so the entire gel 
was well covered and washed (about 500 mL in total). The tissues were removed after 10 
min and the fixative was allowed to drain away. The fixative ensured the DNA would 
remain in the gel when vacuum blotting and stop it diffusing in the gel. 
6. The gel was monitored using a geiger counter for the area of high activity and the 
unneeded gel (lanes not used) was cut away using a scalpel and lifted using Whatman 
3MMpaper. 
7. A piece of Whatman 3MM paper was cut slightly larger than the remaining gel and laid 
over the gel, avoid trapping air bubbles. The paper was pressed down gently on the gel 
and lifted smoothly from one end. The gel should stick to the paper and come away flat. 
8. The gel was covered with glad wrap and cut to the size of the paper. One comer was 
cut to orientate the gel. 
9. The gel lift was laid on a piece of 3MM in the gel drier and covered with the silicon 
rubber seal. The vacuum was turned to full and the gel dried for one hour at 80°C. 
10. Autoradiography was performed as usual with Dupont Cronex 4 X-ray film with 
Quanta III autoradiography intensifying screens at -80°C, for an empirically detennined 
time. 
(ANRI, 1994) 
7.2.7 TPM2 Ssk - 3'UTR SSCP on DNA from 97 Unrelated Individuals 
Primers DS 870 and 867 were used on 97 unrelated individuals to detennine the allele 
frequency of the polymorphism, using the methods described in 7.2.2-6. The samples 
were run on a 6% non-denaturing acrylamide gel. 
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7.2.8 TPM2 Ssk • J'UTR SSCP on DNA from 9 Families to Determine if 
Polymorphb.m Segregates in a Mendelian Fashion 
For those of the 97 individuals that had the rare allele, families were selected, based on 
multigenerations to see if the polymorphism segregated in a Mendelian fashion. Nine 
families were selected and primers DS 870 and 867 were then used on these families as 
in 7.2.2-6. 
7.2.9 Sequencing of the TPM2 Polymorphism from Exon 8sk.F-3'UTR.R 
from Band Stabbing an Acrylamide Gel. 
The -250 bp TPM2 STS (8sk-3'UTR) samples that were homozygous for the rare allele 
were run together side by side on a 6% non-denaturing acrylamide gel, and the samples 
for the conunon allele were run side by side, to compare all the alleles to see if there were 
more than two alleles. The gel was exposed wet, so it wasn't vacuum dried. The lifted 
gel was labelled with fluorescent ink and the at1torad was then matched back with the gel. 
A flame heated iron needle was then pushed through the autorad and into the gel to mark 
where rare and common alieles for several individual samples were. For each individual 
sample, the four corners of the lane where the allele was present was stabbed. The bands 
of 7 heterozygous individuals for the rare allele were cut out with a scalpel and placed 
into separate 1.5 mL eppendorf tubes with 0.5 rnL of TE buffer. The gel bands for four 
individuals, that were homozygous for the common allele, were cut out. 
The gel with the cut out bands was then re-exposed to confirm that the bands were cut 
out exactly where the rare and common alleles were. 
Using the DNA eluted from the bands as template, a 50 J..LL PCR was set up using 
primers DS 870 (ex on 8sk.F) and DS 867 (ex on 3'UTR.R) as in 2.2.6. I, except 5X 
2100 (10 mM MgCl2, 500 11M dNTP's) buffer was used. Three individuals for the rare 
allele and one individual for the common allele were amplified. 5 IlL of the eluted 
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template was used with 20 ~of the reaction mixture. The cycling conditions were: 94oc 
for 5 min, 30 cycles of 94°C for 30 sec and 60°C for 6 min. 3 J.LL of each product was 
run on a 2% agarose gel, at IOOV, for I hr, with 3 J.LL of J..Pst I marker. The DNA from 
each sample was then run on a low melting point agarose gel and purified using 
WizardTM PCR Preps Purification System, as in 2.2.6.1-2. The DNA concentration was 
then measured on the spectrophotometer. 
50 ng each of the four samples were then used in the sequencing reaction as in 2.2.8. 
Sequencing was from primer DS 870 (exon Ssk-forward) and from primer DS 867 
(3'UTR-reverse) for each sample. 
7.2.10 Sequencing Homozygous Individuals for the TPM2 (Ssk.F· 
3'UTR.R) common and rare allele 
After screening the 97 individuals and 9 families, two individuals were discovered to be 
homozygous for the rare allele. The DNA from these two individuals were amplified 
using primers DS 870 and 867 and the polymorphism sequenced as in 7 .2.8. The 
sequence was compared by sequencing two homozygous individuals for the common 
allele. 
7.2.11 Restriction Digest of -250 bp TPM2 STS (8sk-3'UTR) 
After finding a restriction site for the suspected polymorphism base change, a restriction 
digest was set up using Bgl I. A PCR was performed using primers DS 870.F (exon 
8sk) and DS R67.R (3'UTR) on total human genomic DNA from a heterozygous allelic 
individual, a homozygous common allele individual and a homozygous rare allele 
individuaL The subjects were chosen by looking at the SSCP gels. The conditions of the 
PCR were: 
122 
For a 25 LLL Reaction:~ 
Reaction Mixture 
. - __ ,., "'"·'- -··-- .: ... _. --·--~-_.,_,, __ 
Target Genomic DNA (50 ng) 
5X JIOO Buffer (buffer, nucleotides and MgC12) 
(5X Tth buffer, 5 mM MgCh, 500 ~M dNTP's) 
Tth DNA polymerase (Biotech) (5.5 units/mL) 
Primer mix ( 10 ngi~L of each primer) 
H20to25~ 
TOTAL 
Target DNA 
IX hetero7.ygous allelic individual 
IX homozygous common allelic individual 
IX homozygous rure allelic individual 
5.0~L 
5.0~L 
0.1 ~L 
2.0~L 
.!2.2..)!!. 
25.0 ILL 
Final Cone. 
2ngi~ 
I mM,IOO~ 
0.22 u/~L 
0.8 ng/~L 
( 10 ng/~L) 5 ~L 
" " 
" " 
PCR Cycling Conditions: 2 Step on Automatic Thermal Cycler 
time 
temp 94°C 5 min 30 sec (denaturing) 
60°C 6 min (annealing and extension) 
# cycles xl x30 
4oc indefinitely 
The STS product from the PCR was run on a 2% agarose gel at IOOV, for l hour as in 
2.2.3-4. 
The STS products from the three different individuals were digested using the restriction 
enzyme Bgl I, as in 5.2.9, and run on a 3% agarose gel at IOOV for 1 hr and 20 min. 
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The gel was stained with ethidium bromide (0.5 Jlg/mL) for I 0 min and observed on the 
UV transilluminator as in 2.2.4. pGern marker was used to detennine fragment sizes. 
7.3 RESULTS AND DISCUSSION 
7.3.1 Amplifying Exons lsk to 2sk in clonal DNA 
TPM2 primers DS 840 (exon lsk forward) and DS 841 (exon 2sk reverse) were used on 
clones 2 and 4 DNA in a PCR reaction to see if the clones contained exons lsk ~ 2sk of 
the TPM2 gene, which may be used for an SSCP. Clones 2 and 4, had DNA that was 
specific to TPM2 and so was used as target DNA. The clones were used, as the primers 
did not amplify a product when total human genomic DNA was used and by having more 
specific template would increase the probability of the PCR working. There are about 
200 bp between the primers using Clayton et al.'s (1988) structure of TPM3, in Figure 
1.3, 100 bp in the muscle specific exons and 100 bp in the intron. An approximate 200 
bp fragment was expected from TPM2, but there were no discernible bands from the 
amplification when run on a 2% agarose gel (no data shown). This meant that clones 2 
and 4 most likely did not contain exons 1 sk and 2sk. 
The average insert of the TPM2 clones was 15-18 kb, which were already shown to 
contain exons 6- 8sk, in Figure 5.9. Since the TPM3 gene is approximately 42 kb long, 
or 28 kb from ex on lsk-8sk and assuming it has a similar structure to TPM2, then it was 
expected that these clones would most likely not contain these exons (lsk- 2sk) because 
of the limitations on the amount of DNA that can be cloned in the EMBL3 SP6!f7 vector 
(Sambrook, et al., 1989). But it was still worth attempting to confinn this hypothesis. 
7.3.2 Amplifying Exon 8sk to 3'UTR of TPM2 
TPM2 primers DS a?O (exon 8sk forward) and DS 867 (3'UTR reverse) were used on 
clones 2 and 4 DNA in a PCR reaction to see if the clones contained the 3'UTR of the 
124 
'' -· ·- '''~ 
TPM2 gene. Human genomic DNA was also used as a positive controL In Figure 7 .2, 
using the APst I markP-r, it can be seen an approximate 250 bp product was amplified in 
clone 2 (lanes 1&2), clone 4 (lanes 3&4) and in human genomic DNA (lanes 5&6). 
There are 259 bases from and including primer 870 (in exon 8sk) to primer 867 (in 
3'UTR) using the published sequence of (Widada, eta!., 1988). Therefore, there is no 4 
kb intron VIII, before exon !Xsk, which is in the 3'UTR as Clayton et a!., (1988) 
suggests in TPM3, for the skeletal muscle isoform (see Figure 1.3). This would make 
the TPM2 gene at least 4 kb less than the 42 kb TPM3, so the TPM2 gene would be 
approximately 38 kb. 
One can be confident that the amplified -250 bp TPM2 STS (8sk-3'UTR) was not a 
pseudogene, because it was amplified from the two clones and because primer DS 870 
was in a muscle specific exon (2.1.2.2). These clones contained a fragment of the TPM2 
gene in the insert, as had already been shown by sequencing and both were localised and 
the 1-1 ';11ers could only anneal to the target DNA present. The STS was repeated from the 
human g~~lf\r:l\·,· • !NA, as a positive control, so it can be confident the STS was unique to 
TPM2. 
7.3.3 TPM2 Exon Ssk - 3'UTlt SSCP in 10 Unrelated Individuals 
Primers DS 870 (8sk.F) and DS 867 (3'UTR.R) were used on 10 unrelated individuals 
to attempt to discover a polymorphism that would have an allele frequency greater than 
5%. In Figure 7.3, it can be seen in lanes 1 and 3, there was a SSCP. These individuals 
were heterozygous for that allele. The other individuals were all homozygous. The 
products were run on a 12% non-denaturing acrylamide gel at 400V for 24 hour." The 
gel was exposed for 8 hrs at -sooc with an intensifying screen. Lane~ 11 .9.nd 1£ were a 
positive control. The image is not clear, but the PCR and electrophoresis conditions were 
optimised later. 
125 
FIGURE 7.2 
-250 bp TPM2 STS (Exons Ssk- 3'UTR) from Clones 2, 4 & Human Genomic 
DNA 
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-500bp TPM2 STS ... 
(exons 8sk-3'UTR) 
.. 
FIGURE 7.3 
SSCP of DNA from 10 Unrelated Individuals from the -250 bp 
TPM2 STS (exon Ssk · 3'UTR) 
12% SSCP Gel, Run at 400V for 24 hrs at Room TeiT'perature. 
Developed After 8 hrs, at -80°C, I Quanta III Intensifying Screen. 
Annealing Temperature 55°C 
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7.3.4 TPM2 8sk - 3'UTR SSCP in 97 Unrelated Individuals 
Primers DS 870 and 867 were used on 97 unrelated individuals to determine the allele 
frequency of the polymorphism. Out of the 97 individuals, 16 individuals were 
heterozygous with both alleles and one individual (sample 85) was homozygous for the 
rare allele (Figure 7.4 shows samples 61-103). Therefore, the allele frequency was 0.09 
for the rare allele, 0.91 for the common allele and the heterozygosity was 0.16. Note, the 
SSCP running conditions were improved as a 6% non-denaturing acrylamide gel was 
used to separate the alleles more and an annealing temperature of 620C, instead of ssoc 
was used, which increased the annealing specificity of the primers. 
7.3.5 TPM2 8sk - 3'UTR SSCP on DNA from 9 Families to Determine if 
Polymorphism Segregates in a Mendelian Fashion 
The SSCP was then run in nine families from the 17 individuals out of the 97 that had the 
allele. The nine families were selected predominantly to demonstrate the segregation of 
aiieles in a Mendelian fashion, so as many generation~ as could possibly be included in 
the family was the main criterion, as well as large sibship size. 
The segregation of the rare and common alleles was demonstrated in a Mendelian fashion 
in all nine families except one. The segregation data will be shown for just two of these 
families. 
From Figure 7.5 showing the SSCP gel and family 1 's pedigree, it can be seen that the 
rare allele does not segregate in a Mendelian fashion. The granddaughter and grandson 
(samples 5 & 6 respectively) are heterozygous for the alleles yet neither of their parents 
(samples 3 & 4) are heterozygous, but are both homozygous for the common al1ele. 
Likewise, the mothers grandparents (samples 1 & 2) are both homozygous for the 
common allele. It was later demonstrated by microsatellite linkage analysis at Royal Perth 
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FIGURE 7.4 
SSCP Frequency • Unrelated Individuals 61 • 103. 
6% SSCP Gel Run at 400V, for 16.5 hrs at Room Temperature. 
Developed after 4 hrs, at -80°C with 1 Quanta III Intensifying Screen. 
Annealing Temperature 62°C. 
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FIGURE 7.5 
Segregation of Polymorphic Alleles in Family 1. 
6% SSCP Gel Run at 400V for 18.5 hrs at Room Temperature. 
Developed after 3 hrs, at -80°C with one Quanta III Intensifying Screen. 
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FIGVRE 7.~ 
Segregation of Polymorphic Alleles in Family 2 
6% SSCP Gel Run at 400V for 17.5 hrs at Room Temperature, 
Developed after 1.5 hrs, at -sooc, with one Quanta III Intensifying Screen. 
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Hospital, that there was a sample mix~up in the supplied DNA and that the father (sample 
3) was really the son (sample 6), which then shows the rare allele segregating in the 
family. This was quite a useful error to discover, as any other research trying to 
demonstrate Mendelian segregation in this family, would also not have been able to do 
so. It also demonstrates the polymorphism is real and segregates in families as it was able 
to detect a sample mix-up, when blood samples were taken. Therefore, Family 1 was 
very useful for demonstrating the segregation of the TPM2 polymorphic alleles. 
Family 2 (Figure 7 .6) was interesting, because two heterozygous parents for the TPM2 
Ssk- 3'UTR allele (samples 1 & 2) produced a daughter that was heterozygous (sample 
3) and a son who was homozygous for the rare allele (sample 4). The homozygous allele 
can be seen quite clearly in Figure 7.6, sample 4 for Family 2. 
It can therefore, be stated confidently that the TPM2 8sk-3'UTR allelic polymorphism 
segregates in a Mendelian fashion. 
The PCR and electrophoresis conditions were optimised for the SSCP and the conditions 
listed in 7.2.3 were discovered to be optimal, when run on a 6% non-denaturing 
acrylamide gel, at 400V, for 20 hours. Note, the annealing temperature 62°C was quite 
high compared to nmmal PCR anne-aling temperatures. 
7.3.6 Sequencing of the TPM2 Polymorphism from Exon Ssk -3'UTR 
from Band Stabbing an Acrylamide Gel. 
An SSCP gel of the first 55 unrelated individuals was run on a 6% no1J.-denaturing 
acrylamide gel at 300V for 19 hours (see Figure 7.7). The PCR conditions were the same 
as 7.2.3. Samples I, 3, 22, 26, 33,41, 45, and 51 were heterozygous for the allele and 
were run together, to see clearly if there were only two different alleles. There were only 
two alleles present and the rare alleles for these heterozygous individuals were cut out 
using the band stabbing technique dei>cribed in 7 .2.9. The sample eluates were PCR 
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FIGURE 7.7 
Band Stab Gel of Rare Allele from Heterozygous Individuals and 
Common Allele from Homozygous Individuals. 
6% SSCP Gel run at 300V, for 19 hrs at Room Temperature. 
Developed after 29 hrs, at Room Temperature with No Intensifying Screens. 
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Homozygous Common Allele Heterozygous Alleles Homozygous Common Allele 
I I 12 13 14 15 16 17 18 19 20 2 l 23 24 I 3 22 26 33 41 45 51 28 31 32 35 36 37 38 39 40 42 43 44 47 48 49 50 52 53 54 55 
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FIGURE 7.8 
Band Stab Gel Re-exposed to Confirm Exact Alleles were Stabbed. 
Developed after 2 days at Room Temperature with No Intensifying Screens. 
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TABLE 7.1 
Sequence of TPM2 SSCP from Gel Band Stabs 
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TABLE 7.1 
SEQUENCE OF TPM2 SSCP BAND STABS 
clive2 22/12/94 
- -- -
110 210 3f •p sp 
'-
Band Stab Ind3 870F \R NNNNCTC ATTNCGAGNC A'fGGCCATTA GCGAGGAACT 
2. Band Stab 41 870F )A A NNTN CNTNCTAGTN ATGGCCATTA GCGAGGANCT 
3. Band Stab 51 870F )R L NCCCGC ACCNCNGNGA ANAAATNAGA GNAGAAATGG 
4. Fa'llily 2 {4) 870F )E L TANNGNATG TCTTTNGANA CGNCCTGGCA 
5. l:t~mll::!l 2!!1} arn:a 1 E TTAAAATCTA TGCCCAGTAG ATGAAGTACA GAGGCCANTA GCGANGGNCT 
'-
Band stab 48 870F }C L ANGN ACGGNCATTA GCGAGGAACT 
7. Frunily 1 (3) 870F }0 E Bad Sequen ce NTTAANNN ATNCTATANA CAAGGTACNN 
8. Family 1 (3) 867R 1M TTAAAATCTA TTCCCAGTAG NTGAAGTNCA AGGCCATTAA CGAGGANTCT 
9. TPM2(Widada et a1,) )M AATCT ATGCC~.GAA GATGAAGTAC AAGGCCATTA GCGAGGAACT 
0 "'G- Addition 
N 6f 710 Bf 910 ljO 
1. Band Stab rnd3 870F )R GGACAACGCA CTCAATGACA TCACCTCCCT CTGAGCCCCA CACCAGNGTG 
2. Band stab 41 870F )A A GGACAANGCA CTCAATGAGA TCACCTNCCT CTGGGTCCCA CACCAGNGTG 
3. Band Stab 51 870F )R L ACAGNGCATT CAACTGCANA TCACNTCCCT CTGAGTCCCA CACCAGCGAG 
4. I~amily 2 ( 4) 870F }E L NTAGCACTCA TCNGACATCA CCTGCCACTC TGNNACCCCA CACCAGNGTN 
~. :EI.!JIIilY ::1 !11 IJ!i:ZB l E GGACAACACT NTCNATGACA TCACCTCCCT CTGATCCCNA CACCAGCGTG 
6. Band Stab 48 870F }C L GGACAACGCA CTCAATGACA TCACCTCCCT CTGAGCCCCA CGCCAGCGTG 
7. Family 1(3) 870F }0 E NCTATAGGAN NCANTGACAT CACCTCNACT CTGAANCNCA CG~~CAGGGA 
8. Family 1(3) 867R )M GGACNACNCN CTCAATGACA TCACCTCCCT CTGANCCCCA CGCCAGCGTG 
9. TPM2 {Widada et al.) )M GGACAACGCA CTCAATGACA TCACCTCCC'r CTGAGCCCCA CGCCCAGCGT 
0 p olymorphis m" 'Add-C 
N 
'10 '10 '10 '10 '10 
'- Band stab IndJ 870F ,. GGCANCTCAG CTCTCTTCTC TCCTCTCCTT TCCATTCTCT CTATGGGGAG 
2. Band Stab 41 870F )A A, GGCAACTCAG AGTCTCTNCT CTCNTCTCCT TCCCATTCTC TCTNTGGGGA 
3. Band Stab 51 870F }R L ·, GGCAGCTNAG NNATCTCCTN TCTTNTCCTT CCCATNCTCT CTATGGAGAG 
4. Family 2 {4) 870F)EL' GGCAGCNCAG GTCTCTTCTC TCCTCTCCNN GCNANNCTCT CTATGGGGAG 
:2. i:amil:i 2 ! ~ l S2:ZB l E GCCACCNCAT CTCTCTTCTC TCCTCNCCTT TCCATNCTCN CTATGGGGAG 
6. Band Stab 48 870F }C L GGCACCTCAG CTCTCTTCTC TCCTCTCCTT TCCATTCTCT CTATGGGGAG 
7. Family_ 1 {3) 870F }0 E ATGACACCNC AGATCTCTGT CTCTCCTCTC CTTTCCATCC TCTCTATGGG 
8. Family 1 (3 1 867R }H NCCACCTCAG CNCTCTTCTC TCCTCTCCTT TCCATTCTCT CTATGGGGAG 
9. TPM2{Widada et al.) )M GCCACCTCAG CTCTCTTCTC TCCTCTCCTT TCCATTCTCT CTATGGGGAG 
0 "'"Del-G & Sub-G->C 
N 
'10 170 190 2~0 I 'jo I 
. 1. Band Stab Ind3 870F }R GGGAGCAGNN AGGAGGAGCA GAAATTGNCA ACATTGNACA GNCAGGCTGG 
2. Band stab 41 870F )A A GGGGAGGAGA GAGGAGGAGT AGAAATNGCC AATATTGNAN AGNCANTGTN 
3. Band Stab 51 870F }R L GGGAGCGAGG NAGGAGGAGC AGAAGTTGTA GCCATNGANN GAG,_,CAGGCA 
'-
Family 2 ( 4) 870F }E L GGGAGCAGGN AGGAGGAGCA GAANTTGGCA GCATTGAACA GT~_GGTTGG 
:2. Elmlil::!l 2: I~ l 82:ZB l E GGGANNAGGC AGGAGGANCA GAAGTTNCCT ANNATTCACA ACCNGGCANN 
6. Band Stab 48 870F }C L GGGAGCAGGC AGGAGGAGCA GAAATTGCCA ACATTGGACA GCCAGGCTGG 
7. Family 1 {3) 870F }0 E GAGGGGAGCA GGCAGGAGGA GNAGAAATTG ACANCATTGA ACAGTCAGGT 
8. Family 1 {3) 867R }H GGGANNAGGC NGGAGGAGCA Gl~TTGCCT NCNATNCACA TCCNGGCTAG 
9. TPM2(Widada et a1.) )M GGGAGCAGGC AGGAGGAGCA GAAATTGCCA ACATTGCACA GCCAGGCTGG 
0 "AG-D eletion 
N 
210 2)0 2)0 210 210 
1. Band Stab Ind3 870F )R GAGGAGNCTA GGGAGAGCCC CCATCATGAC CACCACCCAC TCTGGNACTG 
2. Band stab 41 870F )A A NGNAGGAGCG GGGGAGAGGC ACACATCATN ACCACCATCA NCTCCTGNAC 
3. Band Stab 51 B70F }R L NGGGNGCAGT AGAGTGAGNG AGAGCCNTCN ATGATNACCC ACCNACCATT 
4. Family 2{4) 870F }E L GGGTAGCCTA GGGAGAGCCC CCATCATGNC CACCACCCAC TCTTANACTG 
.5.........-Ea.UY 2 {~l BQ:ZB l E GANCAGCNTA AGAGAGANCC CCTNTNATAC NTTATCCACA CTANNGGNGN 
6. Band Stab 48 870F }C L GAGCAGNCTA GGGAGAGCCC CCATCATGCC CACCACCCAC TCTGGCACTG 
7. Family 1(3) 870F )0 E TGGGGGTAGT CTAGGGAGAG NCCCCNTCAT GNCCACNTCC CACTCTGGGA 
8. Family 1 (3) 867R )M GATCATCCAA GAGAGAACCC CTAGAATNTC CNCTATCCAC TCTNNNNNGC 
9. TPM2(Widada et al.) )M GAGCAGCCTA GGGAGAGCCC CCATCATGCC CACCACCCAC TCTGGCACTG 
0 
N 
TABLE 7.2 
Sequence ofTPM2 SSCP Homozygous Alleles 
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TA~~i..tE 7 .2 
SEQUENCE OF TP:b-12 SSCP HOMOZYGOUS ALLELES 
Clive SSCP2 22/12/9 
110 210 310 
·e s,o 
1. Family 2 (4) 870F }R AGTCANGG CCATTAGCGA GGAACTGGAC 
2. Family 2 (4) 867R }A A GAGTCTATGC CCAGAAGATG AAGTGCAAGG CCATTAGCGA GGAACTGGAC 
3. Individual 85 870F )R L AGNACAAGG CCATTAGCGA GGAACTGGAC 
4. Indiyidual 85 867R lE L AAGTCTATNC CCAGGAGATG AAGNACGAGN CCATTAGCGA GGAGCTGGGC 
5. Family 2(12) 870F }C E AGCCAAGGC CATTAGCGAG GNAACTGGAC 
6. Family 2 {12) 867R. )0 L Bad Sequen ce ATGN AGANACANGG CGGTTAGNGA TG~_NCANGAC 
7. Band Stab tn48 867R. }M E NAATCTATTC CCAGNAGATG ~GTACAAGN CCATTAGCGA GGNACTGGAC 
8. TPM2(Widada et al.J }M AAGTCTATGC CCAGAAGATG AAGTACAAGG CCATTAGCGA GGAACTGGAC 
M 
0 
N 6f 70 I 80 I 90 I 110 
1. Family 2 (4) 670F )R AACGCACTCA ATGACATCAC CTCCCTCTGA GCCCCACACC AGCGTGGCCA 
2. Family 2(4) 867R. }A A AACGCACTCA ATGANATNAC CTCCCTCTGA GCCCCACACC AGCGTGNCCA 
3. Individual 85 870F )R L AACGCACTCA ATGACATCAC CTCCCTCTGA GCCCCACACC AGTGTGGCCA 
1. lndh:idl.li:!l E!S BJPB. lE L ANCGCACTCA ATGACATCAC CTCCCTCTGA GCCCCACACC AGCNTGGCCA 
5. Family 2 (12) 870F )C E AACGCACTCA ATGACATCAC CTCCCTCTGA GCCCCACGCC AGCGTGGCCA 
6. Family 2 (12) 867R )0 L GACTNANACA ATAANAACAC CTCCCTCTNA ACCCAACTCC ATCNTGTCCA 
7. Band Stab In48 867R }M E AACGCACTCA ATGACATCAC CTCCCTCTGA GCCCCACACC AGCGTGGCNA 
8. TPM2(Widada et al.) }M AACGCACTCA ATGACATCAC CTCCCTCTGA GCCCCACGCC CAGCGTGCCA 
M Polym orphism" 'AddC 'Del 
0 
N 110 110 110 110 110 
1. Family 2(4) 870F )R CCTCAGCTCT CTTCTCTCCT CTCCTTTCCA TTCTCTCTAT GGGGAGGGGA 
2. Family 2(4} 867R )A A CCTCAGCTCT CTTCTCTCCT CTCCTTTCCA TTCTCTCTAT GGGGAGGGGA 
3. Individual 85 870F )R L CCTCAGCTCT CTTCTCTCCT CTCCTTTCCA TTCTCTCTAT GGGGAGGGGA 
1' Im.U.:.:isi~il.l ~2 ~6JB }:;; L CCTCAGCTCT CTTCTCTCCT CTCCTTTCCA TTCTCTCTAT GGGGAGGGGA 
5. Family 2 {12) 870F )C E CCTCAGCTCT CTTCTCTCCT CTCCTTNCAA TTCTCTCTAT GGGGAGGGGA 
6. Family 2 {12 J 867R )0 L CCTCAACTCT CGTCTCTCCT CTCCTTTCCA TTCTCTCTAT GGGGAGGGGA 
7. Band Stab In48 867R )M B CCTCAGCTCT CTTCTCTCCT CTCCTTTCCA TTCTCTCTAT GGGGAGGGGA 
8. TPM2(Widada et al.) }M CCTCAGCTCT CTTC'rCTCCT CTCCTTTCCA TTCTCTCTAT GGGGAGGGGA 
M -G 
0 
1!0 110 ljO 110 210 N 
-
1. Family 2 (4} 870F )R GCAGGCAGGA GGAGCAGAAA TTGCCAACAT NGCACAGNCA GGCTGGGAGC 
2. Family 2 (4) 867R )A A. GCAGGCAGGA GGAGCAGAAA TTGCCAACAT TGCACAGCCA GGCTGGGAGC 
3. Individual 85 870F )R L GNAGGTAGGA GGAGCAGAAN TTGTCAACAT NGCACAGCCA GGTTGGGAGN 
1. Indiviffiwl 85 867.B....ll; L GCAGGCAGGA GGAGCAGAAA TTGCCAACAT TTCACAGCCA GGCTGGGAGC 
5. Fa'llily 2 {12) 870F }C E GCAGGNAGGA GGAGNAt;ANN TTGNCACCAT CGNACAGCCA GGTTGGGAGC 
6. Family 2{12) 867R )0 L GCAGNCAGGA GGAGCAGAAA TTNCCAACAT TTCACANCCA GACTAAGAAC 
7. Band Stab In48 867R )M E GCAGGCAGGA GGAGCAGAAA TTGCCAACAT TGCACAGCCA GNCTGGGAGC 
8. TPM2(Widada et al.) }M GCAGGCAGGA GGAGCAGAAA TTGCCAACAT TGCACAGCCA GGCTGGGAGC 
M "AG-Delet ion 
0 
N 210 210 210 210 2i0 
1. i<amily 2(4) 870F }R AGCCTAGGGA GAGNCCCCAT CATGCCCACC ACCCANTCTG GTACTGGCTT 
2. Family 2 (4) 867R }A A AGCCTAGGGA GAGCCCCCAT CATGCCCACC ACCCACTCGT 
3. Individual 85 870F )R L AGCCTAGGGA GAGCCCCCAT CATGCCCACC ACCNACTCTG GNACTGGNTT 
~' InQiOlidyal !!5 1!27B lE L AGCCTAGGGA GAGCCCCCAT CATGCCCACC ACCCACTCGT 
5. Family 2(12) 870F )C E AGCCTAGGGA GAGCCCCCAT TATGCCCACC ANCCACTCTG GCACTGGCTN 
6. Family 2(12) 867R )0 L ANCCTAGGGG GGNNCCCCNA AAGATNCCCA CCACCCACTC NTANGTNANG 
7. Band Stab In48 867R }M 8 AGCCTAGGGA GAGCNCCCAT CATGCCCACC ACCCACTCGT 
8. TPM2 Ctndada et al.) }M AGCCTAGGGA GAGCCCCCAT CATGCCCACC ACCCACTCTG GCACTGGCTT 
M 
0 
N 
amplified and sequenced. Samples 18, 32, 36, 48 that were homozygous for the 
common allele were also cut out and amplified to c<,mpare the sequence between the two 
alleles. The gel was then re~exposed to show if the exact alleles had been cut out. Figure 
7.8, shows that the exact alleles were cut out. 
Table 7.1 shows the sequence from the band stab amplifications. The samples were 
sequenced from primer DS 870 (Rsk.forward) and also from primer DS 867 
(3 'UTR.reverse ): 
Lines 
1-3. Heterozygous Individuals 3, 41, 51 ) Band stabs of rare allele 
4-5. Family No.2 (sample No.4) ) Homozygous individual for the rare allele 
6. Homozygous lndividuai48 } Band stab of homozygous common allele 
7-8 Family No.1 (sample No.3) } Homozygous individual for common allele 
9. TPM2 sequence (Widada, eta!., 1988) ) Published sequence 
The band stabs were only sequenced from primer DS 870, exon 8sk forward. Any 
samples that were sequenced in the reverse direction (primer DS 867 .R) were rotated and 
the complementary sequence was given in Table 7.1, using SeqEd™ 675 DNA 
Sequencer Editor (ABI). This was to compare the sequencing data from the reverse 
primer, with the forward primer. 
There was a sequence difference between the rare and common alleles at base 92 where 
all the rare alleles had an adenine base and Widada et al. and the common alleles had a 
guanine base. The sequencing for individual473 (7) DS 870.8skF was quite bad though. 
The sequencing was not ideal, as there were a lot of base changes between the samples. 
It was noticed however, that the eequence from the samples in some places consistently 
differed to (Widada, et al., 1988) published sequence in the 3'UTR. At base 93-96 
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Widada's sequence had a CCCA, while the samples mostly just had a CCA, so Widada's 
sequence had an extra C or insertion, which misaligned the bases until Widada has a G 
deletion at 101-102 and a C substituted for a G, so the sequence is realigned after base 
103 (see Table 7.1). 
Widada et al 
Sequencing 
3'UTR 
91 101 
CGCCCAGCGT GCCACCT 
CACCAGCGTG GGCACCT 
• ** 
It was also noticed that Widada had an extra AG at bases 1::)6-157, which were not 
present in 6 out of the 8 samples. The other samples (Family 2 (4)-867.R and Family 1 
(3)-867.R) had bad sequencing at this point. These two bases were not included in the 
TPM2 sequence of Widada et al. in Table 7.1, as it would have meant the comparison 
and alignment ofTPM2's sequence with the other samples would be difficult to follow, 
but it is shown below: 
Widada et al 
Samples 
3'UTR 
151 161 
GGGAGAGCAG GCAGGAG (AG inserted) 
GGGAGCAGGC AGGAGGA 
.. 
So there were five consistent changes in the sequence data from that of Widada et al.'s 
published sequence, all in the 3'UTR, and a highly probable cause for the TPM2 SSCP 
polymorphism. 
138 
7.3.7 Sequencing Homozygous Individuals for the TPM2 (8sk • 3'UTR) 
common and rare allele 
Another homozygous individual for the rare allele was discovered when screening the 97 
individuals. The most direct method for sequencing the polymorphism was now 
therefore to amplify the DNA of the two individuals that were homozygous for the rare 
allele and sequence the fragment. The sequence could then be compared t0 ampliJ·ed 
DNA from individuals that were homozygous for the common allele. 
The samples were sequenced using primers DS 870 (8sk.F) and 867 (3'UTR) and the 
results are shown in Table 7.2: 
Lines 1-2 Family No.2 (sample No.4) 
Lines 3-4 Individual 85 
) Homozygous rare allele TPM2 exon S·.k-
3'UTR 
) " " " " " 
Lines 5-6 Family No.2 (sample No.12) ) Homozygous r<'""non allele 
Family No.2 (sample No. 13) ) " 
Line 7 Band stab individual48 ) " " Only used primer DS 867.R 
To compare the sequencing from the reverse and forward primers, the sequencing results 
from the 3'UTR r~verse primer (DS 867.R) were rotated and the complementary 
sequence was given in Table 7.2. 
The results were similar to the band stab sequencing, except the sequf':ncine was more 
accurate and precise, when compared to Widada et al.'s published sequence. Family No. 
2 (13) did not sequence very well, so the results were not included in Table 7.2. Tl • .._ 
band stab individual 48 was sequenced from primer DS 867 (3'UTR reverse), as the 
template sequenced well last time in the forward direction in Table 7.1 and so it was 
repeated in Table 7.2, in the reverse direction. 
139 
The suspected polymorphism was at base 88 this time in Table 7 .2. All the rare alleles 
were adenine again at this base. For the common alleles: sample 5 read a guanine, sample 
6- a thymine and sample 7 (the band stab of individual 48) -an adenine, yet last time it 
sequenced as a guanine. So out of 9 rare alleles sequenced, 9 out of 9 times it sequenced 
as adenine, which is different to \'!idada et al.'s guanine. 4 out of the 6 common alleles 
sequenced agreed with Wid:tda et al. 's guanine at the polymorphic site. The other two 
samples read once an adenine and the other a;\ a thymine, though the thymine sequence 
was quite bad (sample 6- Table 7.2). So the base change causing the polymorphism still 
needed to be confirmed. 
The variations from Widada's TPM2 sequence, mentioned in the band stab sequencing, 
were repeated for these samples: 
There was a cytosine addition in Widada's sequence at base 91. 14 out of 15 independent 
sequencing samples of the rare and common alleles showed Widada et al. had an 
additional C. This may be explained, as in 1988 they would have used manual 
sequencing methods and it could have been fairly easy to read two C's in a row as three 
C's, as the b<mds would have been very close (Laing, 1994a). 
11 out 15 independent sequencing samples showed that Widada et al. had a guanine 
deletion at base 97 in Table 7 .2. However, there was no C substituted for a G at base 98 
like in Table 7.1 and it was likely that Table 7.2 sequencing was more accurate. 
14 out of 15 independent sequencing samples showed Wid ada et al. had an AG insertion 
after base 152 in Table 7.2. This was not shown in Widada's sequence, as otherwise all 
the bases from the other samples after this insertion would not be aligr..ed with Widada's 
sequence anrl the ~~-lJ'lence would have been more difficult to compare. 
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Therefore, there were four consistent base changes to Widada et al.'s published sequence 
in·the 3'UTR from the sequencing results, which was similar to the sequencing in Table 
7.1. 
The sequence variation between the polymorphic aJleles still needed confirmation, but it 
was suspected that the eleventh base in the 3'UTR was an adenine in the rare allele and a 
guanine in the common allele that caused the polymorphism, seen in the SSCP gels. 
7.3.8 Restriction Digest of 259 bp TPM2 STS (8sk - 3'UTR) 
Using the consistent TPM2 STS sequence defined by primers DS 870 and 867, a 259 
base sequenc~ was typed into a computer application package DNA Strider version 1.0. 
Two versions of the STS sequence were typed in, what was suspected for the common 
allele (Figure 7.9) and the rare allele (Figu'e 7. 10). The application worked out most of 
the restriction sites for the two STSs. At base 83 (guanine) in Figure 7.9 (the common 
allele) there was a unique restriction site (Bgl I) present at the suspected site of the 
polymorphism that was not present in base 88 (adenine) for the rare allele, in Figure 
7.10. This can be seen more clearly in Figure 7.11 showing a simplified restriction map 
of the common allele STS (a) and the rare allele STS (b). There is a unique restriction site 
(Bgl I) at base 83 seen in (a), but not in (b). 
The sequence where the restriction enzyme Bgl I splices DNA is: 
Bgl I restriction enzyme 
Suspected 259 bp TPM2 STS polymorphism (common allele) 
Suspected 259 bp TPM2 STS polymorphism (rare allele) 
GCCNNNN/NGGC 
GCCAGCG/TGGC 
ACCAGCG/TGGC 
This meant a restriction digest could be carried out on a PCR STS from different 
individuals. An STS from a homozygous individual for the rare allele would produce a 
single 259 bp fragment on a gel, as there is no restriction site for Bgl I. Bgl I would cut 
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an STS for a homozygous individual for the common allele into two fragments, a 88 bp 
and 171 bp fragment. The STS for a heterozygous individual would be cut into three 
fragments (88, 171 and 259 bp) as they have two alleles. One allele would not be cut by 
Bgl I (259 bp) and the other allele would be cut producing the two fragments (88 & 171 
bp) (see Figure 7.12). 
The restriction digest in Figure 7.13 showed that the TPM2 STS was polymorphic at 
base 88 and confirmed the sequencing results that it was ihe site for the polymorphism. 
Therefore, primers DS 870 (exon 8sk.F) and DS 867 (3'U."R.R) can now be used as 
unique markers in the human genome project for linkage analysis and entered on the 
CEPH linkage map. The polymorphism is quite useful, because the TPM2 gene has been 
localised to 9pl3.1 and so the polymorphi$m when it is entered on the CEPH map can be 
correlated to the physical map. 
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FIGURE 7.9 
Restriction Sites for the 259 bp TPM2 STS Sequence of the Common Allele. 
The Common Allele has an extra Restriction Site (Bgll) at Base 88. 
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jff DNA Strider 1 . 0 lit Sunday , 11 December 199q 
TPM2 Common Allele -> Restriction Map 
DNA sequence 259 b.p. aagtctatgccc . . . cttcatccttta 
10:48 : 30 PM 
linear 
Bsp1286 I 
Ban II 
Mnl I Dde I 
Mbo II 
I 
Hae III 
Hae I 
~ Mnl I 
I 
.I:U2h...l Mnl I 
I II I I I I I 
aagtctatgcccagaagatgaagtacaaggccat t agcgaggaactggacaa cgcactcaatgacatcacctccctctga 80 
ttcagatacgggtctt ctacttcatgttccggta atcgctccttgacctgttgcgtgagttactgtagtggagggagact 
I I I I • I • I I I I I • 
.Bsl..J. 
I 
14 23 39 67 7q 
Hae 
Hae I 
~ 
~ 
II 
Mnl I 
III 
Ode I 
II I 
28 
29 
Mbo II 
I 
Mnl I 
I 
Mnl I 
I 
70 77 
79 
79 
Mnl I 
I 
gccccacgccagcgtggccacctcagctctcttctctcctctcctttccattctctctatggggaggggagcaggcagga 160 
cggggtgcggtcgcaccggtggagtcgagagaagagaggagaggaaaggtaagagagatacccctcccctcgtccgtcct 
I • I I • I I I I I • I I • 
88 95 102 110 118 144 159 
95 105 
95 
96 
101 
Sl;.J::f__l 
EcoR II 
~
I 
.t:1a.e..._l 
.s.t.y_l 
~ 
AYL...ll 
Fnu4H I 
~ 
I II 
Bsp1286 I 
Ban II 
I 
Nla III 
I 
ggagca gaaattgccaacattgcacagccaggctgggagcagcctagggaqagcccccatcatgcccaccacccactctg 240 
cctcgtctttaacggttgtaacgtgtcggtccgaccctcgtcggatccctctcgggggtagtacgggtgqtgggtgagac 
.E2lL.l. 
I 
gcactqgcttcatccttta 259 
cgtgaccgaagtaggaaat 
•I 
251 
I • I • I I · I · I 
188 199 211 221 
188 199 211 
188 203 
203 
203 
2oq 
FIGURE 7.10 
Restriction Sites for the 259 bp TPM2 STS Sequence of the Rare Allele 
The Rare Allele does not have the Restriction Site (Bgl I) at Base 88. 
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ill DNA Stridor 1.0 ltB Sunday, 11 December 1994 
TPM2 Rare Allele -> Restriction Map 
DNA sequence 259 b.p. aagtctatgccc .•. cttcatccttta 
Mba II 
I 
Hac li I 
Hac I 
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10:50:15 PM 
linear 
Mol 
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ttcagatacgggtcttctacttcatgttccggtaatcgctccttgacctgttgcgtgagttactgtagtggagqgagact 
I J I I • I• I I I I I • 
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79 
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gccccacaccagcgtggccacctcagctctcttctctcctctcctttccattctctctatggggaggggagcaggcagga 160 
cggggtgtggtcgcaccggtggagtcgagagaagagaggagaggaaaggtaagagagatacccctcccctcgtccgtcct 
II • I J I I I • I I • 
95 102 110 118 11~ 159 
95 105 
95 
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WI 
scrLl 
EcoR 11 
Jl.illL1 
I 
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lit>-1 
s=J. 
AlLLll 
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"""--t 
I II 
Bspl2B6 I 
Ban I I 
I 
Nl a III 
I 
ggagcagaaattgccaacattgcacagccaggctgggagcagcctagggagagcccccatcatgcccLccacccactctg 210 
cctcgtctttaacggttgtaacgtgtcggtccgaccctcgtcggatccctctcgggggtagtacgggtggtgggtgagac 
£Q1Ll 
I 
gcactggcttcatccttta 259 
cgtgaccgaagtaggaaat 
• I 
251 
I • I • I I • I • I 
188 199 211 221 
188 199 211 
188 203 
203 
203 
"' 
FIGURE 7.11 
Graphic Map Showing the Restriction Sites of the 259 bp TPM2 
STS 
(A) The Common Allele has an extra Restriction Site (Bgl l) at Base 88. 
(B) The Rare Allele does not have the Restriction Site (Bgl I) at Base 88. 
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DNA st!quence 259 b.p. aagtctatgccc •.. cttcatccttta linear 
221 N1a III 
20< Mae I 
203 sty I 
203 Sec I 
203 Avr II 
199 Fnu4H I 
95 Eae I 199 Bbv I 
95 Ba1 I 
"' 
SerF I 
6B Bg1 I laB EcoR II 
23 Rsa I 67 Hph I 105 A1" I 166 BstN I 251 Fok I 
1PM2 Common Allele 259 base pairs Unique Sites 
DNA sequence 259 b.p. aagtctatgccc , .. cttcatccttta linear 
221 N1a III 
20< Hae I 
203 Sty I 
203 Sec I 
203 Avr II 
199 Fnu4H I 
199 Bbv 1 
95 Eae I 166 S-.;rF I 
95 Ba1 I 188 EcoR II 
23 Rsa I 67 /I ph I 105 Alo I 166 PstN I 251 Fok I 
1PM2 Rare Allele 259 base pairs Unique Sites 
FIGURE 7.12 
Predicted Restriction Digest of 259 bp TPM2 STS (Exon 8sk- 3'UTR) 
Polymorphism using Bgl I 
146 
259bp 
171 bp 
88bp 
Heterozygous Homozygous 
Common 
Allele 
Homozygous 
Rare 
Allele 
FIGURE 7.13 
Restriction Digest of 259 bp TPM2 STS (Exon 8sk - 3'UTR) 
Polymorphism using Bgl I 
Lane 1 
Lane2 
Lane3 
Lane4 
Laoe5 
pGEMMarker 
Heterozygous Individual for Allele 
Homozygous Individual for Common Allele 
Homozygous Individual for Rare Allele 
pGEM M<uker 
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pGEM 
Heterozygous Allele 
Homozygous Common Allele 
Homozygous Rare Allele 
pGEM 
CHAPTER 8 
GENERAL DISCUSSION 
8.1 Localised Inherited Muscle Disorders 
At present there are no known inherited muscle disorders linked to the 9p t3 region 
(Klinger, 1992). The alpha-tropomyosin gene TPMI has recently been localised to 15q22 
(Eyre, et a!., 1994) and has been shown to be mutated ia some cases of familial 
hypertrophic cardiomyopathy (Thicrfelder, et al., I 99~', ). The alpha·tropomyosin gene 
TPM3 has been recently localised to lq22-q23 (Wilton, eta!., 1995) and has been shown 
to be mutated in a family with autosomal dom~nant nemaline myopathy (Laing, et al., 
1994). Therefore, at present, TPM2 be\.:0mes a candidate disease causing gene for any 
unlinked inherited myopathie.'i: ;,nJ muscle related disorders. Also, in the future inherited 
muscle disorders may b..: linked to chromosome 9pl3 and, in this case, TPM2 would 
become a candidate disea'ie causing gene. 
8-2 Determining if the 259 bp TPM2 STS is a Pseudogene 
It is extremely unlikely that the 259 bp TPM2 STS is a pseudogene as the STS was 
sequenced and it had a muscle specific exon Ssk, which will not be found in processed 
pseudogenes (2.1.2.2.). However, this STS could be excluded as a pseudogcne, if it 
were radiolabelled and then the STS hybridised to a genomic blot cut with a restriction 
enzyme, such as Taq I, that does not cut the STS. If the autorad revealed only a single 
band, then the STS would be most likely hybridising to the TPM2 gene alone and not to 
pseudogenes. However, because a process~d pseudogene has a similar sequence to the 
real gene, it can be cut by the restriction enzyme, and travel in the gel to the same location 
on the Southern blot as the real gene. So when th~ probe hybridises as a single band it 
could be hybridising to the real gene, or the pseudogene. By hybrictising the STS to a 
few genomic blots, cut with different restriction enzymes, then if this probe hybridises as 
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a single band to all the genomic blots, one can be confident the STS is belongs to the real 
TPM2 gene. This is because it is extremely unlikely that the pseudogene would always 
be cut at the same points as the real gene, with the different restriction enzymes. The 
greater the number of different genomic blots, cut With different restriction enzymes, that 
are used, the greater the certainty that this is the TPM2 gene. 
8.3 Long Range PCR STSs for use in FISH 
The methods of isolating genomic clones for use in FISH have almost been superseded 
with the new technique of long range PCR. Since 1992 researchers have increased the 
conventional range of PCR from typically 5 kb to now 5 kb to 40 kb, ···-'it.' averages of 
5- 15 kb in genomic DNA (Cheng, eta!., 1994; Kainz, eta!., 1992; Ponce & Mica!, 
1992). The key to long range PCR is the new DNA polymerase, U/Tma ™ DNA 
polymerase which has an inherent 3'- 5' exonuclease ("proofreading") activity which not 
only increases the length of PCR fragments produced, but also the accuracy of the 
amplified copies. Perkin Elmer have produced a PCR kit in 1994 that can perform long 
range PCR (Perkin-Elmer, 1994). 
Producing long PCR fragments increases the amount of specific genomic DNA 
comparable to genomic clones (8 - 21 kb) that can be used in FISH. This, therefore, 
greatly reduces the time and effort in localising genes by isolating a genomic clone. The 
only problem is that the technique is new and many of the PCR parameters still need to 
be optimised. Also there is no guarantee that a long range PCR product will work in 
FISH (Wilton, 1994). Likewise, however, there is no guarantee that isolating a genomic 
clone for use in FISH will be successful. 
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8.4 Linkage of the TPM2 Polymorphism 
Linkage of a polymorphism is performed using known markers. These are usually 
polymorphic regions of DNA like the polymorphism for TPM2 described in chapter 7. 
The 259 bp TPM2 STS polymorphism is called a restriction fragment length 
polymorphism (RFLP), because the restriction enzymes produce different sized 
fragments in polymorphic STSs (Gelehrter & Collins, 1990). 
Another more informative class of marker in the genome are microsatellites. 
Microsatellites are tandem repeats of base sequences, usually less than 100 bp in total 
length and occur on average approximately every 6000 bp in the human genome. Since 
humans have 3xl09 bp in the genome, then there are about 5xl09 microsatellites, so 
every gene should have a microsatellite near it (Cooper, 1994). 
The function of microsatellites is not well understood, but one theory is that they are 
conL'TIOB !ocations for recombinations (Cooper, 1994). Of the microsatellite repeat 
sequences, 76% of them in decreasing frequency are: 
A, AC, AAAN, AAN, or AG 
N = any nucleotide A G C or T 
(Cooper, 1994) 
Microsatellites are inherited in a strict Mendelian pattern, except for the rare occasions 
when the number of repeats alters from one generation to the next by mutation. Different 
alleles may vary in the repeat number, for example, there may be an (AC)n repeat on a 
chromosome at a known locus. A mother may have 4 and 9 tandem repeats of the 
sequence on the two different alleles at the locus and the father 6 and 3 repeats. Therefore 
a child of theirs can only have one tandem repeat from either allele of the parent, with the 
following possible combinations - 9,6; 9,3; 4,6; and 4,3 unless there is a mutation. These 
microsatellites would be included in an PCR STS that can be identified by acrylamide gel 
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electrophoresis, to detennine the segregation of alleles for different individuals in a 
pedigree. In this way they are more informative than a RFLP, as there are more 
combinations of microsatel!ite alleles at a locus, in a pedigree, than a single RFLP 
(Sheffield & Stone, 1994). 
Another marker is minisatellites or variable number of tandem repeats (VNTRs) which 
were discovered before microsatellites. VNTRs a·" less common and less evenly 
distributed through the genome, so they are not quite as useful as microsatellites. VNTRs 
are bigger than microsate11ites and their repeating unit is 30 to 35 bp in length and have a 
variable sequence but contain a repeating core sequence 10 to 15 bp in length. 
Minisatellite repeats range in size from 200 bp up to several thousand bp and tend to 
occur in greater numbers toward the telomeric ends of chromosomes. Because VNTRs 
are much bigger than microsatellites they are harder to amplify using PCR. They are 
separated on agarose (not acrylamide gels) or are probed on Southern blots (Cooper, 
1994). 
8.5 Linkage Results and CEPH Mapping 
Helen Eyre and Dr John Mulley at the Department of Cytogenetics and Molecular 
Genetics at Adelaide Children's Hospital, have linked the TPM2 polymorphism in CEPH 
families, in comparison with known markers in the region 9p21-13. This confirms the 
FISH localisation to 9p13 as well as the somatic cell hybrid localisation to chromosome 
9. 
The distance apart of two loci, is defined as in linkage terms as the Kosambi mapping 
function, which is measured in centiMorgans (eM). If two loci are 1 eM apart, there is an 
approximate, average probability of 0.01 of recombination taking place between these 
loci. It is difficult to be more precise than this because recombination frequency varies 
Utroughout the genome and between the sexes (Gelehrter & Collins, 1990). 
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FIGURE 8.1 
Genetic linkage map of sex-averaged chromosome 9, showing CEPH 
polymorphic markers. An asterix (*) next to a marker indicates loci with 
heterozygosities of at least 70%. Microsatellite markers assayed by PCR are 
shown in italics. The graphic chromosomal idiogram depicts the Giernsa staining 
pattern. The D9S numbers to the right of the sex averaged map that point to the 
chromosomal idiogram, indicate those markers that have been cytogenetically 
mapped. 
(NIH/CEPH Collaborative Mapping Group, 1992) 
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The most likely location for the TPM2 SSCP was between markers D9S!9 (a Taq I 
RFLP) and D9S 175 (an (AC)0 microsatellite repeat) (the highlighted markers in Figure 
8.1, were those found to be closely linked to the TPM2 polymorphism). The DS 
numbers refer to the CEPH notation system. The 9 after the D refers to chromosome 9 
and the numbers after the S are the order in which the polymorphic markers were found. 
(Klinger, 1992). 
TABLE 8.1 
Markers and their Recombination Frequency with the TPM2 
Polymorphism 
Locus Symbol Recombination Frequency eM 
with TPM2 Polymorphism 
D9Sl04 0.02 19.7 
D9S52 0.00 21.3 
D9S43 0.00 22.1 
D9Sl8 0.08 25.2 
D9S19 0.00 33.0 
TPM2SSCP 
D9SI75 0.08 47.2 
The low recombination values between the markers in Table 8.1 and the TPM2 SSCP 
indicate that they are closely linked to TPM2. However, with a heterozygosity of 0.16, 
the TPM2 polymorphism is relatively uninformative and the chances of recombination 
between the TPM2 SSCP and these markers in the CEPH families is quite low. This 
means that caution ntl:st be exercised in interpreting these results. A more informative 
marker closely linked to TPM2 is required to confirm the localisation of TPM2 between 
D9Sl9 and D9SI75. 
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8.6 Finding a Microsatellite Close to the TPM2 Gene 
The most informative markers used in gcae mapping projects today are microsatellites. 
Had time permitted, the next stage of this project would have been the discovery of a 
microsatellite closely linked to TPM2. There are two ways in which the identification of 
such a microsatellite could have been achieved. 
Firstly, from a yeast artificial chromosome or Y AC cantle covering the presumed D9S 19 
• D9Sl75 linkage region of TPM2, a Y AC clone(s) would have been isolated that 
contained a TPM2 STS. Microsatellites would then be sought in any TPM2 positive 
YAC(s). 
Y ACs are cloning vectors that replicate as chromosomes in yeast cells and can 
accommodate human DNA inserts as large as 1 million base pairs. These large inserts are 
extremely useful for attaining long-range continuity in contig or overlapping maps and are 
therefore useful in large-scale mapping of the human genome (Cooper, 1994). 
A YAC contig covering the 9p13 region would have been identified using the MOSAIC 
database program. The Y,\C(s) in the 9p13 contig containing all (or part) of the TPM2 
gene would then be identified by PCR assay using the Y AC(s) as target DNA for the 
TPM2 STS primers. Those YAC clones that produced a positive res1Jlt must contain a 
segment of the TPM2 gene. An important control for theY AC TPM2 STS PCR would be 
the yeast DNA of S. cervisae and the TPM2 STS primers. S. cervisae is the yeast host 
strain for the 9pi3 YAC contig. Homology between the TPM2 STS primers and S. 
cervisae DNA does not occur (Genebank), nevertheless a negative yeast DNA control for 
the PCR amplification is required (Laing, 1994a). 
Positive TPM2 PCR STS assay isolated clones, would then be screened for di, tri, tetra 
and penta nucleotide tandem repeat sequences (or microsatellites), especially tht. most 
common (CA)n repeat most typical of microsatellite polymGrphisms. This would have 
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been achieved by digesting DNA from isolated YAC clones specific to 1'PM2 STSs with 
restriction enzymes and then identifying those fragments which anneal to 32p labelled eg. 
(GT)to on a Southern blot. Once localised, these (CA)" containing fr.1gments would be 
subcloned into a selected plasmid, wsing a modification to the technique described by 
(Feener, et al., 1991). The sequence of the plasmid either side of the insert is known and 
primers have been designed so the insert can be PCR amplified and then sequenced. An 
insert less than 1000 bp would be ideal, as the maximum sequencing range from each 
primer on either side of the insert is approximately 500 bp. If the insert is much larger 
than 1000 bp, then the fragment would be cut again with another restriction enzyme and 
reprobed on a Southern blot and then subcloned and sequenced. Alternatively new 
primers could be designed from the information obtained at the end of one sequence to 
continue the sequencing of the insert until the microsatellite is sequenced. Primers would 
then be designed on either side of the microsatellite to produce an STS that includes the 
microsatel!ite (Laing, 1994a; Sambrook, et a!., 1989). 
A random population can be screened using these primers to determine the allelic 
frequency of these microsatellite polymorphisms, as in 7.2.7. Once a suitable panel of 
microsatellites had been identified, they would have been screened against the CEPH 
panel of families in collaboration with Department of Cytogenetics and Molecular 
Genetics at Adelaide Children's Hospital to localise the polymorphisms position on the 
CEPH map (Laing, 1994a). 
Similarly, somatic cell hybrids that contain parts of chromosome 9p13 can be isolated 
using TPM2 STSs and the methods repeated, as for Y ACs to isolate a microsatellite 
repeat that can be localised in the CEPH map, that would also have a physical location to 
9pl3 (Laing, 1994a). 
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8. 7 Conclusion 
The somatic cell hybrid and FISH localisation of human skeletal tropomyosin (TPM2) to 
9pl3 paper has been accepted by the Cytogenetics and Cell Genetics Journal. (see 
Appendix 3). The detection of the Bgl I RFLP in the 3'UTR of TPM2, and linkage of 
this polymorphism will be submitted to Genomics and entered on the CEPH map. 
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APPENDIX 1 
TROPOMYOSIN GENE 
SEQUENCES 
1 j 
1 
·,1. 
1 
TPMl - McLeod and Gooding, (1988). 
TPM2 - B tropomyosir1 - Widada et al., (1988). 
TPM3 Reinach and McLegd. 0986!. 
TPM4 - MacLeod, Talbot, SmiJ.lie, Houlker - J Mol Biol 194:1-10, (1987). 
cccgctccgtcctcctcgcctgccaccg 
DS1095 TPMl-Exl-F 
ccgcgcgctcgccccgccgctcctgctgcagccccaggcccc'.:.cgccgccgccacc 
DS1083 TPM2-Exl-:;> 
gtgcacccagtccgctcacccagcccagt;.ccgtccggtcctcaccgcctgccggccggcccaccccccaccgcaggcc 
DS886 TPM3 (14) 
ttgcqccagtctccagttctqca9tgttcacaggtgagcctaccaacagccactgctc 
Exon Isk 
atggacgccatcaagaagaagatgcaga tgctgaagctcgacaaggagaacgccttggatcgagctgagcaggcggag 
DS840 TPM2, lskF 
atggacgccatcaagaagaagatgcagatgctgaagctggacaaggagaacgccatcgaccgcgccgagcaggccgaa 
atggaggccatcaagaaaaagatgcagatgctgaagtt agacaaggagaatgctctggatcgggctgagcaagctgaa 
DS1094 TPMl-Exl-R 
gccgacaagaaggcggcggaagacaggagcaagcag 
DS1082 TPM2-Exl-R 
gccgacaagaagcaagctgaggaccgctgcaagcag 
DS1018 TPM3-2002 
gctgagcagaagca99cagaagaaagaagtaaacag-
Exon II.sk 
ctggaagatgagctggtgtcactgcaaaagaaactcaagggc 
ctggaggaggagcagcaggccctccagaagaagctgaagggg 
ctggaggatgagctggcagccatgcagaag-aag-ctgaaaggg 
accgaagatgaactggacaaatactctgaggctctcaaagatgcccaggagaagctggagctggcagagaaaaaggcc 
DS841 TPM2.IIskR 
acagaggatgaggtggaaaagtattctgaatccgtgaaggaggcccaggagaaactggagcaggccgagaagaaggcc 
acagaggatgagctggacaagtattctgaagctttgaaggatgcccaggagaagctggaactggcagagaagaaggct 
accgat 
actgat 
gctgat 
Exon II 
gctgaagccgacgtagct tctctgaacagacgcatccagctggt tgaggaagagt tgga tcgtgcccaggag 
gctgaggcagatgtggcctccctgaaccgccgcattcagctggttgaggaggagctggaccgggcccaggag 
gctgagqctgaggtggcctqcttgaaccgtaggatccagctggttgaagaagagctggaccgtgctcaggag 
DS1372-
gctgaaggtgatgtggccgccct_caaccgacgcatccagctcgttgaggaggagttggacagggctcaggaa 
cgtctggcaacagctttgcagaagctggaggaagctgagaaggcagcagatgagagtgagag 
cgcctggctacagccctgcagaagctggaggaggccgagaaggcggctgat::gagagcgagag 
cgcct ggcc a ctgccc t gca a a a gc t gga a ga a gctga a a a a gc tqc tga t Q'a ga gt gagag: 
TPM4IIF 
cgactggccacggccctgcagaagctggaggaggcagaaaaagctgcagatgagagtgagag 
Exon III 
aggcatgaaagtcatt 
aggaatgaaggtcatc 
aqgtatqaaggttatt 
aggaatgaaggtgata 
gagagtcgagcccaaaaagatgaagaaaaaatggaaattcaggagatccaactgaaagaggccaagcacattgctgaa 
gaaaaccgggccatgaaggatgaggagaagatggaactgcaggagatgcagctgaaggaggccaagcacatcgctgag 
qaaaacCgggccttaaaaqatqaagaaaaqatqgaactccaggaaatccaactcaaaqaaqctaaqcacattqcaqaa 
gaaaaccgggccatgaaggatgaggagaagatggagattcaggagatgcagctcaaagaggccaagcacattgcggaa 
gatgccgaccgcaaatacgaagag 
gattcagaccgcaaatatgaagag 
gaqgcagataggaagtatgaagag 
DS1373 - TPM4IIIR 
gaggctgaccgcaaatacgaggag 
Exon IV 
gtggcccgtaagctggtcatcattgagagcgacctggaacgtgcagaggagcgg 
gtggccaggaagctggtgatcctggaaggagagctggagcgctcggaggagagg 
gtggctcgtaagttggtgatcattgaaggagacttggaacqcacagaggaacga 
DS1052 TPM4.4F 
gtagctcgtaagctggtcatcctggagggtgagctggagagggcagaggagcgt 
gctgagctctcagaagg 
gctgaggtggccgagag 
gctgagctqgcagagtc 
gcggaggtgtctgaact 
Exon Vsk 
g g TPMla=rat 
caaatgtgc~gagcttgaagaagaattgaaaactgtgacgaacaacttgaagtcactggag 
DS752 TPM2.VF 
taaatgtggggacctagaggaggagctgaaaattgttaccaacaactt~aaatccctggag 
taagtgttctgagctggaggaggagctgaagaatgtcaccaacaacctcaagtctcttgag 
gctcaggctgagaag 
gcccaggcggacaag 
gctcaggcggagaag 
Exon VI 
tactcgcagaaggaagacagatatgaggaagagatcaaggtcctttccgacaagctgaaggag 
DS869 TPM2.6F 
tattccac~aaagaagataaatatgaagaggagatcaaactgttggaggagaagctgaaggag 
tactctcaaaaagaagataaatatgaggaagaaatcaagattcttactgataaactcaaggag 
DS'/54 - TPM4a 
tattctgaaaaggaggacaaatatgaagaagaaattaaacttctgtctgacaaactgaaagag 
Exon VII 
TPMlb=rat 
gctgagactcgggctgagtttgcggagaggtcagtaactaaattggagaaaagcattgatgacttagaag 
DS868 TPM2.7F DS753 TPM2.7R 
gctgagacccgagcagagtttgccgagaggtctgtggcaaagttggagaaaaccatcgatgacctagaag 
gcagagacccgtgctgagtttgctgagagatcggtagccaagctggaaaagacaattgatgacctggaag 
DS755 TPM4b 
gctgagacccgtgctgaatttgcagagagaacggttgcaaaactggaaaagacaattgatgacctggaag 
Exon VIIIsk 
acgagctg 
atgaagtc 
atgagctc 
tacgctcagaaactgaagtacaaagccatcagcgaggagctggaccacgctctcaacgatatgacttccata 
DS870 TPM2 . SF DS866 TPM2. 8R 
tatgcccagaagatgaagtacaaggccattagcgaggaactggacaacgcactcaatgacatcacctccctc 
tatgccca~aaactyaagtacaaggccattagcgaggagctggaccacgccctcaatgacatgacctctatg 
3' untranslated 
taagtt 
tgagcc 
;t.aatta 
tctttgcttcacttctcccaagactccctcgtcgagctggatgtcccacctctctgagctctgcatttgtctattctc 
ccacgcccagcgtgccacctcagctctcttctctcct~tcctttccattctctctatggggaggggagagcaggcagg 
tcaccgtttctgctctgttctggatctgccccctttactcctcggggaacccaaggccccactctggctctggattcc 
cagctgaccctggttctctctcttagcatcctgccttagagccaggcacacactgtgctttctattgtacagaagctc 
aggagcagaaattgccaacattgcacagccaggctgggagcagcctaggg-agagcccccatcatgcc-::.accacccact 
atttgggtcagcctggctggtccccaaggcattaggatgggggagcaaaaagcaacttatgtattttcttccaccccc 
ttcgtttcagtgtcaaataaacactgtgtaagctaaaaaaa 
DS867 TPM2.3'UTR 
ctggcactggcttcatcctttacctatccccttccaccctcctttgcttgcttaataaattctgaacttggaaaaaaa 
accccaaattaaaatgttaagctgctggaaaaaaaaaa 
a a 
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APPENDIX 2 
BUFFERS AND SOLUTIONS 
GENERAL SOLUTIONS 
% Agarose 
Weight agarose per volume in !X TAB 
ie. 1% Agarose gel= lg agarose in 100 rnL !X TAB 
O.SM EDTA (pH 8.0) 
Add 186.1 g of disodium ethylenediaminetetra-acetate·2H20 to 800 rnL of H20. Stir 
vigorously on a magnetic stirrer. Adjust the pH to 8.0 with NaOH (-20g of NaOH 
pellets). The disodium salt of EDT A does not go imo solution until the pH of the solution 
is adjusted to approximately 8.0 by the addition of NaOH. Dispense into aliquots and 
sterilise by autoc1aving (Sambrook, et al., 1989). 
10% SDS (Sodium dodecyl sulfate or sodium lauryl sulfate 
Dissolve 100 g of electrophoresis-grade SDS in 900 mL of H20. Heat to 680C to assist 
dissolution. Adjust the pH to 7.2 by adding a few drops of concentrated HCI. Adjust the 
volume to 1 L with HzO. A mask was vvorn weighing out the SDS as the fine crystals 
dispersed easily (Sambrook, et al., 1989). 
2ox sse 
Disse!ve 175.3 g of NaCl and 88.2 g of sodium citrate in 800 rnL of H20. Adjust the pH 
to 7.0 with a few drops of a 10 N solution of NaOH. Adjust the volume to 1 L with 
H20· Sterilise by autoclaving (Sarnbrook, eta!., 1989). 
1 
STE (Sodium Chloride, Tris, EDT Al 
0.1 MNaCI 
10 mM Tris.CI (pH 8.0) 
I mM EDTA (pH 8.0) 
TE {Tris EDTA Buffer) 
(Sambrook, et al., 1989) 
TE is used as a buffer for DNA. DNA being a weak acid will undergo autocatalysis in the 
absence of a buffering agent (Sambrook, et al., 1989). 
IM Tris 
Dissolve 121.1 g of Tris base in 800 mL of H20. Adjust the pH to the desired value by 
adding concentrated HCI. Allow the solution to cool to room temperature before making 
the final pH adjustments, as the pH ofTris is temperature dependent. Adju.st the volume 
to I L with H20. Sterilise by autoclaving (Sambrook, eta!., 1989). 
SX Tth Buffer 
335 mM Tris HCI (pH8.8) at 25oc 
83 mM (Nfl4)2 S04 
I mM each dNTPs 
!OmMMgCI2, 
I mg gelatin/ml 
2.25% Triton (X-100) 
(ANRI, 1994) 
2 
ETHIDIUM BROMIDE 
STOCK CQNCENTRA TION STAINING CONCENTRATION 
10 mg/mL (lg Ethidium Bromide in IOOmL H20 0.5 ~g/mL 
ELECTROPHORESIS BUFFERS 
BUFFER 
Tris-acetate 
(fAE) 
Tris-borate 
(!'BE) 
WORKING SOLUTION CONCENTRATED STOCK 
SOLUTION (per litre) 
IX: 0,04 M Tris-acetate SOX: 242 g Tris base 
0.001 MEDTA 57.1 mL glacial acetic acid 
IX: 0.09 M Tri-borate lOX : 108 g Tris base 
0.002MEDTA 
3 
27.5 g boric acid 
20 mL 0.5 M EDTA (pH 8.0) 
use double distilled water as 
lOX TBE otherwise 
precipitates 
(Sambrook, et al., 1989) 
GEL LOADING BUFFERS 
BUFFER TYPE 
Agarose Buffer 
Ficoll (6X) 
SSCP Buffer 
Formamide (2x) 
BUFFER STORAGETEMPERATURE 
0.25% bromophenol blue room temperature 
0.25% xylene cyanol FF 
15% Fico II (Type 400; 
Pharmacia in water 
I mL de ionised forrnamide 40C 
I EDTA (pH 8.0) 
0.025% bromophenol blue 
0.025% xylene cyanol FF 
4 
(ANRI, 1994) 
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BACTERIAL MEDIA AND REQUIRED SOLUTIONS 
1.5% bottom agar 
Add agar (Difco Laboratories) weight to volume of 2X YT and made to 10 mM MgS04 
and 0.2% maltose. 
For example to make I L of bottom agar added: 
15 g agar/L and autoclave to sterilise and cool to approximately sooc. Usually some 
volume is lost so make to 980 mL with distilled water. 
At sooc add 10 mL 20% maltose and 10 mL I M MgS04. The solution was left to cool 
to around SOOC because at high temperatures the maltose caramelises. 
(Sambrook, et a!., 1989) 
0.7% top agarose 
Add agarose (Progen Industries) weight to volume of 2X YT and made to 10 mM 
MgS04 and 0.2% maltose. 
For example to make 100 mL of top agarose added: 
0.7 g agarose to 100 mL of 2X YT and boiled in microwave until dissolved. 
Cooled to 'pproximately SOOC and added 1 mL of20% maltose and 1 mL 1M MgS04. 
(ANRI, 1994) 
DNA denaturing solution 
1.5 M NaCI 
0.5 M NaOH 
(Clontech, 1994) 
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lOX Lambda dilution bull'er 
l.OMNaCl 
0.1 M MgS04.1H20 
58.3 g 
24.65 g 
350.0mL 1.0 M Tris-HCl (pH 7.5) (final concentration 0.35 M) 
Added HzO to a final volume of l L. Autoclaved and stored at 40C (Clontech, 1994). 
IX Lambda dilution bull'er 
100 mL lOX Lambda dilution buffer 
5 mL 2% Gelatin 
Added HzO to a final volume of I L. Autoclaved and stored at 40C (Clontech, 1994). 
100 mL 20% Maltose 
20 g maltose in 80 mL HzO. Filter sterilised (ANRI, 1994). 
100 mL l M MgS04 
Added 24.65 g MgS04 with HzO to make l 00 mL. Filter sterilised using 0.22 f(m pore 
filter unit (Millipore- Millex- OS) and 50 mL syringe (Terumo) (ANRI, 1994). 
Phenol: Chloroform 
Mix equal amounts of equilibrated phenol and chloroform. Equilibrate the mixture by 
extracting several times with 0.1 M Tris-HCI (pH 7 .5). Store the equilibrated mixture 
under an equal volume ofO.Ol M Tris-HCI (pH 7.5) at 40C in dark glass bottles. 
Phenol must be equilibrated to a pH > 7.8 because DNA will partition into the organic 
phase at acidic pH (Sarnbrook, et al., 1989). 
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Chloroform:Isoamyl Alcohol (24:1) 
A mixture of chloroform is mixed with isoamyl alcohol in L~e ratio of 24: 1 respectively. 
The mixture is used to remove proteins from nucleic acids. The chlorofonn denatures 
proteins and facilitates the separation of the aqueous and organic phases, and the isoamyl 
alcohol reduces foaming during extraction from the SDS. The chloroform:isoamyl 
alcohol mixture is stored under 0.1 M Tris-HCI (pH 8.0) in a dark bottle at 40C for 
periods of up to one month (Sambrook, et al., 1989). 
Tris neutralising solution 
1.5 M NaCI 
0.5 M Tris-HCI (pH 7.5) 
(Clontech, 1994) 
2X YT Medium 
Per litre: 
To 900 mL of MilliQ water (deionised water) 
Bacto-trypone 
Bacto-yeast extract 
NaCI 
16g 
lOg 
5g 
Mixed until solutes had dissolved and made up to 1 L with H20 
Sterilised by liquid autoclave. 
(Sambrook, et al., 1989) 
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POLYACRYLAMIDE GEL ELECTROPHORESIS FOR SSCP 
GELS AND SOLUTIONS USED 
40% Acrylamide Stock (39:1 Acylalmide:Bisacrylamide) 
Wearing a face mask, 390 g acyrlamide and 10 g bisacylarnide were dissolved in 600 mL 
of MiiiiQ water. The solution was deionised by adding two dessert spoonfuls of Mixed 
Bead Resin (AG 501-X8 (D) Resin, 20-50 mesh, Bio-Rad) and stirring for 30 min. The 
solution was filtered using 305 rnrn diameter Postlip Paper (Hollingsworth & Vase Co. 
Ltd). The bottle was wrapped in foil and kept at 4°C (Sambrook, et al., 1989). 
6% or 12% Nondenaturing SSCP Gel 
To make a 12% nondenaturing SSCP gel, 300 mL of the 40% acrylamide stock was 
dissolved in 600 mL of Mi!liQ water and 100 mL of !OX TBE was added. 
To make a 6% nondenaturing SSCP gel, 150 mL of the 40% acrylamide stock was 
dissolved in 750 mL of MilliQ waler and 100 mL of !OX TBE was added. 
Ammonium persulphate 
Ammonium persulphate was made up at 25% weight/volume in MilliQ water and store.d 
at 4oc, usually 2.5 gin 10 mL ofMilliQ water (ANRJ, 1994). 
Fixative (10% Methanol and 10% Acetic Acid) 
Usually malce 1L by adding 100 mL of glacial acetic acid and 100 mL of methanol to 800 
mL ofMilliQ water in a fumehood cupboard (ANRl, 1994). 
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Abstract. A sequence tagged site (STS) was developed for the human beta 
tropomyosin gene (TPM2). The STS was used to amplify DNA from somatic cell 
hybrids to localise TPM2 to human chromosome 9. Genomic clones isolated with the 
STS product were in turn used in fluorescence in situ hybridisatlon to metaphase 
chromosome spreads to further localise TPM2 to 9p13. 
Each muscle-specific gene should be associated with an inherited muscle disease, 
unless mutations do not occur in that gene or all mutations of that gene are lethal. 
Precise mapping of muscle genes therefore becomes important in relation to mapping 
muscle diseases (Eyre et al., 1993). 
Tropomyosin is one of the components of the thin filaments of muscle, binding to 
actin, and, together with troponin, regulating contraction in a calcium-dependent 
manner (Cho et al., 1990). There are at least four distinct tropomyosin genes in 
vertebrates and each may encode six different isoforms of tropomyosin by alternate 
splicing (Navy et a!., 1993; Macleod et al., 1988). The alpha-tropomyosin gene 
TPM1 has recently been localised to 15q22 (Eyre et al., 1994) and has been shown 
to be mutated in some cases of familial hypertrophic cardiomyopathy (Thierlelder et 
a!., 1994). The alpha-tropomyosin gene TPM3 has be<:ln recently localised to 1 q22-
q23 (Wilton et al., 1994) and has been shown to be mutated in a family with 
autosomal dominant r.emaline myopathy (manuscript submitted). 
We describe the mapping of the human beta tropomyosin gene TPM2 (Widada et al., 
1988) to 9p13 by development of a sequence tagged site (STS) (Olson et al., 1989), 
testing of a somatic cell hybrid panel, and fluorescence in situ hybridization (FISH) 
(Callen et al., 1992). 
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Materials and Methods 
STS for the TPM2 gene. 
The eDNA sequence of the skeletal muscle transcript of the TPM2 gene (Widada, et al., 
1988) was used along with the known conserved exon pattern of the tropomyosin genes 
(Ruiz-Opazo et al., 1987; Clayton et a/., 1988) to design primers for amplification 
which would amplify across intronic sequences. The primers were chosen such that at 
least one was located in a skeletal muscle specific exon (Clayton, et a/., 1988; Ruiz~ 
Opazo & Nadai~Ginard, 1987; Widada, et ai., 1988) to avoid amplifying pseudogene 
sequences. The primers eventually used were in the muscle specific exon Vlllsk 
(TPM2.8R: 5'-AGTIACTGTAGTGGAGGGAG·3') and the common exon VI (TPM2.6F: 5'-
ATICCACCAAAGA.~GATAAA-3') (Widada, eta/., 1988). These primers amplified an STS 
product of approximately 1.5 kb long. The amplification conditions for a reaction volume 
of 25~1 were: 5~1 of SX buffer (335mM Tris HCI [pH8.8] at 25°C; 83mM (NH4)2 S04, 
1 mM dNTPs, 10 mM MgC/2, 1 mg gelatin/ml, and 2.25% Triton X-100), 50 ng target 
DNA and 0.5 Unit of Tth polymerase (Biotech International). Thermal cycling conditions 
were: 35 cycles of 94oc for 30 sees, saoc for 6 mins, with an initial denaturing period 
at 94oc for 4.5 mins. The 1.5 kb product was sequenced using an ABI 373A DNA 
sequencer tc confirm that the STS product did indeed contain parts of the TPM2 gene. 
Isolation of genom;c clones 
The genomic library was constructed in AEMBL3 SP6ff7 (Cionetech) following a partial 
BamH1 digestion. The library was plated out at S~fold redundancy and duplicate lifts 
made using Hybond N+ colony/plaque screening membranes (Amersham). The probe used 
was the 1.5 kb PCR amplified STS of the TPM2 gene which was radiolabel/ed with o: p32 
dCTP (Bresatec) using a random-prime kit (Promega). The duplicate lift!': were 
hybridised with probe at 42°C for 16 hours in a hybridi~ation solution of 50% 
formamide, 10% dextran~sulphate, 1M NaCI, 50mM Tris~HCI pH7.5, 0.1 mg/ml 
herring sperm DNA. Lifts were washed in 0.1% SDS and 0.1x sse at 65°C for 30 
minutes. Autoradiography was carried out with Dupont Cronex 4 X~ray film with Quanta 
3 
Ill autoradiography screens at ~8ooc overnight. Plaques showing up in duplicate on the 
autoradiographs were considered positive. Confirmation of the TPM2 sequence in the 
genomic clones was ensured by STS PCR assay and sequencing. 
Pure clones were then amplified by the plate lysate method (Sambrook et al., 1989). 
Phage were eluted in Lambda dilution buffer (100mM NaCI, 10 mM MgS04.?H20, 100 
mM Tris pH 7.5, 0.01% gelatin solution) at 4oc overnight. Eluates were collected and 
phage were purified on caesium chloride gradients (Sambrook, et al., 1989} and DNA 
extracted. Di\JA integrity was checked by running each sample on a 0.8% agarose gel at 
100 volts for 30 minutes and ntaining with ethidium~bromide. Extracted DNA was 
confirmed to contain the TPM2 gene by STS PCA and sequencing. Whole clones were then 
used for In situ hybridisation. 
In situ hybridisation 
The probes were nick-translated with biotin-14-dATP and each was hybridized in 
situ at a final concentration of 20 ng/!ll to metaphases from two normal males. The 
fluorescence in situ hybridization (FISH} method was modified from that previously 
described (Callen et a/., 1990} in that chromosomes were stained before analysis 
with both propidium iodide (as counterstain) and DAPI (for chromosome 
identification). Images of metaphase preparations were captured by a CCD camera 
and computer enhanced. 
Cell fines 
A panel of rodent-human somatic cell hybrids was obtained from the National 
Institute of General Medical Sciences Human Genetic Mutant Cell Repository 
[NIGMS/mapping panel #2]. The construction of the mouse-human hybrid cell lines 
was described by Dubois and Naylor (1992}. PCR amplification of the STS was 
performed with 50 ng of hybrid 1 !A and the primers TPM2.6F and TPM2.8R as 
above. 
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Results and discussion 
Somatic cell hybrid panel 
The TPM2 STS gave an amplification product from only the control human DNA and 
the somatic cell hybrid GM/NA10611 (Dubois et al., 1992) (data not shown). Only 
chromosome 9 was unique to this cell line indicating that TPM2 is on human 
chromosome 9. 
FISH 
The STS PCR product was used as a hybridization probe to the genomic library which 
has an average lnsei1 size of 15 kb. Four positive plaques were picked and respread 
at lower density enabling individual plaques to be isolated. The STS primer set was 
used to assay selected pure plaques. Two of those which gave positive STS signals, 
TPM2.2 and TPM2.4 , were further propagated. 
TPM2.2 and TPM2.4 were then used for FISH to metaphase spreads from three 
normal males. Twenty-five metaphases from the first normal male were examined 
for fluorescent signal with TPM2.2. Eighteen of these metaphases showed signal on 
one or both chromatids of chromosome 9 in the region 9p13-p21; 95% of this 
:;;ignal was at 9p13.1 (Fig. 1 ). There was a total of 11 nonNspecific background dots 
observed In these 25 metaphases. A similar result was obtained from hybridization 
of this probe to 15 metaphases from the second normal male and from hybridization 
using the probe TPM2.4 to 20 metaphases from the 3rd normal male (data not 
shown). 
The localization of TPM2 to 9p13 should be of interest to laboratories positional 
cloning inherited muscle disorders, especially any that have already linked such 
diseases to this region. 
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Figure Legend 
Figure 1 Metaphase showing FISH with the probe TPM2.2. a) Normal male 
chromosomes stained with propidium iodide. Hybridization sites on 
chromosome 9 are indicated by arrows. b) The same metaphase as (a) 
stained with DAPI for chromosome identification. 
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